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Currently more than 70 % of people with active tuberculosis (TB) in South Africa are dually
infected with HIV. The incidence of new TB cases in South Africa is approximately 1 % of
the adult population per year and the incidence of new HIV cases is over 15 % of the adult
population; in some townships this figure is 33 %. The past decade has seen the emergence of
the immune reconstitution inflammatory syndrome (IRIS) in HIV patients who have a concurrent
infection and who have recently initiated their highly active anti-retroviral therapy (HAART),
the most common co-infection associated with IRIS being TB. IRIS is characterised by an
excessive inflammatory immune reaction to the co-infecting pathogen, normally within the
first three months of initiation of HAART. The incidence of TB associated IRIS (TB-IRIS)
varies between 7 - 43 % of TB positive and HIV positive patients. Currently there is no
pre-symptomatic diagnostic test available for clinicians and TB-IRIS patients are therefore
only diagnosed after presenting clinical symptoms. In 2009, a double blinded, randomised,
placebo controlled drug trial was performed to assess the effectiveness of prednisone in the
treatment of TB-IRIS cases. The outcome determined that prednisone treatment reduced the
need for hospitalization and therapeutic procedures and hastened improvements in symptoms,
performance, and quality of life. However, the underlying molecular mechanism of action of
this treatment still remains largely unknown.
Immune responses to Mycobacterium tuberculosis antigens are known to differ in vivo between
TB-IRIS and control patients who are dually infected with HIV and TB and who are on HAART
and anti-TB therapies but who do not develop IRIS symptoms (‘TBART’ patients). This thesis
therefore describes proteomic research aimed at determining the molecular origin of these
differences using an in vitro model of TB-IRIS, based on use of cultured peripheral blood
mononuclear cells (PBMCs) isolated from TB-IRIS and TBART patients, the goals being to
1) identify a potential diagnostic protein biomarker for the TB-IRIS condition, 2) provide an
improved understanding of the molecular origin of TB-IRIS, and 3) aid development of more
targeted suppression of TB-IRIS.
Results from this study have determined a fundamental difference in the proteomic profiles of
TB-IRIS and TBART patient derived PBMCs in response to re-stimulation using heat killed
H37Rv as well as to treatment using dexamethasone. These results form the bases of a new
hypothesis that TB-IRIS derived PBMCs mount an uncoordinated immune response which
appears to become a co-ordinated innate response in the presence of dexamethasone, whereas
TBART derived PBMCs display the capacity to produce a co-ordinated adaptive immune












1. I know that plagiarism is wrong. Plagiarism is to use another’s work and pretend that it is
one’s own.
2. I have used the . . . ......................................... convention for citation and referencing.
Each contribution to, and quotation in, this thesis from the work(s) of other people has
been attributed, and has been cited and referenced.
3. This thesis is my own work
4. I have not allowed, and will not allow, anyone to copy my work with the intention of
passing it off as his or her own work.
5. I acknowledge that copying some else’s assignment or essay, or part of it, is wrong and













This thesis has taken many years of sacrifice from many people who are involved in my life.
I would firstly like to thank my mother, Colleen, without whose support emotionally and
financially I would never have made it to the start of my thesis, never mind the end. You
have been the single greatest blessing in my life mom and I hope this thesis makes you proud.
Equally I would like to thank my supervisor, Prof. Jonathan Blackburn who has given me the
opportunity to explore this fantastic field of Science and whose guidance during troubled times
can not be overstated enough. There are many others who have helped along the way with
encouraging words in times of need (and there were many), too numerous to name here but
you know who you are. I would also like to thank those who helped me by providing tools
that I have used for my thesis. In this regard I would like to thank my fellow lab members,
chief amongst them are Shaun Garnett and Katie Viljoen, who respectively; single handedly
put together our proteomic data processing pipeline, and who conquered the scripting language
R to make sense of the processed data. I have been fortunate enough to complete my Ph.D
in a lab filled with fantastic people and to all of you I have had the pleasure of working with
along the way I want to say thank you for making my journey memorable. I would also like to
thank Dr Salome Smit at the Central Analytical Facility based at the University of Stellenbosch
who helped me to generate my proteomics data, although overworked you always have a smile.
Lastly I would like to thank the Big Guy upstairs, this journey has been illuminating for myself
about myself and I thank you for being there when I needed it.
I would also like to thank the University of Cape Town and the National Research Foundation












1 Immunology Literature Review 1
1.1 Tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 The bacterium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.2 Distribution and burden of disease . . . . . . . . . . . . . . . . . . . . 2
1.1.3 Aetiology and pathogenesis . . . . . . . . . . . . . . . . . . . . . . . 4
1.1.4 Diagnosis and testing . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.1.4.1 Tuberculin skin test . . . . . . . . . . . . . . . . . . . . . . 9
1.1.4.2 Sputum smear staining . . . . . . . . . . . . . . . . . . . . 10
1.1.4.3 M.tb culture . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.1.4.4 Nucleic acid amplification testing . . . . . . . . . . . . . . . 11
1.1.4.5 Interferon-γ release assays (IGRAs) . . . . . . . . . . . . . 11
1.1.5 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.1.5.1 Multi-drug resistant TB (MDR-TB) . . . . . . . . . . . . . . 12
1.1.5.2 Extensively drug resistant TB (XDR-TB) . . . . . . . . . . . 14
1.1.5.3 Totally drug resistant TB (TDR-TB) . . . . . . . . . . . . . 14
1.1.5.4 Isoniazid preventative therapy . . . . . . . . . . . . . . . . . 14
1.2 HIV/AIDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.2.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.2.2 Distribution and burden of disease . . . . . . . . . . . . . . . . . . . . 17
1.2.3 Viral life cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.2.3.1 Viral entry . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.2.3.2 Viral Transcription . . . . . . . . . . . . . . . . . . . . . . . 19
1.2.3.3 Viral Replication . . . . . . . . . . . . . . . . . . . . . . . . 20
1.2.3.4 Virion assembly and budding . . . . . . . . . . . . . . . . . 20
1.2.4 Transmission and pathogenesis . . . . . . . . . . . . . . . . . . . . . . 21
1.2.5 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.2.5.1 Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . 22











1.3 Immune reconstitution inflammatory syndrome (IRIS) . . . . . . . . . . . . . 25
1.3.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.3.2 Incidence and risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.3.3 Treatment challenges . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.3.3.1 HAART initiation . . . . . . . . . . . . . . . . . . . . . . . 27
1.3.3.2 Corticosteroid treatment . . . . . . . . . . . . . . . . . . . . 29
1.3.4 Potential mechanisms of disease progression . . . . . . . . . . . . . . 30
1.4 Aims of thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2 Proteomics Review 34
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.2 Basics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.2.1 Theory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.2 Hardware . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.2.1 Ion sources . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.2.2 Mass analysers . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.2.3 Detectors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.2.3 Software and algorithms . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.2.3.1 Spectral matching . . . . . . . . . . . . . . . . . . . . . . . 41
2.2.3.2 Probability matching . . . . . . . . . . . . . . . . . . . . . 42
2.2.3.3 Database filtering using sequence tags . . . . . . . . . . . . 42
2.3 Databases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.3.1 UniProtKB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.3.2 International Protein Index (IPI) . . . . . . . . . . . . . . . . . . . . . 43
2.4 Shotgun Proteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.4.1 Protein-centric approaches (gel based) . . . . . . . . . . . . . . . . . . 45
2.4.2 Peptide-centric approaches (gel free) . . . . . . . . . . . . . . . . . . . 46
2.4.2.1 MS/MS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
2.4.2.2 Peptide fragmentation strategies . . . . . . . . . . . . . . . . 47
2.4.2.3 LC-MS/MS . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.4.2.4 De novo sequencing . . . . . . . . . . . . . . . . . . . . . . 49
2.4.3 Fractionation strategies . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.4.3.1 SDS PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.4.3.2 2D PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.4.3.3 DIGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.4.3.4 Ion Exchange Chromatography . . . . . . . . . . . . . . . . 54
2.4.3.5 Reverse phase chromatography . . . . . . . . . . . . . . . . 55











2.4.3.7 Off-gel (iso-electric focussing) . . . . . . . . . . . . . . . . 58
2.4.3.8 Sub-cellular fractionation . . . . . . . . . . . . . . . . . . . 58
2.4.4 Middle-out approach . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.4.4.1 Protein fractionation . . . . . . . . . . . . . . . . . . . . . . 61
2.4.4.2 Peptide fractionation . . . . . . . . . . . . . . . . . . . . . . 61
2.5 Quantitation strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.5.1 Absolute and relative quantitation . . . . . . . . . . . . . . . . . . . . 62
2.5.2 Labelling strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.5.2.1 Metabolically integrated labels . . . . . . . . . . . . . . . . 62
2.5.2.2 Chemically added isotopic labels . . . . . . . . . . . . . . . 64
2.5.2.3 Enzymatic . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2.5.2.4 Isobaric approaches . . . . . . . . . . . . . . . . . . . . . . 64
2.5.3 Label-free strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
2.5.3.1 Spectral counting . . . . . . . . . . . . . . . . . . . . . . . 66
2.5.3.2 Extracted ion chromatograms (XIC) . . . . . . . . . . . . . 68
2.5.3.3 Label-Free Quantification of Multidimensional LC-MS Data 68
2.6 Targeted proteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.6.1 Directed approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.6.2 Selected reaction monitoring . . . . . . . . . . . . . . . . . . . . . . . 71
2.7 Discovery to validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2.7.1 Proteomics pipeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2.7.2 Proteomics question . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3 Materials and Methods 75
3.1 Patient recruitment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
3.2 PBMC preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.2.1 Cell counting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.3 PBMC culture: general conditions . . . . . . . . . . . . . . . . . . . . . . . . 78
3.4 Quantitative real-time PCR range-finding experiment . . . . . . . . . . . . . . 80
3.4.1 RNA extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
3.4.2 Quantitative real-time PCR . . . . . . . . . . . . . . . . . . . . . . . . 83
3.4.3 qPCR data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.5 Proteomic experiment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.5.1 Method development . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.5.1.1 MALDI ToF/ToF workflow . . . . . . . . . . . . . . . . . . 85
3.5.1.2 Q-ToF workflow . . . . . . . . . . . . . . . . . . . . . . . . 88
3.5.1.3 LTQ-Orbitrap workflow . . . . . . . . . . . . . . . . . . . . 91











3.5.3 Protein extraction and fractionation . . . . . . . . . . . . . . . . . . . 94
3.5.3.1 Phospho-enrichment: . . . . . . . . . . . . . . . . . . . . . 94
3.5.3.2 SDS PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
3.5.4 Protein digestion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
3.6 Mass spectrometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
3.7 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
4 Quantitative Results 98
4.1 PBMC culture optimisation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
4.2 qPCR work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
4.3 Protein extraction method development: . . . . . . . . . . . . . . . . . . . . . 102
4.3.1 MALDI-ToF/ToF workflow: . . . . . . . . . . . . . . . . . . . . . . . 102
4.3.2 ESI Q-ToF workflow: . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
4.4 Peptide Fractionation strategies: . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.4.1 Off-gel fractionation: . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
4.4.2 High pH C-18 reverse phase fractionation: . . . . . . . . . . . . . . . . 107
4.5 Protein fractionation strategies: . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.5.1 Crude sub-cellular fractionation: . . . . . . . . . . . . . . . . . . . . . 108
4.5.2 Phosphoprotein enrichment: . . . . . . . . . . . . . . . . . . . . . . . 109
4.5.3 Improved discovery strategy for shotgun proteomics: . . . . . . . . . . 110
4.5.3.1 Protocol finalisati n . . . . . . . . . . . . . . . . . . . . . . 111
4.5.3.2 Initial phospho-depleted results . . . . . . . . . . . . . . . . 111
4.5.3.3 Secondary phospho-depleted results . . . . . . . . . . . . . 112
4.6 Data processing for downstream software analysis . . . . . . . . . . . . . . . . 113
4.6.1 Barista identification . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.6.2 Protein quantification . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5 Qualitative Results 116
5.1 Data set pairing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.2 Systems analysis using Ingenuity Pathway Analysis data . . . . . . . . . . . . 117
5.2.1 Intra-condition protein level analysis . . . . . . . . . . . . . . . . . . . 117
5.2.2 Intra-condition biological pathway level analysis . . . . . . . . . . . . 123
5.2.3 Inter-condition Canonical Pathways Analysis: TBART vs TB-IRIS . . 127
5.2.4 Pathway analyses of the effect of dexamethasone . . . . . . . . . . . . 131












6.1 Pathway level analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
6.1.1 The differing patient responses: TBART vs TB-IRIS . . . . . . . . . . 137
6.1.1.1 Actin cytoskeleton organisation . . . . . . . . . . . . . . . . 139
6.1.1.2 Cellular motility . . . . . . . . . . . . . . . . . . . . . . . . 139
6.1.1.3 Phagocytosis . . . . . . . . . . . . . . . . . . . . . . . . . . 140
6.1.1.4 Antigen presentation . . . . . . . . . . . . . . . . . . . . . . 144
6.1.1.5 Extra-cellular signalling and leukocyte recruitment . . . . . . 146
6.1.1.6 Apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
6.1.2 The effect of dexamethasone . . . . . . . . . . . . . . . . . . . . . . . 147
6.1.3 Unique canonical pathways . . . . . . . . . . . . . . . . . . . . . . . 148
6.2 Protein level analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
6.2.1 Protein profiles of TBART and TB-IRIS cultured PBMCs . . . . . . . 149
6.2.2 Changes in protein expression in response to dexamethasone . . . . . . 149
6.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6.3.1 The molecular origin of TB-IRIS . . . . . . . . . . . . . . . . . . . . 150
6.3.2 The mechanism of action of dexamethasone . . . . . . . . . . . . . . . 152
6.3.3 Identification of possible biomarkers . . . . . . . . . . . . . . . . . . . 152













1.1 Schematic representation of the cell envelope of Mycobacterium tuberculosis . 2
1.2 Estimated global incidence rates of TB in 2010 . . . . . . . . . . . . . . . . . 3
1.3 Global geographic distribution of M.tb phylogenetic lineages . . . . . . . . . . 4
1.4 Macrophage phagocytosing M.tb bacilli . . . . . . . . . . . . . . . . . . . . . 5
1.5 The drivers behind a Th1 and Th2 response . . . . . . . . . . . . . . . . . . . 6
1.6 Ziehl-Neelson staining of M.tb . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.7 Human Immunodeficiency Virus . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.8 Estimated global prevalence of HIV in 2009 . . . . . . . . . . . . . . . . . . . 18
1.9 HIV life cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.10 Virion budding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.11 Prevalence of HIV in new TB cases . . . . . . . . . . . . . . . . . . . . . . . 24
1.12 Kaplan–Meier survival curves for integrated and sequential HAART therapy . . 28
1.13 Kaplan–Meier survival estimates according to study group . . . . . . . . . . . 29
1.14 IRIS is associated with polymorphisms in the TNF-α , IL12B and IL6 genes . . 32
2.1 Plasma protein dynamic range . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.2 Basic proteomic workflow . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.3 Popular mass analysers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.4 Spectral matching . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.5 Overview of proteomic approaches . . . . . . . . . . . . . . . . . . . . . . . . 44
2.6 Comparison of proteomic approaches . . . . . . . . . . . . . . . . . . . . . . 45
2.7 Peptide mass fingerprinting (PMF) . . . . . . . . . . . . . . . . . . . . . . . . 46
2.8 Roepstorff Nomenclature Scheme . . . . . . . . . . . . . . . . . . . . . . . . 48
2.9 Protein identification using de novo sequencing . . . . . . . . . . . . . . . . . 50
2.10 SDS PAGE gel (1DE PAGE) . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.11 2D PAGE gel (2DE PAGE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.12 2D DIGE gels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.13 Reverse phase chromatography . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.14 LOPIT organelle fractionation . . . . . . . . . . . . . . . . . . . . . . . . . . 60











2.16 Structure of iTRAQ labels . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
2.17 Outline of a directed proteomic approach . . . . . . . . . . . . . . . . . . . . 71
2.18 A basic SRM analogy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
2.19 Typical proteomics pipeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.1 Cohort recruitment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.2 Basic workflow of sample culturing for qPCR experiment . . . . . . . . . . . 82
3.3 Basic setup for qPCR plate . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.4 Simplified protein extraction protocol described by Skopeliti et al. . . . . . . . 86
3.5 Basic workflow for sample culturing for proteomic experiment . . . . . . . . . 94
3.6 Proteomic data processing pipeline . . . . . . . . . . . . . . . . . . . . . . . . 97
4.1 ARV cytotoxicity study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.2 Dexamethasone and heat killed H37Rv cytotoxicity study . . . . . . . . . . . . 100
4.3 qPCR results - intra-condition analysis . . . . . . . . . . . . . . . . . . . . . . 101
4.4 Initial iTRAQ compatible protein extractions . . . . . . . . . . . . . . . . . . 102
4.5 Comparison of completeness of extraction . . . . . . . . . . . . . . . . . . . . 104
4.6 Nano-LC digest trace . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.7 Effectiveness of Off-gel fractionation on crude PBMC protein extract . . . . . 106
4.8 Crude sub-cellular fractionation . . . . . . . . . . . . . . . . . . . . . . . . . 109
4.9 Phospho-protein extraction (Silver stained and CCB) . . . . . . . . . . . . . . 110
4.10 TBART phospho-depleted gel . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.11 TB-IRIS phospho-depleted gel . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5.1 Protein expression profile distribution of TBART MP samples . . . . . . . . . 120
5.2 Protein expression profile distribution of TB-IRIS MP samples . . . . . . . . . 121
5.3 Protein expression profile distribution of TB-IRIS PP samples . . . . . . . . . 122
5.4 Overview of differences in biological functions . . . . . . . . . . . . . . . . . 124
5.5 How the z-score is calculated . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.6 Delving deeper into biological functions . . . . . . . . . . . . . . . . . . . . . 126
5.7 IPA generated stacked bar chart of TB-IRIS MP/MM dataset . . . . . . . . . . 128
5.8 Over-representation analysis of canonical pathways . . . . . . . . . . . . . . . 129
5.9 Differential analysis of significantly over-represented canonical pathways . . . 130
5.10 Canonical pathway analysis of effect of dexamethasone . . . . . . . . . . . . . 131
5.11 Effect of dexamethasone on canonical pathway profiles . . . . . . . . . . . . . 132
5.12 Venn diagram of canonical pathway analysis . . . . . . . . . . . . . . . . . . . 133
6.1 Integration of multiple canonical pathways . . . . . . . . . . . . . . . . . . . . 138











6.3 Fcγ Receptor-mediated phagocytosis: TB-IRIS MP/MM . . . . . . . . . . . . 142
6.4 Fcγ Receptor-mediated phagocytosis: TB-IRIS PP/MM . . . . . . . . . . . . . 143
6.5 Integration of Fcγ receptor-mediated phagocytosis . . . . . . . . . . . . . . . . 145
6.6 Time lapse sequence of GFP-actin stained ruffles in mouse fibroblast . . . . . . 150
7.1 Th1/Th2 response mechanism . . . . . . . . . . . . . . . . . . . . . . . . . . 154












1.1 Array of some TB diagnostic tests currently in use . . . . . . . . . . . . . . . . 8
1.2 Comparison of sensitivities and specificities of commonly used TB diagnostic
tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.3 First line drugs for TB treatment . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4 Classes of second line drugs for TB treatment . . . . . . . . . . . . . . . . . . 13
1.5 List of drugs for MDR-TB treatment . . . . . . . . . . . . . . . . . . . . . . . 13
1.6 List of HIV (poly)proteins, functions and locations . . . . . . . . . . . . . . . 16
1.7 Table of incidence rates of TB-IRIS stratified by CD4 counts . . . . . . . . . . 26
1.8 Primary outcomes of prednisone vs placebo treatment . . . . . . . . . . . . . . 30
2.1 Comparison of characteristics of common mass spectrometers . . . . . . . . . 40
2.2 Differing types of label free quantitation using LC-MS/MS . . . . . . . . . . . 66
2.3 Technical parameters of the different quantitation strategies for LC-MS/MS . . 67
3.1 Final condition-specific reagent concentrations per well . . . . . . . . . . . . 78
3.2 Condition-specific stock solution volumes . . . . . . . . . . . . . . . . . . . . 79
3.3 Culture conditions for qPCR experiment. . . . . . . . . . . . . . . . . . . . . 81
3.4 Culture conditions and corresponding data labels . . . . . . . . . . . . . . . . 81
3.5 Reagent volumes per well for each qPCR plate . . . . . . . . . . . . . . . . . 83
3.6 qPCR machine cycling conditions . . . . . . . . . . . . . . . . . . . . . . . . 83
3.7 Culture conditions for proteomics workflow . . . . . . . . . . . . . . . . . . . 93
4.1 Initial high pH RP protein numbers . . . . . . . . . . . . . . . . . . . . . . . . 107
4.2 Non-redundant protein numbers per sample group . . . . . . . . . . . . . . . . 114
5.1 Pairwise protein datasets for downstream IPA analysis . . . . . . . . . . . . . . 116
5.2 IPA core analysis predicted protein changes: up-regulated . . . . . . . . . . . . 118
5.3 IPA core analysis predicted protein changes: down-regulated . . . . . . . . . . 119
5.4 IPA biomarker analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
5.5 Non-significant TB-IRIS analysis . . . . . . . . . . . . . . . . . . . . . . . . . 127



























ABC 50 mM Ammonium bicarbonate
ACN Acetonitrile
AFB+ Acid-fast bacilli
AIDS Acquired immunodeficiency syndrome
APCs Antigen presenting cells

















Cdc42 Cell division cycle 42 protein
cDNA Complimentary DNA
CFL Cofilin
CFP-10 Culture filtrate protein-10
CFU Colony forming unit
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
CID Collision induced dissociation
CNS Central Nervous System
CPGR Centre for Proteomic and Genomic Research








DOTS Directly observed treatment, short course
DST Drug susceptibility test













eIF2 Eukaryotic initiation factor-2
ELISA Enzyme-Linked Immunosorbent Assay
ELISpot Enzyme-Linked Immunospot Assay
emPAI Exponentially modified protein abundance index
ESAT-6 Early secreted antigenic target 6 KDa protein
ETD Electron transfer dissociation
FA Formic acid
FASP Filter aided sample preparation
FcγR Fc-gamma receptor
FCS Fetal calf serum
FDR False discovery rate
H37Rv Mycobacterium tuberculosis strain type
HAART Highly active anti-retroviral therapy
HILIC Hydrophilic interaction liquid chromatography
IAA 50 mM Iodoacetamide in 8M Urea and 0.1 M Tris-Cl pH 8.5
iBAQ Intensity based absolute quantitation
ICAT Isotope-coded affinity tag












IGRA Interferon gamma release assay
IIDMM Institute for Infectious Diseases and Molecular Medicine
IMAC Immobilized metal affinity chromatography
INH Isoniazid
IPA Ingenuity Pathway Analysis
IPI International Protein Index
IPT Isoniazid preventive therapy
IRD Immune Restoration Disease
IRIS Immune reconstitution inflammatory syndrome
IRS Immune Reconstitution Syndrome
IT Ion trap
ITAM Immunoreceptor tyrosine activation motifs
iTRAQ Isobaric tags for relative and absolute quantitationb
LC Liquid chromatography
LIMK LIM-kinase
LOPIT Localisation of organelle proteins by isotope tagging














MHC Major histocompatibility complex
MLCP Myosin light chain phosphatase
MM Minus dexamethasone / Minus re-stimulation with H37Rv
MMTS S-methylmethanethiosulphonate
MOAC Metal oxide affinity chromatography
MOI Multiplicity of infection
MP Minus dexamethasone / Plus re-stimulation with H37Rv
MRM Multiple reaction monitoring
MS Mass spectrometry
MudPIT Multi-dimensional protein identification technology
MWCO Molecular weight cut-off filter, measured in Daltons
MYL Myosin light chain
NAAT Nucleic acid amplification testing
NK Natural killer
NSAF Normlised spectral abundance factor
OGP n-octyl 3-D-glucopyranoside
OI Opportunistic infection
PAGE Polyacrylamide Gel Electrophoresis











PBS Phosphate buffered saline
PD Phospho-depleted
PDE Phospho-depleted and -enriched
PDGF Platelet-derived growth factor
PE Phospho-enriched
PFF Peptide fragment fingerprinting
PI Protease inhibitor
pI Iso-electric point
PMF Peptide mass fingerprinting
PP Plus dexamethasone / Plus re-stimulation with H37Rv
PPD Purified protein derivative
ppm Parts per million
PSMs Peptide-spectrum matches
PTM Post translational modification
PTPs Proteotypic peptides
Q Quadrupole
qPCR Quantitative real-time PCR















S/N Signal to noise ratio
SAB Laemmli gel sample application buffer
SAX Strong anion exchange
SCX Strong cation exchange
SDS Sodium dodecyl sulfate
SILAC Stable isotope labelling by amino acids in cell culture
SRM Selected reaction monitoring
SYK Spleen tyrosine kinase
TB Tuberculosis
TB-IRIS TB associated immune reconstitution inflammatory syndrome
TBART Patients receiving TB and ART treatment who do not develop IRIS
TCEP Tris(2-carboxyethyl)phosphine
TDR-TB Totally drug resistant TB
TEAB Tri-ethyl ammonium bicarbonate
TFA Tri-fluoro-acetic acid
Th1 Type 1 helper T cell
Th17 Type 17 helper T cell
















TST Tuberculin skin test
UA 8M Urea in 0.1 M Tris-Cl pH 8.5
UnitProtKB UniProt Knowledge Base
WAX Weak anion exchange
WHO World Health Organisation












1 Immunology Literature Review
1.1 Tuberculosis
Mycobacterium tuberculosis (M.tb) is the primary infectious agent responsible for tuberculosis
(TB), a common infectious disease - especially in resource poor countries. Other mycobacteria,
such as M. bovis, M. africanum and M. microti, can cause non-granulomatous TB, however
they do not normally infect healthy or immunocompetent human adults. The most common
site of disease for TB is the lungs (pulmonary TB). However, M.tb can also be found in tissues
and organs outside of the lungs, referred to as extra-pulmonary TB, such as the central nervous
system (CNS), lymph nodes, gastro-intestinal tract, bones, skin and even the heart (pericardial
TB). It is estimated that as many as a third of the world’s population are latently infected with
M.tb [1].
1.1.1 The bacterium
M.tb is an Actinomycete, first discovered by Robert Koch in 1882, although archaeological
evidence of human infection with M.tb dates back thousands of years [2]. M.tb is a small
rod-like aerobic bacterium that has a very slow metabolism, dividing approximately every 15
- 20 hours. It has a waxy cell wall, due to the high lipid content, and is fairly impermeable
to most dyes unless they are attached to phenol. Consequently, M.tb is classified neither as a
gram negative or gram positive bacterium, but is rather identified as being acid fast since, once
stained, it resists decolourisation with acidified solvents.
The nature of the unique architecture of the mycobacterial cell wall envelope and how it anchors
to the plasma membrane results in a very well protected environment for the bacteria that makes
it difficult for small molecules, such as drugs, to permeate and also provides a source for a large
number of antigenic compounds. The mycobacterial plasma membrane is surrounded by three
covalently linked structural layers that can loosely be described as a peptidoglycan/arabino-
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the mycolic acids) provides a hydrophobic layer of extremely low fluidity. The outermost
section of the mycolic acid layer contains various free lipids, such as phenolic glycolipids,
phthiocerol dimycocerosates, and phosphatidylinositol mannosides, that are intercalated with
the mycolic acids, the majority of which are specific for mycobacteria. The mycolic acid layer
is in turn linked to the outer polysaccharide layer, which is generally called the capsule, contains
molecules such as glucan and arabinomannan. A basic diagram of these layers and their relation
to the mycobacterial plasma membrane can be seen in Figure 1.1.
Figure 1.1: Schematic representation of the cell envelope of Mycobacterium tuberculosis
The diagram represents a basic cross section of a typical mycobacterial cell envelope, containing three different
linked structures, namely: the peptidoglycan/arabinogalactan layer (grey and blue); the mycolic acids layer (green)
which is also referred to as the mycomembrane; and the outer polysaccharide layer. Figured sourced from Abdallah
et al 2007 [3].
1.1.2 Distribution and burden of disease
The global distribution of TB is skewed mainly towards resource limited countries with over 80
% of TB infections occurring in 22 countries across Africa and Asia - as shown in Figure 1.2.
The five countries with the largest number of incident cases of TB in 2010 were India (2.0
million–2.5 million), China (0.9 million–1.2 million), South Africa (0.40 million–0.59 million),
Indonesia (0.37 million–0.54 million) and Pakistan (0.33 million–0.48 million). India alone
accounted for an estimated one quarter (26%) of all TB cases worldwide, and China and India
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Figure 1.2: Estimated global incidence rates of TB in 2010
The global distribution of new cases of TB in 2010. Source = Global Tuberculosis Control: WHO report 2011 [4].
In South Africa, the incidence rate for TB has more than tripled from 301 to 981 new cases
per 100 000 population between 1990 and 2010. Currently the incidence of new TB infection
is approximately 1 % of the population of which more than half are co-infected with HIV [4].
In specific informal settlements in South Africa, e.g. Kayelitsha, Cape Town, the incidence of
active TB is currently 1.6 %, with 70 % of new active TB patients being HIV positive.
This co-incidence of HIV and TB disease causes major complications in disease management
for a number of reasons, such as adverse drugs reactions, incompatible dosing regimes and the
development of life threatening secondary syndromes. The net result being that in co-infected
individuals, TB and HIV can no longer realistically be viewed as separate diseases. The high
level of HIV/TB co-infection has led the South African National AIDS Council to call for
integration of care for these two diseases in their National Strategic Plan [5, 6].
The M.tb genome has been shown to exhibit a large amount of variation and currently
thousands of strains have been identified using various genetic methods, these strains also
exhibit considerable differences in clinical phenotype. The distribution of these strains has
been shown to be phylogeographical in nature and each lineage appears to have links to specific
sympatric human populations [7? ].
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Figure 1.3: Global geographic distribution of M.tb phylogenetic lineages
The six main lineages of M.tb are geographically distributed, each dot corresponds to 1 of 80 countries represented
in the global strain collection. The colours of the dots relate to the six main lineages as represented in the table
provided below the figure and indicate the dominant lineage(s) in respective countries. Figured sourced from
Gagneux et al. 2006 [8].
1.1.3 Aetiology and pathogenesis
It is important to distinguish active TB disease (primary and reactivation) from a latent TB
infection (LTBI) when discussing aetiology and pathogenesis. Primary disease is the result of
active disease on first exposure to the TB bacillus, whereas reactivation disease occurs when
a LTBI infection becomes an active infection. Re-infection occurs in people who have been
able to eliminate M.tb entirely but are then subsequently exposed and infected at a later stage.
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A latent TB infection is thought to occur when inhaled TB bacilli are engulfed by the host
macrophages but then prevent the fusion of the host macrophage with lysozyme vesicles (highly
acidic and contains proteases). Fusion of these two entities would normally results in a highly
destructive phagolysosome that is capable of eliminating intracellular pathogens effectively -
however this prevented during an LTBI infection. The mechanism of prevention of fusion
amongst these vesicles is poorly understood, and it is thought that the host response maintains
the infected macrophages in a contained, hypoxic environment within a granuloma. In some
cases the host response are capable of eradicating bacilli effectively, however in LTBI or active
disease this is not the case. The M.tb bacilli revert to a low metabolic or dormant state until
such time as the host response in maintaining the granulomatous is disturbed and presents the
M.tb bacilli with a chance to regroup and develop into an active TB infection. This is not the
only way that active disease may be acquired however, as it is possible for active TB to develop
from a infection with TB bacilli.
Figure 1.4: Macrophage phagocytosing M.tb bacilli
This scanning electron micrograph shows the phagocytosis of Mycobacterium tuberculosis bacilli (orange) by the
host macrophage (green) in the lungs. (Scale: White bar = 2 µm.) Sourced from Kaufmann, Stefan H E, Deadly
combination, Nature 453, May (2008) [9].
In a typical TB infection, droplet nuclei containing the infectious M.tb antigens are inhaled into
the lungs from the air where they come to rest in the pulmonary alveoli. The infectious bacilli
stimulate alveolar macrophage toll-like receptors, resulting in cytokine and chemokine release
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become macrophages and engulf bacilli and remain in the lung (Figure 1.4 illustrates a
macrophage phagocytosing M.tb bacilli). Dendritic cells that are also present at the site of
infection, engulf the bacilli and migrate to local draining lymph nodes to activate lymphocytes.
The infected dendritic cells are capable of presenting M.tb antigens from the replicating bacilli
to circulating CD4 lymphocytes using MHC class II proteins on their cell surface, triggering a
cell-mediated adaptive immune response [10]. An initial clonal expansion of the lymphocytes
occurs before migrating to the site of infection. Here the infected phagocytic antigen presenting
cells (APCs) skew the balance of IL-12:IL-4 and results in a Type 1 helper T cell (Th1) response
as opposed to a Type 2 helper T cell (Th2) response. The Th1 response is characterised by the
clonal expansion of CD8+ T-cells and natural killer (NK) cells and an increase in the production
of interferon-gamma (IFN-γ) - an end product of the Th1 response - at the site of infection. The
increased production of IFN-γ activates macrophages to improve their microbicidal activity and
drives the release of chemokines, other pro-inflammatory cytokines and tumour necrosis factor
alpha (TNFα). There is a delay of approximately two weeks after initial exposure before the
cell mediated immune response kicks in as the lymphocytes have to be activated in the lymph
nodes. IL-12 has also been shown to be a growth factor for preactivated T- and NK cells, thus
enhancing the cytotoxic activity of CD8+ T-cells and NK cells, and is important for optimal
differentiation of CD8+ T-cells. Patients who have a strong Th2 response (anti-inflammatory)
to M.tb infections have been shown to have a decreased cell mediated immune response and
subsequently have been more susceptible to TB infection. The balance between the Th1/Th2
response mechanism can be seen in Figure 1.5.
Figure 1.5: The drivers behind a Th1 and Th2 response
The mechanisms behind the balance of the Th1 and Th2 response. Solid lines indicate stimulatory pathways and
dotted lines indicate inhibitory pathways. APC = Antigen presenting cell, Th0 = uncommitted CD4+ T helper cell
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The Th1 response results in the recruitment of a number of different cells that form a granuloma
to contain the infected APCs [12]. The infected macrophages are surrounded by foamy
macrophages and multinucleate Langerhans giant cells [13]. These in turn are surrounded by
CD4 and CD8 lymphocytes as well as B cells. The final layer of an established granuloma
is characterised by collagen producing fibroblasts. If the granuloma fails to contain the M.tb
infected macrophages, it breaks open and releases bacteria that then infect surrounding
macrophages, leading to cavities forming at other locations in the lung and eventually to a
disseminated infection [10]. Damage to lung tissue also results in a persistent cough, providing
the mechanism for transmission of M.tb bacilli through aerosols, thus beginning the cycle again.
For individuals with a latent TB infection, it is thought that lipid vacuoles in macrophages
latently infected with TB bacilli actually provide nutrition for the latent bacilli, as they have
switched their metabolism from carbohydrates (their preferred energy-source) to lipids.
Interestingly, there is some evidence to suggest that accumulation of tri-acyl gycerol lipids in
bacilli in sputum correlates with a more dormant-like phenotype which may conceivably differ
between clinical strains of M.tb and may also link to observed differences in virulence [14].
1.1.4 Diagnosis and testing
It is important to distinguish between LTBI and active infections when discussing diagnosis and
treatment of TB, with latent infection being defined as “the presence of any tuberculous lesion
which fails to produce symptoms of its presence” [15]. The chance of disease progression from
asymptomatic latent TB, to active TB is approximately five to 10% per lifetime and the chance
of acquiring a TB infection from a person who has an active infection is also approximately 10
% per lifetime [16].
The M.tb genome was first sequenced in 1998 [17, 18] but despite this, there have been few
advancements in how active or latent TB is diagnosed in patients. Diagnosis of TB still relies
heavily on techniques that were developed over 100 years ago, the most widely spread method
being the tuberculin skin test (TST) [4]. The TST is often used in conjunction with other more
modern methods, such as chest radiography, sputum smear microscopy or culture from infected
fluids; these techniques are currently the predominant methods used in resource limited settings
for the diagnosis of TB.
Typically the first test done on adult patients suspected of having TB (based on clinical
symptoms and history of exposure) is sputum smear microscopy, with or without a chest x-ray.
The trouble with chest x-rays is that because TB can resemble various other pulmonary
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lung damage which may leave residual signs on x-ray (this requires the presence of a baseline
x-ray in order to compare the new x-ray to, and this is often not available). Children and
HIV+ patients often have a low sputum bacillary load, meaning that they have more false
negative sputum smear microscopy results. The gold standard for diagnosis is a positive culture
result (the material to be cultured is determined by the clinical site of disease, e.g. sputum for
pulmonary TB, ascitic fluid for GIT TB, blood for disseminated TB, etc), although this takes
time.
The main underlying issue with the TST and certain other assays is that they are incapable of
distinguishing latent infection from active disease as their outcome is determined due to the
patient having acquired an immune response to a previous infection that is detectable when
re-challenged with an antigen, thus the outcome is not directly linked to the presence of viable
bacilli. The TST test is also usually reactive in people from high-prevalence areas (because
almost everyone has been exposed to TB in these areas, and therefore their immune systems are
primed by TB antigens), and also in people who have received the Bacillus Calmette–Guérin
(BCG) vaccine. Whilst the last decade has seen the development of newer diagnostic techniques
based primarily on PCR technology, the major obstacles for many of the TB diagnostic tests
currently in use world wide remain the relationship between the sensitivity and the accuracy of
detection of M.tb as well as the cost of the test: some tests are sensitive but can give a high
number of false positives whilst others are not as sensitive and can be prone to false negatives
depending on the stage and duration of infection, see Table 1.1.
Test Exposed Infected Diseased Days to result
X-ray - ± + / ++ 1
TST - + ++ 3
ZN smear microscopy - - ++ 1
Culture methods
Solid media - + ++ 42 - 56
Liquid media (MGIT) - + ++ 3 - 14
Serological tests - + + 2
Urine LAM - ± (HIV+) + 1
ELISpot ± ++ ++ 1 - 2
Quantiferon - ++ +++ 1 - 2
NAAT/PCR (XPERT) ± ± (HIV+) +++ 2
Table 1.1: Array of some TB diagnostic tests currently in use
The table illustrates the potential role of different tests in diagnosis of tuberculosis at different stages of disease.
TST = tuberculin skin test; LAM = lipoarabinomanan; PCR = polymerase chain reaction; -, not helpful; +, helpful;


















Automated liquid culture Quicker to result than solid
culture
ZN smear microscopy Quick, inexpensive and
relatively easy to implement
Urinary LAM ELISA [20] 80.3 99 Higher sensitivity in HIV
co-infected patients
XPERT [21] 80 - 99 98.4 Capable of determining Rif
resistance
Latent TB infections
TST Sensitive to prior BCG
vaccination
IGRAs
QuantiFERON Gold Not sensitive to prior BCG
vaccination
ELISpot.TB 90 23 - 81 Not sensitive to prior BCG
vaccination
Table 1.2: Comparison of sensitivities and specificities of commonly used TB diagnostic tests
1.1.4.1 Tuberculin skin test
The TST, is the diagnostic test still used in many countries today. Tuberculin, or purified protein
derivative (PPD), used for this test is a composition of over 200 antigens crudely purified
from M.tb, M. bovis, the BCG vaccine strain and many other common mycobacteria [22].
A small amount of the PPD is injected into the epidermal layer of the skin, this results in
an inflammatory response, mediated by the recruitment of antigen specific lymphocytes that
is generally exaggerated in patients that have previously been been exposed to any of those
antigens [23]. The difference in the inflammatory response between naive and infected patients
is crudely determined by the size of the indentured ring that forms at the site of the infection.
A positive test result would be a ring of inflammation that has a diameter greater than 10 mm
in width. However, the TST does not distinguish well between active or latent TB infections
(since both have prior exposure to TB antigens) [24], especially where patients are infected with
HIV [25, 26]. Furthermore false positives occur because the purified protein derivative contains
many antigens that are present in BCG and non-pathogenic mycobacteria, and false negatives
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1.1.4.2 Sputum smear staining
The high lipid content in the waxy M.tb cell envelope makes Gram staining very ineffective.
The presence of M.tb in sputum smears is determined using acid-fast staining, otherwise known
as Ziehl-Neelson (ZN) staining. Sputum from infected patients will often identify acid-fast
bacilli (AFB+) as red rods once stained. The limit of detection for acid-fast staining in an active
TB patient sputum sample is between 5,000 - 10,000 bacilli / mL [27].
Figure 1.6: Ziehl-Neelson staining of M.tb
Acid-fast stained M.tb appear red when examined under a normal light microscope. Image obtained courtesy of
Dr George Kubica, CDC [28].
Auramine staining with fluorescence microscopy is also routinely used for sputum smear
microscopy.
1.1.4.3 M.tb culture
Fluids such as blood, serum or sputum can be used in cell culture techniques to detect the
presence of M.tb bacilli within those fluids. The exact methodology differs depending on the
fluid used but the basic concept is similar. The fluids are treated to remove other contaminants
before being placed into culture using specific media. After six to 12 weeks of culture M.tb
bacilli, if present, can be detected using ZN staining or by detecting the release of 14CO2 in
the case of the rapid radiometric culture system [29]. Newer culture techniques based on on
mycobacterial growth in liquid culture (e.g. MGIT) can give quicker results, but can still take
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1.1.4.4 Nucleic acid amplification testing
A relatively new diagnostic tool that has been implemented in the TB field is the use of nucleic
acid amplification testing (NAAT). This technique uses PCR to amplify regions from M.tb
specific genes of cultured patient samples. There are a number of possible targets for the
PCR probes and as such a number of tests are commercially available. The most robust and
automated system is the recently World Health Organisation (WHO) endorsed Gene Xpert
Mtb/Rif test [30, 31], which test is capable of detecting Rifampicin resistant TB infections
whilst concurrently detecting the presence of M.tb.
1.1.4.5 Interferon-γ release assays (IGRAs)
IGRAs make use of in vitro re-stimulation of lymphocytes using M.tb specific antigens such as
early secreted antigenic target 6 KDa protein (ESAT-6) and culture filtrate protein-10 (CFP-10)
[32, 33], both of which represent potent T and B-cell antigens that are secreted by M.tb [34].
Re-exposure to these antigens causes T cells to produce interferon-γ (IFN-γ) which is then
measured using one of the in vitro assays: Enzyme-Linked Immunosorbent Assay (ELISA)
based QuantiFERON-TB Gold; or the Enzyme-Linked Immunospot Assay (ELISpot) based
TSPOT.TB. It should be noted however that these two tests are not inter-changeable as the
former is a whole blood assay and the latter is a PBMC based assay, thus as CD4+ T cells
decline (for example in patients dually infected with HIV) there may be a biased outcome in
terms of a lack of sensitivity of the whole blood based QuantiFERON tests in comparison to the
ELISpot.TB assay [35, 36].
1.1.5 Treatment
There are many M.tb strain types and disease pathology can vary from strain to strain. Since
the 1940s and 50s treatment for an active infection has normally involved a combination of
drugs to increase efficacy and to minimise the rate at which resistance to any single drug
can be acquired. The most frequently recommended and effective combination for a primary
TB infection is isoniazid (INH), rifampicin (Rif), pyrazinamide, and ethambutol for 2 months
(termed the “intensive phase”), followed by isoniazid and rifampicin for 4 months (termed the
“continuation phase”) to theoretically induce complete eradication of all TB bacilli in the body
[37]. Using multiple agents concurrently reduces the chances of selecting for a clone that is
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Name Single letter abbreviation Drug target
Isoniazid H InhA
Rifampicin R DNA-dependent RNA bacterial polymerase
Pyrazinamide Z Accumulation of pyrazinoic acid in bacterium
Ethambutol E Arabinosyl transferase
Table 1.3: First line drugs for TB treatment
The table above represents the first line drugs, and their single letter abbreviations, for treatment of active TB as
well as the putative targets of these drugs in the M.tb organism itself.
A number of factors have combined to cause the emergence and proliferation of multi-drug
resistant (MDR) M.tb strain types, spread across all M.tb lineages, withi in the last decade.
Primary among these factors has been the failure of many patients to complete their full course
(6 months) of treatment and is characterised by many patients stopping treatment once their
symptoms subside despite not having effectively cleared the infectious pathogen from their
systems leading to acquired resistance over a period of time in the remaining bacilli. To
combat this the World Health Organisation (WHO) has implemented the “Directly Observed
Treatment, Short course” (DOTS) which is comprised of 5 key areas. These are: 1) government
commitment to control TB, 2) diagnosis based on sputum-smear microscopy tests done on
patients who actively report TB symptoms, 3) direct observation short-course chemotherapy
treatments, 4) a definite supply of drugs, 5) standardized reporting and recording of cases and
treatment outcomes.
1.1.5.1 Multi-drug resistant TB (MDR-TB)
MDR-TB strains are defined as resistant to at least INH or Rif [38–40]. Effective treatment of
MDR-TB requires prior drug susceptibility testing (DST) in order to determine the appropriate
second line drug combinations to use. The incidence of MDR-TB in South Africa has been
estimated to be 1.8 % of new cases of TB and 6.7 % of re-treatment TB cases according to the
Global Tuberculosis Control: WHO report 2011 [4], although the incidence has been proven
to increase drastically, when patients are co-infected with HIV, with some studies indicating an
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Drug class Examples Drug target
Aminoglycosides Amikacin




Enviomycin / Tuberactinomycin N
Fluoroquinolones Ciprofloxacin





Table 1.4: Classes of second line drugs for TB treatment
This is not an exhaustive list but represents the main drug classes that are used in the treatment of MDR-TB [42].
A suspected MDR-TB patient will typically start on a course of treatment consisting of a
combination of streptomycin, INH, Rif, ethambutol, pyrazinamide, moxifloxacin and
cycloserine pending the result of a DST. Once the DST result has been received and the nature of
the resistance is known an appropriate combination of five drugs should be used for a treatment
course lasting 18 months.
Drug class or name Example or additional information







4-Aminosalicylic acid Otherwise known as PAS
Macrolide Clarithromycin
Linezolid -




Table 1.5: List of drugs for MDR-TB treatment
The order in which the five drugs for the treatment of the case specific MDR-TB strains should be chosen is in
descending order from top to bottom (based on known DST sensitivities). The isolate should also be confirmed as
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Interestingly most MDR-TB strains in South Africa appear to be derived from the Western
Beijing strain [44]. Furthermore, it is thought that Rif mono-resistance in clinical isolates is
a driver in the development of MDR-TB. The molecular basis of these observations however
remains unknown.
1.1.5.2 Extensively drug resistant TB (XDR-TB)
Extensively drug-resistant tuberculosis is a TB isolate resistant to INH and Rif plus any
fluoroquinolone and at least one of the three injectable second-line drugs (e.g. capreomycin,
kanamycin, or amikacin) [45, 46]. The incidence of XDR-TB in Kwa-Zulu Natal, South Africa
has been shown to be as high as 5 % [41]. Treatment of XDR-TB is similar in nature MDR-TB,
allowing for the additional resistance in choice of second line drug cocktails, but it becomes
exceptionally costly since the second line drugs are far more expensive. The treatment regime is
normally two years long and can often lead to other complications such as hepatitis, depression
and hallucinations due to the cytotoxicity of the chemotherapy. For both MDR- and XDR-TB
the mortality rate is high despite optimal treatment regimes.
1.1.5.3 Totally drug resistant TB (TDR-TB)
Alarmingly, there is recent evidence to suggest the emergence of TDR-TB strains [47, 48].
Infection with these strains can not be effectively treated or brought under control using any of
the current drugs available.
1.1.5.4 Isoniazid preventative therapy
There is an increase in the support for placing HIV+ patients, who do not have active TB,
on isoniazid preventive therapy (IPT) due to the high risk of tuberculosis infection that these
patients are subject to [49, 50] as well as the evidence that there is a 32 % decrease in the
incidence of active TB cases in patients infected with HIV who receive IPT [51]. IPT
monotherapy is administered to HIV+ patients for six to nine months, thus reducing the
reactivation of latent M.tb infections and preventing a LTBI from propagating into an active
disease state. There are two important factors to consider with regards to IPT. The first is the
incidence of TB for the location in which the patient resides as initiating IPT in a high burden
setting is likely to quicken the spread of drug resistance in the long run, but this risk is not as
prevalent in low TB incidence settings [52, 53]. The second is that the benefit of IPT is only
significant for patients who are TST positive (0.5 mm) and with a risk ratio of 0.38 compared
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1.2 HIV/AIDS
Human Immunodeficiency Virus (HIV) is a Lentivirus (lenti meaning “slow” in Latin), from the
Retroviridae family [54]. Most lentiviruses have characteristically long periods of incubation
in their hosts and normally do not cause immediate fatality of the host. There are two HIV
subtypes, namely HIV-1 (the more wide spread and genetically diverse strain) and HIV-2 (largely
restricted to West Africa and not nearly as genetically diverse) [55]. The virus itself is roughly
spherical and approximately 120 nm in diameter. It contains 2 copies of positive single stranded
genomic RNA (ssRNA), that code for 9 genes. These 9 genes encode for the all the proteins
(approximately 20 in total depending on the strain type) that HIV is capable of producing [56],
a summary of the proteins can be seen in Table 1.6. Retrovirus replication within a host cell is
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Table 1.6: List of HIV (poly)proteins, functions and locations
The list of HIV proteins, as well as the polyproteins, including brief description of the protein function and it’s
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Figure 1.7: Human Immunodeficiency Virus
A simplified diagram of the HIV-1 virion [57].
1.2.1 Background
HIV is the causative agent of acquired immunodeficiency syndrome (AIDS) [58]. The first
clinically observed AIDS patients appeared in the early 1980s on the East coast of the United
States of America [59–63]. However the first literature to appear linking HIV and AIDS was
published concurrently in 1983 by two separate research groups in the same issue of the journal
Science [64, 65].
1.2.2 Distribution and burden of disease
Currently there are an estimated 33.3 million people globally who are infected with HIV, with
sub-Saharan Africa being the worst affected. The estimated prevalence of HIV infections in
sub-Saharan Africa is 22.5 million. Despite the global incidence of new HIV infections peaking
at 3.2 million per annum in the late 90’s there were still an estimated 2.6 million people who
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Figure 1.8: Estimated global prevalence of HIV in 2009
Figure 1.8 is the estimated prevalence as a percentage of HIV infected adults, between the ages of 15 and 49, per
country in 2009 [66].
The number of HIV related deaths has decreased from it’s peak in 2004 of an estimated 2.1
million deaths to the 2009 estimate of 1.8 million deaths (1.3 million in sub-Saharan Africa).
This decrease is presumably due to the increase in the availability and distribution of ARVs
globally. South Africa has one of the highest burdens of disease, in terms of absolute numbers,
as well as one of the highest prevalence rates for HIV in the world, with approximately 10%
of the adult population (5.6 million) infected with HIV [66]. In some informal settlements in
South Africa, (e.g. Kayalitsha, Cape Town) the HIV prevalence is > 33 %.
1.2.3 Viral life cycle
1.2.3.1 Viral entry
The HI virus infects cells of the immune system, most notably CD4+ T cells, macrophages and
dendritic cells. Viral entry into these cells is set in motion when the virion surface glycoprotein,
GP120, binds to the cellular host cell receptor CD4. It is thought that this initial binding
causes a conformational change in the GP120 protein allowing for binding to additional cellular
chemokine receptors - generally either CXCR4 or CCR5. This more stable two pronged
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Repeat sequences of GP41, HR1 and HR2 proteins interact, driving formation of a hairpin
structure by collapsing the extracellular portion of the GP41 molecule. The resultant loop
structure brings the virus and cell membranes together allowing them to fuse easily and the
viral capsid to enter the cell [67, 68].
Figure 1.9: HIV life cycle
The simplistic life cycle of HIV from viral entry to reverse transcription, integration, production and budding.
Source Wikimedia Commons [69].
Interestingly, a small percentage of the human population have a 32-bp deletion in the gene
coding for the CCR5 receptor. Individuals with a homozygous deletion on both alleles for the
gene have a fairly stringent resistance to HIV-1 viral entry into CD4 cells [70].
1.2.3.2 Viral Transcription
After gaining entry into the host cell, the positive single stranded genomic RNA is transcribed
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viral reverse transcriptase has ribonuclease activity (degrading the viral RNA) as well as DNA-
dependent DNA polymerase activity. The sense cDNA strand is then copied into an anti-sense
strand by the viral reverse transcriptase and the two strands combine to form a viral genomic
DNA sequence. This viral DNA sequence is integrated into the host genome by the viral
protein integrase [71], as depicted in the simplified graphic in Figure 1.9. The integrated DNA
effectively becomes a pro-virus. The integrated viral DNA can lie dormant in the host genome
until specific cellular transcription factors are present, most notably NF-κB [72]. The presence
of these factors normally corresponds to the activation of the host T-cell response, normally due
to an infection; thus cells actively fighting infections become machines for producing the virus
they are carrying.
1.2.3.3 Viral Replication
Within an activated host cell, the integrated DNA pro-virus is transcribed into mRNA which is
spliced into smaller pieces. The smaller pieces are transported to the cytoplasm where they are
translated into the viral proteins Tat and Rev. The Tat protein encourages new virus production
and the Rev protein accumulates in the nucleus and binds to viral mRNAs. The Rev-bound
mRNAs leave the nucleus unspliced. These full length mRNA sequences produce the Gag
and Env viral proteins. The Gag protein binds to the full length RNA (viral genome) and
incorporates the complex into new viral particles [73].
1.2.3.4 Virion assembly and budding
New HIV-1 virions are assembled using the cleaved products of the Env polyprotein (GP160).
GP160 is cleaved by protease into two units that are processed in the Golgi complex to form
the envelope proteins GP41 and GP120. The envelope proteins are then transported to the host
cell plasma membrane. The GP41 protein anchors the GP120 protein to the membrane, after
which the Gag (p55) and Gag-Pol (P160) polyproteins follow suit, bringing the HIV genomic
RNA along with them. The virion that forms begins to bud from the host cell. Maturation of
the virion is achieved once HIV proteases cleave all the viral polyproteins into functional HIV
proteins and enzymes which then assemble. This cleavage induced assembly can occur either
during the formation of the virion bud that is still part of the host cell or once the immature
virion has budded off from the cell. Once mature, the virus particles are capable of infecting
other cells and perpetuating the life cycle of the virus itself. Figure 1.10 below is a scanning
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Figure 1.10: Virion budding
A scanning electron micrograph of HIV-1 budding (in green) from cultured lymphocytes. The multiple round
bumps on cell surface represent sites of assembly and budding of virions. This image has been adapted from the
original black and white picture by adding colour to highlight important features [74].
1.2.4 Transmission and pathogenesis
The HI virus is transmitted via body fluids from an infected person to an uninfected person. Post
infection, the newly infected person undergoes a period of rapid viral replication. During this
time there is a decline in the number of circulating CD4+ T cells and a concomitant increase in
the activation of CD8+ T cells. During the acute phase of infection the circulating CD8+ T cells
contain and even suppress the HIV viral load, inducing a rebound in the number of circulating
CD4+ T cells [31].
The strong immune response that clears the viral load marks the start of the chronic stage of
infection. This stage of the infection can vary greatly in length but is characterised by increased
quantities of viral load in the lymph nodes. This could be attributed to the reservoir of virus that
becomes prevalent in the follicular dendritic cells, which trap the virus and which reside close
to the lymph nodes [75].
Although the population of activated CD4+ T cells is reduced by HIV infection, there remains
a relatively high number of IFN-γ secreting CD4+ T cells, resulting in a bias towards one
functional population of CD4+ T cells during an infection [76].
1.2.5 Treatment
Currently there are a number of different drugs that can be used to treat HIV positive individuals.











1 Immunology Literature Review
using combinations of anti-retrovirals (ARVs). The three main classes of ARVs are Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside/Nucleotide Reverse
Transcriptase Inhibitors (NRTIs), and Protease Inhibitors (PIs).
NRTIs are analogues of naturally occurring deoxynucleotides required for the formation of
DNA strands. This class of drugs causes chain termination when the single stranded viral
RNA is converted into dsDNA during the process of reverse transcription. This is achieved
by virtue of the fact that DNA synthesis and elongation requires a free 3’-hydroxyl group on
the deoxyribose moiety; during DNA strand formation the next incoming nucleotide forms a
phosphodiester bond with this hydroxyl group in the 5’ – 3’ direction and without this 3’-
hydroxyl group chain elongation can not occur. NRTIs lack this hydroxyl group and as such
prevent further DNA strand synthesis or elongation. NRTIs are classed as competitive inhibitor
drugs because they compete with host nucleotides for incorporation into the dsDNA molecules
that the virus attempts to synthesize using its reverse transcriptase enzyme.
NNRTIs directly interfere with the viral reverse transcriptase protein itself by binding to the
protein and inhibiting the movement of its domains. This class of drugs is classed as non-
competitive inhibitors because they do not compete with substrate molecules (dNTPs) during
catalysis.
Protease inhibitors (PI) prevent the progression o HIV infection by inhibiting the HIV-1 protease
enzyme. This enzyme is responsible for the cleaving of nascent viral proteins for incorporation
into new virion particles.
Highly active anti-retroviral therapy (HAART) involves using a combination of three ARVs.
1.2.5.1 Guidelines
HAART is not capable of realistically curing a patient infected with HIV or completely
removing all virus particles from an infected host (projections estimate this would take as long
as 60 years). The drugs used for treatment are cytotoxic, especially during prolonged exposure,
and their side effects cannot be ignored. In light of this there is debate over the CD4 threshold
at which a patient should initiate HAART. However patients with a low threshold CD4 count,
200 cells / mm3 or less (350 cells / mm3for pregnant women or children), should begin HAART
immediately. This threshold should ideally be set at 350 cells / mm3 for all groups to initiate
HAART, however it is a massive expense.
In 2009 Dr Gero Hutter and colleagues successfully reduced the quantity of HIV in a previously
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was treated for this condition using a bone marrow transplant that had a homozygous deletion of
the CCR5 gene [77]. That patient stopped ART after the transplant and has not had to start again
since biopsies of tissue throughout his body have not yielded detectable HIV levels and his HIV
anti-body titre continues to drop as time progresses. Although this isolated case has presented
an interesting opportunity, there are a number of factors preventing it from being implemented
universally, e.g. the complexity and high cost of the treatment, the risk of acquiring graft
versus host disease, the difficulty in obtaining bone marrow for all HLA types that have the
homozygous deletion of the CCR5 are some of the many reasons that this can not be considered
a realistic option as a widely applicable cure for HIV infection.
1.2.6 Complications during HIV infection
HIV weakens the immune system by infecting and subsequently depleting CD4 lymphocytes
and helper T cells. Thus providing the platform for an opportunistic infection (OI), such as an
active TB infection, to manifest. The compromised immune system is incapable of effectively
containing inhaled M.tb bacilli in granulomas, and infection can lead to rapid progression to
disease symptoms [78, 79]. HIV infection can also lead to reactivation of a LTBI. Under
normal circumstances, a healthy person has approximately a 10% risk of developing an active
TB infection during their lifetime. This risk increases drastically to approximately 7 - 10 % per
year for people who are infected with HIV [80, 81], with the risk of TB reactivation rising as the
CD4 cell count drops [82–84]. The effective combination of these two converging pandemics
has caused TB to become the leading cause of death in HIV infected individuals, with South
Africa alone reporting an incidence of 134 deaths per 100 000 population from TB among HIV+
people in 2006 [85]. The synergistic effect of these two pathogens is of greater concern when
considering that in South Africa in 2009 the incidence of new TB cases was approximately 1 %
[4] of the population and of these more than 50 % were dually infected with HIV [4]. Today, as
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Figure 1.11: Prevalence of HIV in new TB cases
Estimated prevalence of HIV in new TB cases globally. The estimates are based on percentage of prevalence.
Image sourced from the WHO [4].
HAART has been shown to play an effective role in preventing the development of active TB in
HIV+ patients, reducing the incidence of TB by up to 90% in patients receiving HAART when
compared to those not receiving anti-retroviral drugs [80, 86, 87]. It appears however, that
despite viral suppression with HAART, the risk of TB remains higher in HIV-infected persons
than in HIV-uninfected persons, suggesting incomplete or a dysregulated immune restoration
post HAART treatment [88]. The timing of HAART initiation needs to be considered carefully
in terms of the risk factors for each patient, since premature therapy can lead to the onset of
TB associated immune reconstitution inflammatory syndrome (IRIS), whilst delayed therapy
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1.3 Immune reconstitution inflammatory syndrome
(IRIS)
1.3.1 Background
IRIS has previously been referred to by numerous other names and acronyms such as immune
restoration disease (IRD) [89], immune reconstitution disease, or immune reconstitution
syndrome (IRS) [90–93]. It is possible for IRIS to be associated with a number of pathogens, of
either a viral (cytomegalovirus, hepatitis B, herpes simplex and herpes zoster), fungal
(cryptococcal meningitis and Pneumocystis jirovecii) or bacterial (M.tb, M. xenopi, M. kansasii,
M. avium complex) nature [92, 94, 95]. The central and defining prerequisite for IRIS though,
is that patients experience a relative immune defect that is then corrected whilst concurrently
being infected with another pathogen. Most often this occurs in patients infected with HIV
and who have initiated HAART, resulting in a severe inflammatory response to the infectious
pathogen by the recovered, but apparently now dysregulated, immune system. However, by far
the most commonly associated IRIS pathogen is M.tb and further references to or discussion of
the IRIS condition hereafter will be to tuberculosis associated IRIS (TB-IRIS) unless otherwise
stated.
Initially TB-IRIS was described as being the onset of a severe inflammatory response or
“paradoxical worsening” of clinical symptoms in patients dually infected with TB and HIV,
who had recently begun HAART - normally within the previous two weeks to one year. As
the incidence of TB-IRIS increased however it became apparent that TB-IRIS had different and
distinct forms. In 2006 at a conference in Kampala, Uganda, approximately 100 researchers
from various fields around the world, debated and decided upon a standardised set of case
definitions for TB-IRIS. These definitions are now used in both resource limited and resource
rich settings alike, the aim behind standardising the definitions being to enable further insight
into incidence rates, clinical symptoms and risk factors, as well as to make further research
in this field more readily comparable [96]. The importance of having simple and practical
case definitions for resource limited countries can not be overstated since these countries are
generally afflicted with the highest incidences of both HIV and TB and yet in most cases do not
have access to the same equipment and technologies to use when identifying cases of TB-IRIS.
Within TB-IRIS there are three case definitions that have been developed for the following
clinically relevant and distinct TB-IRIS forms, namely:
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2. ART-associated tuberculosis (develop a new TB infection post HAART initiation)
3. Unmasking tuberculosis-associated-IRIS (uncover a TB infection post HAART initiation)
The fundamental difference between “paradoxical TB-IRIS” and the other two forms of TB-
IRIS is that they will have already been diagnosed with a TB infection prior to initiation of
HAART. Whereas, patients from groups two and three will not have been diagnosed with TB
before initiation of HAART but develop TB after the initiation HAART. The differential in the
latter two groups, “ART-associated TB” and “unmasked TB-IRIS”, is that patients from the
former group develop TB from a new infection whereas patients from the latter group develop
TB from a latent TB or sub-clinical TB infection.
1.3.2 Incidence and risk
The reported incidence of TB-IRIS has varied greatly, from anywhere below 10 % to above 40
%, across a broad range of locations and cohort sizes [97–107]. A recent meta-analysis was
performed on data in the literature to determine the general incidence and mortality of TB-IRIS
in relation to the degree of immunodeficiency [108], with the degree of immunodeficiency being
determined by CD4 cell count. Based on this meta-analysis TB-IRIS develops globally in 15.7
% of patients dually infected with HIV and TB, with the mortality rate estimated to be 3.2
% [108]. Recent figures show that the prevalence of HIV co-infection in people with TB
in South Africa is approximately 70 % [109] and the incidence of paradoxical TB-IRIS has
been estimated to be approximately 20 % although different studies have found varied results
regarding the precise incidence rate.
Some of the risk factors that have been identified so far for the development of TB-IRIS include:
1) disseminated and extrapulmonary tuberculosis [101, 104, 106]; 2) a shorter delay between the
start of tuberculosis treatment and initiation of ART [107]; 3) a more vigorous immunological
and virological response to ART [101]; and 4) more advanced HIV disease with lower CD4 cell
count [103, 105].
CD4 counts (cells / µL) Incidence Rates (%) [105] Incidence Rates (%)[107]
< 50 63 36
>50 34 24
Table 1.7: Table of incidence rates of TB-IRIS stratified by CD4 counts
The table represents the incidence of TB-IRIS for patients within the first 30 days HAART initiation in studies
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In one study by Lawn et al. in South Africa, 12% of TB patients developed IRIS. However,
the proportion of those who developed TB-IRIS was much higher (32%) among the subset
who initiated ART in the first 2 months of TB treatment [105]. In an adjusted analysis, early
initiation of ART (in the first month of TB treatment) was associated with a 70-fold higher risk
of developing TB-IRIS when compared against patients who had a delayed initiation of ART
(after at least 3 months of TB treatment). A separate study from the United States determined a
rate of 15 % in a prospective cohort, but there was considerable morbidity and a frequent need
for interventions. This study also highlighted the increased risk that is posed for early initiation
of ARV treatment post TB treatment, with 69 % (75 / 109) of patients who registered an IRIS
event having initiated HAART within 3 months of TB treatment [106].
1.3.3 Treatment challenges
1.3.3.1 HAART initiation
The treatment of both TB and HIV poses a number of challenges, of which perhaps the most
important factor is the timing of the initiation of HAART relative to TB treatment. Patients with
a low CD4 count and who could potentially undergo a rapid rise in their CD4 count post HAART
as their viral load decreases are at an increased risk of developing TB-IRIS. The underlying
mechanism associated to this increased risk factor are not entirely clear and may be due to
the increased likelihood of disseminated TB as a result of a low CD4 count, or it could be
indicative of the extent of an increased immune response related to the immune re-activation
[102, 110–112]. However these patients do not have a strong enough immune system to afford
an extensive delay in initiation of HAART to allow their TB treatment to clear the burden of TB
antigen. Delaying HAART until after they have completed their TB treatment also has risks that
must be considered, as the early initiation of HAART for HIV-infected patients has been shown
to reduce the risk of AIDS progression as well as maintain a more effective immune system for
a longer period [113].
Due to concerns that even brief delays in HAART initiation might lead to substantial increases
in mortality in HIV-TB patients [114], a number of clinical trials have been conducted in an
attempt to determine the best time point at which to initiate HAART. For example, Karim et
al. conducted a three branch open label, randomized controlled trial through a large clinic
Durban, South Africa. The three branches of this treatment study were: 1) sequential initiation
of HAART treatment subsequent to completion of TB treatment; 2) early integration of HAART
within four weeks of starting TB treatment; and 3) late integration of HAART four weeks after
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as the integrated treatment branches had a significant, 56 %, combined decline in mortality in
comparison, strongly suggesting integrated therapy would be better but this still does not fully
answer the question of when is the best time to initiate HAART.
Figure 1.12: Kaplan–Meier survival curves for integrated and sequential HAART therapy
Image obtained from Abdool Karim et al. [115].
A separate open label, randomized control study performed in Cambodia by Blanc et al. has
provided further insight in this regard. This trial involved 2 arms, an early arm where patients
initiated HAART two weeks after starting their anti-TB treatment, and a late arm where patients
initiated HAART eight weeks after starting their anti-TB treatment. The preliminary report from
this trial indicated that mortality in the early arm was a significant 34 % lower than mortality in
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Figure 1.13: Kaplan–Meier survival estimates according to study group
Image obtained from Blanc et al. [117].
The findings of these trials as well as a number of other prospective trials suggest that early
initiation of HAART would yield the best outcome in terms of mortality for patients co-infected
with TB and HIV. WHO guidelines thus currently suggest initiation of HAART within two to
eight weeks of starting anti-TB treatment for patients with a CD4 count of less than 200 cells
/ mm3 [118], thereby effectively committing circa 20 % of HIV-TB patients on average to
develop TB-IRIS and requiring concomitant management of those TB-IRIS patients.
1.3.3.2 Corticosteroid treatment
Prednisone - a broad spectrum immune suppressant - has been administered to TB-IRIS patients
in an attempt to reduce the often severe inflammatory response that such patients produce if they
initiate HAART too early. After anecdotal results appeared to favour this treatment regime it
was decided to test this in a proper trial setting. The recent double blinded, randomized, placebo
control study was performed by Meintjes et al. to test the effectiveness of prednisone therapy
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occurring more often in the prednisone arm than the placebo arm for the trail, there was no
difference in the incidence of severe infections. However, treatment with prednisone was found
to “reduce the need for hospitalization and therapeutic procedures and hastened improvements
in symptoms, performance, and quality of life” [119]. An important point to take note of is that
prednisone helps to suppress the symptoms of IRIS but it does not treat the underlying cause.
The most important factor to consider when treating paradoxical TB-IRIS in this manner, is that
infection with drug resistant TB must be ruled out as well as any other causes of deterioration
in the patient’s health before administering corticosteroids [119].
Primary outcomes Placebo Arm
(n = 55)
Prednisone
Arm (n = 55)
P value
Karnofsky performance score
(wk 2, n = 92)
70 [50 - 90] 90 [80 -90] <0.01
Karnofsky performance score
(wk 4, n = 86)
80 [60 - 90] 90 [80 - 100] <0.01












Infections while on study
medication
17 [31%] 27 [49%] 0.05
Median hospital days 3 [0 - 9] 0 [0 - 3] 0.04
Severe infections 2 4 0.4
Table 1.8: Primary outcomes of prednisone vs placebo treatment
Values shown are medians (interquartile range) or numbers (%). ART, antiretroviral therapy; MOS, Medical
Outcomes Study. Adapted from Meintjes et al [120].
1.3.4 Potential mechanisms of disease progression
The underlying mechanism of action in TB-IRIS disease progression is poorly understood.
There are a number of theories that have been put forward on the possible mechanism behind
disease aetiology and natural history but these are complicated by the fact that symptoms
of TB-IRIS do not develop at a consistent period of time post HAART initiation. Instead,
symptoms may develop anywhere from within the first week or two post HAART initiation up
to a year after commencing HAART, indicating that there could be a number of mechanisms
involved in its development, including inter alia:
Innate response. Research on the immunopathological mechanism has revealed that the innate
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but no clear mechanism has yet been elucidated in this regard;
Adaptive T-cell mediated immunity. TB-IRIS has also been shown to be associated with
a heightened Th1 response [122, 123], resulting in an increase in the number of circulating
IFN-γ producing T cells and the restoration of delayed type hypersensitivity (DTH) responses
to mycobacterial antigens [124, 125]. The regulation of the Th1 response is maintained by
circulating Treg cells and whilst the numbers of circulating Treg cells for both TB-IRIS and
HIV/TB co-infected patients who are on HAART and who do not develop TB-IRIS (otherwise
referred to as “TBART” patients) are similar, the strength of the response is unbalanced in the
case of TB-IRIS patients, perhaps suggesting that Treg function as opposed to the absolute
number of Treg cells may underpin the dysregulation. HAART has been shown to restore
the host granulomatous response to mycobacteria in HIV infected individuals [126–129], but
the rapid rate at which this occurs and perhaps a lack of compensating immunoregulatory
mechanisms may lead to the uncontrolled tissue-damaging responses that is a defining
characteristic of TB-IRIS [92].
Another suggested mechanism could lie in a dysregulation of the Type 17 helper T cell (Th17)
response: tissue suppuration of lymph nodes or other affected organs may occur in some
TB-IRIS patients and, although the underlying immunopathology remains unclear, it may be
indicative of a Th17 mediated immune response. Whilst both Th1 and Th17 responses tend
to induce inflammation, the Th17 response is mediated by neutrophils [130, 131] and the Th1
response is mediated by macrophages;
Host genetic factors. It is also conceivable that host genetics may play a role in the underlying
mechanism of the development of TB-IRIS, with individual patients having a genetic
predisposition to the development of TB-IRIS [90, 132]. It is plausible for example that
polymorphisms in cytoki e genes may influence the rate of clearance of opportunistic pathogens
or, alternately may cause dysregulation of the inflammatory response. The association of such
polymorphisms with the development of TB-IRIS has been described for a number of associated
organisms [132], but if there is a connection to an underlying mechanism it still needs to
be elucidated. the association between certain polymorphisms in various cytokines and the
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Figure 1.14: IRIS is associated with polymorphisms in the TNF-α , IL12B and IL6 genes
Results are presented as the percentage of individuals carrying the alleles shown. A| n = 100 HIV-negative controls.
B| Significantly different from patients with no IRD (Fisher’s exact test, P, 0.05). C| Significantly different from
HIV- negative controls (Fishers exact test, P, 0.05) [132].
1.4 Aims of thesis
Immune responses to M.tb differ in vivo between TB-IRIS and control patients (dually infected
with HIV and TB but do not develop IRIS symptoms, herewith referred to as TBART patients).
This thesis describes proteomic research aimed at determining the molecular basis of these
differences using an in vitro model of TB-IRIS, based on the use of cultured peripheral blood
mononuclear cells (PBMCs) isolated from TB-IRIS and TBART patients, the goals being to:
1. Identify a potential protein biomarker for the IRIS condition
2. Provide the basis for a better understanding of the molecular origin of TB-IRIS
3. Serve as the basis for development of more targeted suppression of TB-IRIS.
As discussed earlier in this Chapter, it is possible that the mechanism that causes TB-IRIS
could be due to a combination of innate immunity, adaptive T-cell mediated immunity and
host genetic factors [133]. Consequently, the choice of sample with which to perform this
study is important. Notably, the sites of TB infection in patients dually infected with TB and
HIV are often extra-pulmonary and as such it is likely that the circulating lymphocytes will
have been exposed to a number of TB specific antigens. Obtaining ethical clearance for tissue
biopsies of sites of infection is extremely difficult and provides it’s own unique difficulties
when the issue of control samples is raised. Thus, the choice of using PBMCs which represent
a well defined system that has fewer variables when compared with other easily obtainable
samples (such as plasma) is an attractive one. Some may argue that sorting PBMCs into
sub-populations would be a better approach in attempting to identify the differing immune
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responses however it would be worthwhile to first establish what the differences for these
two groups are utilising PBMCs before undertaking the vastly more technical and exhaustive
approach of analysing where exactly these differences in signalling are generated. To date,
analysis of the mechanism of TB-IRIS has been of a strictly immunological nature and it
remains possible that further studies involving more diverse techniques could offer greater
insight. Transcriptomic analysis may reveal differential patterns in mRNA expression pertaining
to a number of
interesting mechanisms however it has been well established that the correlation between mRNA
levels and protein levels in a system is poor. Likewise, an epigenetic analysis would highlight
those patients with different risk thresholds for developing TB-IRIS but would not ultimately
result in a point of care diagnostic test. A more complete description of the differences between
TB-IRIS and TBART patients at the protein level would extend our understanding beyond
just the usual cytokines that have been previously studied to a more complete underlying set
of proteins that are expressed. This would require using techniques that lie in the field of
proteomics.
Proteomics is the large-scale study of proteins in a biological system during specific biological
events [134]. Proteomic methodologies have been used to study a number of biological systems
ranging in complexity from simple prokaryotes to complex organisms such as Homo sapiens.
Discovery of disease-associated biomarkers or mechanisms of drug action are problems that
can, in principle, be solved by modern mass-spectrometry-based proteomics since it is now
possible to measure changes in expression levels of thousands of discrete proteins in a given
biological system in response to, for example, bacterial challenge or drug perturbation. When
considering the properties of what constitutes a good candidate biomarker the following three
fundamental properties should be kept in mind: 1) it should be present in an easily accessible
source material (e.g. blood, saliva, urine etc.), 2) it should be easy to detect and quantify in
a robust and affordable manner, 3) it should be specifically associated with a disease state or













Proteomics has often been considered to be complementary to genomics or transcriptomics.
However, proteomics research immediately encounters far greater difficulties that arise due
to the fact that the complement of proteins expressed in any given sample has a far higher
complexity and dynamic range and, moreover, different proteins typically do not share common
physical or chemical properties or functions [136]. The sheer scale of protein variability can
be estimated when considering that the human genome consisting of approximately 20 000
genes could produce up to 100 0000 proteins through differential splicing. Additionally, many
proteins undergo dynamic post-translational modification (PTM) which further adds to the
complexity of the target proteome, potentially producing millions of different proteins [137,
138]. Compounding this sheer complexity, protein quantities expressed in biological systems
have been shown to have up to 12 orders of magnitude in difference of expression levels within












Figure 2.1: Plasma protein dynamic range
Abundance for 70 protein analytes in plasma is plotted on a log scale spanning 12 orders of magnitude. The
classical plasma proteins are clustered to the left (high abundance), the tissue leakage markers (e.g. enzymes and
troponins) are clustered in the center, and cytokines are clustered to the right (low abundance). Hemoglobin is
included (far left) for comparison. Sourced from Anderson et al. 2002 [139]
Classically, the main techniques used for protein identification, such as western blotting or
Edman degradation, were based on the isolation and characterisation of single proteins. The
advent of Laemmli gels and, later, of 2D PAGE allowed for a broader, though still relatively
crude, analysis of protein profiles to occur. However, the inherent low resolving power of 2D
gels, coupled with the limiting sensitivity and poor gel-to-gel reproducibility has meant that
2D PAGE based technologies (including 2D DIGE) have increasingly been overtaken in recent
years by direct liquid chromatography-mass spectrometry based approaches to high throughput
protein identification and quantification. Thus, as technology has improved in general, and
mass spectrometry (MS) instrumentation in particular, the study of proteins has gone from the
study of an isolated protein or pathway to that of a global proteome within a biological system.
MS has thus had a massive impact on making the field of proteomics a dynamic and rapidly
evolving field of science.
2.2 Basics
A successful proteomics experiment requires an understanding of a number of intricacies, from












the experimental pipeline there are a number of considerations and choices to be made and
identifying the best approach, technique or piece of equipment to use often comes from an
understanding of the strengths and weaknesses of each of these choices and how they relate to
the fundamental experimental question that is being investigated.
2.2.1 Theory
The basic workflow that underpins any proteomic experiment can be broadly identified as
follows: the generation or isolation of sample in a preparation step; the analysis of the sample
using an appropriate mass spectrometer; and finally the output from the mass spectrometer is
used in combination with search algorithms and databases to identify particular proteins.
Figure 2.2: Basic proteomic workflow
Sample preparation is a broad topic of discussion and would be better served through specific
analysis of the literature for protocols that have already been successfully identified for the
sample concerned, a broad review of this topic will therefore not be given here. In order to
perform mass spectrometric analysis of a sample, the sample must be ionised before being
subjected to analysis within the mass spectrometer. Finally, mass spectra that are produced are
then used to identify the compounds (either whole proteins, peptides, proteolytic peptides or













Mass spectrometers have 3 basic components, namely: an ionisation source, a mass analyser
and a ion detector. There are several types of mass analyser that are currently in use today, each
with specific strengths and weaknesses. There are two main types of ionisation source that are
regularly used in proteomics to ionise the analytes.
2.2.2.1 Ion sources
Proteins and peptides have varying degrees of polarity, are non-volatile and are thermally
unstable molecules that require an ionisation technique that transfers them into the gas phase
(without extensive degradation) for further analysis using a mass analyser. There are two
sources of ionisation for molecules that are to be analysed by mass spectrometry. The first
is based on the sample being in a solid form and is known as matrix-assisted laser desorption/
ionisation (MALDI) ionisation [140–144]. Briefly, the MALDI matrix absorbs laser energy and
transfers it to the acidified analyte that it encapsulates, the rapid laser heating causes desorption
of the matrix and [M+H]+ ions of analyte into the gas phase. The second ionisation technique
that is regularly used is electrospray ionisation (ESI) [145]. ESI produces ions from a solution
and the process is driven by high voltage (normally between 2 – 6 kilo volts) that is applied
across the emitter at the end of the separation pipeline of the liquid chromatography (LC)
instrument and the inlet of the mass spectrometer. This produces an electrically charged spray,
known as a Taylor cone [146], that is followed by formation and desolvation of analyte-solvent
droplets into a gas phase. Both sources produce ions that are then accelerated through
an electric field before entering into the mass analyser. Interestingly, both Koichi Tanaka
(MALDI ionisation of biological macromolecules) and John Fenn (ESI ionisation of biological
macromolecules) received the Nobel Prize for Chemistry in 2002 - demonstrating the massive
impact these technologies have had in the field of mass spectrometry.
2.2.2.2 Mass analysers
Mass analysers are the heart of any mass spectrometer and separate molecular ions based on
their mass-to-charge (m/z) ratios. In addition, some analysers are capable of storing ions for
short periods based on their m/z ratios. Analysers make use of either electrical or magnetic
fields, or a combination of both, to move and select the ions from the source to the detector. As
the motion and separation of ions is based on electrical and/or magnetic fields, the m/z ratio, and












ions from colliding with neutral gas atoms whilst travelling through the analyser, thus providing
a clean environment and allowing the ions to reach the detector with a sufficient yield [147].
Mass spectrometers tend to be named based on the mass analyser they contain and there are
a number of different models that are commonly used in the proteomic field. Ion trap (IT)
and Orbitrap mass analysers separate ions based on their m/z radio frequency, quadrupoles (Q)
use m/z stability, and time-of-flight (ToF) analysers use flight time through an evacuated tube
[147]. Each mass analyser has unique properties, such as mass resolution, scanning speed, mass












Figure 2.3: Popular mass analysers
The top most images depict two of the most common ion sources, ESI (top left) and MALDI (top right). Below that
from A to F are schematics some of the more popularly distributed mass analysers and describes the movement of
ionised molecules through them. A = a ToF-ToF instrument with a collision cell incorporated between the two ToF
sections. Ions of a specific mass-to-charge (m/z) ratio are selected in the first ToF section and fragmented in the
collision cell, after which the masses of the fragments are separated in the second ToF section. B = a quadrupole
mass spectrometer, these machines select ions in the first quadrupole (Q1) by varying electric fields as a function
of time between four parallel rods, allowing a stable trajectory for ions of a desired m/z ratio. These ions are then
fragmented in a collision cell (q2) and the fragments are separated again in Q3. C = a Q-ToF mass analyser that has
a quadrupole coupled to a ToF. The quadrupole allows highly sensitive selection of ions before they are fragmented
in a collision cell and their fragment products are analysed by the ToF. D = a three-dimensional ion trap which
captures ions using resonance of electric field frequencies (similar to how the Q3 functions in a triple quadrupole)
which are subsequently scanned out creating tandem mass spectra. E = the orbitrap has two traps, of which the
linear ion trap performs an initial scan of the m/z ratio of the ions before they undergo collision and their fragments
are collected by the C-trap and then analysed by the orbitrap mass analyser (F) which identifies ions based on their
cyclical trajectory in an electric field that is applied between two electrodes. Adapted from [148–150].
Depending on the combination of the different components used, a mass spectrometer can have
a broad dynamic range, or high sensitivity, a high resolving power (resolution) or any of a
number of other attributes. A basic comparison of some common mass spectrometers can be
seen in Table 2.1. It is technically difficult to build a mass spectrometer that has all these
attributes as the complexity of the physics that would be involved is prohibitive.
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Analyser Resolving power Mass Accuracy Sensitivity Dynamic Range
ToF-ToF 20 000 5 - 10 ppm Attomole 104
Q-ToF 60 000 5 - 10 ppm Attomole 106
Orbitrap 150 000 2 - 5 ppm Femtomole 104
Table 2.1: Comparison of characteristics of common mass spectrometers
Relative comparison of the resolution, mass accuracy, sensitivity, and dynamic range of the most popular
instrument used in proteomic studies[147, 150].
The best mass spectrometers for specific applications will be discussed later in this review in
connection to the experimental functions they are to perform.
2.2.2.3 Detectors
The most ubiquitous part of any mass spectrometer is the detector which, generally speaking,
does not differ greatly between the various mass spectrometers currently on the market. The
majority of mass spectrometers use an analogue ion detector, but there are a few exceptions that
use a digital ion detector.
2.2.3 Software and algorithms
In proteomic experiments, a significant number of protein matches are incorrect due to a high
rate of false positives. One reason for this is that a peptide mass does not uniquely define its
sequence and a peptide sequence may not uniquely define a protein. Results from search engines
should therefore be interpreted carefully in order to understand strengths and weaknesses of
different search algorithms not least because the scoring functions of these engines are based
on a number different algorithms.
Identifying proteins from a collection of tandem mass spectra involves assigning spectra to
peptides, using either a de novo or database search strategy, and then inferring the protein set
from the resulting collection of peptide-spectrum matches (PSMs). The peptide sequences in
the database are generated by an in silico digest of the appropriate protein sample set according
to the known cleavage pattern for the protease that was used for the in vitro digest. The
normal experimental goal is to identify as many distinct proteins as possible at a specified
false discovery rate (FDR). The majority of shotgun proteomic experiments to date have been













Most companies provide proprietary software for the analysis of mass spectra and identification
of proteins from the data that the machine generates. Some of the more popular software suites
include Protein Pilot (ABSciex), Spectrum Mill and MassHunter (Agilent), MASCOT (Matrix
Science) and SEQUEST amongst many others. There have also been a significant number
of open source software packages that have been developed for proteomic applications, most
prominent amongst these being the Trans-Proteomic Pipeline (TPP).
2.2.3.1 Spectral matching
The spectral matching approach is based on algorithms that correlate experimental MS/MS
spectra with theoretical spectra and count the number of peaks common to two spectra (“shared
peak count”). Common search algorithms include SEQUEST, Spectrum Mill or X!Tandem
[158]. Crux is an open source program that re-implements and extends the database search
algorithm SEQUEST. However, Crux is quicker and returns a higher number of correct
identifications than SEQUEST by using a peptide indexing scheme to rapidly retrieve candidate
peptides for a given spectrum and then generating shuffled decoy peptides “on the fly” for each
peptide in the target database. This approach ensures that each decoy peptide exhibits precisely
the same amino acid composition and total mass as the corresponding target peptide [159].
Consequently, this provides a good null model and an accurate means of estimating the FDR
[159]. The FDR is a measure of the percentage of PSMs that have been incorrectly accepted as
true.













Another approach is the use of a probabilistic algorithm that provides information about the
probability that a particular peptide sequence produced the spectrum being analysed by chance.
Popular probability based search algorithm engines are MASCOT, Andromeda and Peptide
Prophet. The MASCOT algorithm itself is based on the probability that a match is a random
event and is essentially evaluated using a MOWSE score. By adding the size of the database,
an objective score is created, demonstrating the significance of a given hit [158].
2.2.3.3 Database filtering using sequence tags
A third approach makes use of sequence tags and database filtering. One algorithm that performs
this function is InsPecT [160], which uses peptide sequence tags as efficient filters to reduce the
size of the database by a few orders of magnitude while retaining the correct peptide with very
high probability. In addition to filtering, InsPecT also uses novel algorithms for scoring and
validating in the presence of modifications.
2.3 Databases
There are a number of protein sequence databases that are currently available to the scientific
community. However, the vast majority of proteomics experiments make use of either the
UniProt Knowledge Base (UnitProtKB) or the International Protein Index (IPI) databases -
although the latter is quickly becoming obsolete due to the decision to stop updating IPI from
late 2010. Both databases have extensive repositories of protein sequences although they do
have subtle differences, the main difference being the level of annotation and curation for the
UniProtKB database whereas the IPI database is essentially a meta-database formed from a
number of other databases.
2.3.1 UniProtKB
The UniProtKB (http://www.uniprot.org) actually consists of 3 databases, namely the
SwissProt, TrEMBL and PIR databases. The SwissProt database in particular is highly curated
and has a high degree of annotation, containing data on protein sequences and associated












species-dependent databases and within these there are subsets of the databases that allow for
variables such as redundancy in the form of splice variants or isoforms as well as non-redundant
database where one gene equals one protein: these 2 different databases are referred to as the
Homo sapiens Reference Global Proteome and SwissProt Organism 9606 databases respectively.
The Organism 9606 database contains protein sequences for only human proteins and excludes
human like proteins that occur in other organisms, this database has approximately 20 000
proteins. The Reference Global Proteome database also contains only human proteins but
allows for splice variants as well. This database contains approximately 100 000 proteins.
2.3.2 International Protein Index (IPI)
The IPI database (http://www.ebi.ac.uk/IPI) is a meta-database composed of a
combination of other databases (including UniProtKB, Ensembl, RefSeq, HinvDB, and VEGA).
IPI uses a complex algorithm to minimize sequence overlap while maintaining comprehensive
proteome coverage for a given organism [161]. This database allows for splice variants as well,
but curation of the database was recently terminated, thus new protein sequences will not be
updated. This database contains close to 100 000 proteins.
2.4 Shotgun Proteomics
There are a number of strategies that can be employed to analyse proteins using mass
spectrometry. The choice of which strategy to use is best informed by the biological question
that is being investigated. Figure 2.5 provides a basic graphical overview of the different












Figure 2.5: Overview of proteomic approaches
Each proteomics approach has an inherent advantage or potential disadvantage that should be
considered prior to deciding which approach to use. Figure 2.6 describes a basic outline of













Figure 2.6: Comparison of proteomic approaches
The fundamental differences in top-down (right hand side) and bottom up (left hand side) proteomic approaches.
LC = liquid chromatography, 2D = two-dimensional, PTM ID = Identification of post-translational modifications.
2.4.1 Protein-centric approaches (gel based)
The protein centric approaches are all based on identifying proteins from a sample using
enzymatic digestion of the proteins and subsequent analysis of their proteolytic fragments and
are often referred to as being a top-down approach. This technique was first published in the
early 90’s [162, 163], however the term used to describe the method, peptide mass fingerprinting
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Figure 2.7: Peptide mass fingerprinting (PMF)
The most commonly used enzyme is trypsin however other there are a number of other enzymes
that can be used such as chymotrypsin or endonuclease-Lys C. Trypsin is a well characterised
protease that cleaves proteins on the C-terminus side of lysine and arginine residues, provided
they are not followed by a proline, thus generating peptides that have a free N-terminal amine.
This predictable cleavage pattern is integrated into subsequent data processing by generating in
silico peptide fragments of each theoretically possible protein within the parameters of a given
database.
The resultant proteolytic peptide fragment spectra of each digested protein can then be used to
identify experimentally observed proteins by comparing the peptide-spectral-matches (PSMs)
with the proteolytic peptides associated to an in silico digestion of the proteins. This was
one of the earliest proteomic techniques that was widely employed and many of the PMF
approaches rely on gel based separation of proteins, reviewed later in this Chapter, prior to
enzymatic digestion. As mass spectrometers have evolved so to has the manner in which PSMs
are determined, this term is now more commonly associated with MS/MS fragment data.
2.4.2 Peptide-centric approaches (gel free)
There are a number of peptide-centric approaches employed in proteomics and they are normally
referred to as being a bottom up approach as they rely on the identification of proteins based on
the fragmentation of their proteolytic peptides using MS/MS.
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Protein identification using peptide-centric approaches is heavily reliant on having a database
that exists whereby in silico enzymatic digestions of the proteins can be performed providing
a reference set of spectra against which the experimentally observed MS/MS spectra can be
analysed and peptides can be identified using PSM.
2.4.2.1 MS/MS
This approach has been further developed as mass spectrometers have developed the capacity
for tandem MS analysis, providing a second dimension MS analysis of fragment ions. Peptide
fragment fingerprinting (PFF) [147, 165, 166] is the analysis of proteolytic peptides that are
scanned in the first MS dimension after which, selected precursor ions are then subjected to
fragmentation and their subsequent fragment ions are then analysed in the second MS dimension.
This approach significantly increases sample complexity as each protein is digested into a
number proteolytic peptides, of which a selection are then fragmented further during MS/MS.
However most mass spectrometers can not perform scans on precursor ions and their subsequent
fragmented ion products concurrently (with a few exceptions, such as an LTQ Orbitrap) and thus
the machine cycles between MS and MS/MS scans - this is often referred to as the duty cycle or
cycle rate of a mass spectrometer. Accurate MS scans are often used to provide quantitative data
on precursor proteolytic peptide ions and MS/MS scans are used to confidently identify those
ions. In order to increase the number of proteolytic peptides, and consequently their parent
proteins, identified using MS/MS it has emerged that fractionation strategies are integral. One
of the early strategies in this regard was the multi-dimensional protein identification technology
(MudPIT)[167].
2.4.2.2 Peptide fragmentation strategies
As discussed in the previous sub-section, tandem mass spectrometry allows for specific parent
ion species to be selected and fragmented and their subsequent ion fragments are then analysed
in a second dimension. There are a number of possible techniques that can be employed to
fragment the precursor ions.
The most broadly implemented approach is known as collision induced dissociation (CID).
This approach involves accelerating the selected precursor ions through a collision chamber
that is filled with an inert gas (normally nitrogen). The accelerated peptides collide with the
inert gas molecules and fragment into component ion species. These component ion species (or












ions produced by CID for peptides are b and y ion series. CID is the major fragmentation
approach employed in mass spectrometers but is not the only approach employed for proteomic
studies.
Figure 2.8: Roepstorff Nomenclature Scheme
Illustration of fragment ions formed from the backbone cleavage of protonated peptides. Fragment ions retaining
the positive charge on the amino (N) terminus are termed a, b, or c type ions. Fragment ions retaining the positive
charge on the carboxy (C) terminus are termed x, y, or z type ions. Adapted from Mikesh et al. 2006 [168].
Electron transfer dissociation (ETD) [169] provides an orthogonal alternative to CID for
fragmentation analysis of peptide ion species [168] [170]. ETD forms unstable radical ions by
using anions, commonly fluoranthene ions, to transfer electrons to the analyte that then fragment
at sites that are the weakest bonds in the molecular structure. The resultant fragment ions
produced are predominantly c and z ions from the parent peptides [169]. These radical-based
fragmentations are very useful and powerful in the analysis of labile post-translational
modifications, where sites of modification can be determined on peptides bearing modifications
that are highly labile under CID conditions [171].
2.4.2.3 LC-MS/MS
In-line fractionation of proteolytic peptides using a liquid chromatography system that is
coupled directly to the mass spectrometer (for ESI) or to a robotic spotter (for MALDI) form
the basis for LC-MS/MS. As previously alluded to, MudPIT describes one of these in-line
fractionation techniques. Essentially MudPIT is underpinned by a two dimensional orthogonal
fractionation of peptides before analysis using a mass spectrometer. In the original experiment












cerevisiae sample were solubilised and injected into an HPLC system coupled to a mass
spectrometer. The peptide solution was separated by strong cation exchange in the first
dimension and then subsequently by reverse phase in the second dimension before being
analysed by MS/MS. Since then a number of methodologies have been developed to perform
two dimensional orthogonal fractionation of peptides before subsequent MS/MS analysis. Not
all of these methodologies are in-line, indeed some are off-line (the fractionation is performed
on systems not directly connected to the mass spectrometer or spotter - a good example would be
any of the gel based methods described earlier), however there are many different combinations
of fractionation techniques and this will be discussed shortly hereafter.
2.4.2.4 De novo sequencing
In situations where a database does not exist or is incomplete/insufficient, it is possible to
employ a different strategy in the bottom up approach whereby peptides undergo PFF and the
subsequent ion fragments can be used to determine an amino acid sequence, in a similar manner
to how Edman degradation works, by piecing together the component amino acid sequence
within a given MS/MS spectrum. The amino acid sequence can then be used to perform a
classical BLAST search to identify the protein that it belongs to. This strategy is referred to as
de novo sequencing [172, 173].
The one constant that unites these three main forms of protein identification is the effect high
mass accuracy mass spectrometers on the ability of algorithms to increase the number of proteins
that are identified with a high confidence [174]. Higher mass accuracy machines have improved
mass spectra resolution massively, contributing to the ability of algorithms to identify potential
peptides and proteins. Another key development in improving the number of proteins that are
routinely identified in modern shotgun proteomic experiments is sample fractionation.
Simplifying complex samples has lead to a greater total number of ionised peptides as well












Figure 2.9: Protein identification using de novo sequencing
2.4.3 Fractionation strategies
A number of methods have been developed to try and delve deeper into the proteomes of
complex samples. The uniting characteristic behind all these strategies is that they all involve
fractionating a complex proteomic sample into a number of less complex fractions that can be
run on a mass spectrometer without subsequently overburdening the capacity of the detector
of the machine during any one experimental run. When deciding which method to use for
fractionating a complex sample there are a number of key performance metrics that must be
considered, namely: resolving power, orthogonality, and sample loss.
2.4.3.1 SDS PAGE
One of the first popular methods for identifying proteins using mass spectrometry involved
separating the protein or proteins using sodium dodecyl sulfate (SDS) polyacrylamide gel
electrophoresis (PAGE) also often referred to as one-dimensional electrophoresis (1DE). SDS
PAGE is one of the simpler forms of fractionation that can be performed on a complex protein
sample as it does not require expensive equipment or extensive training and has been in existence
for a long time [175]. SDS PAGE separation of proteins is based on size exclusion as they
migrate through a gel-like matrix when placed in an electric field. The sample protein mixture is
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incubated in a buffer containing SDS and reducing agent, normally β -
mercaptoethanol or dithiothreitol (DTT), to reduce any disulphide bonds. The reduced and
denatured proteins bind SDS, a polar negatively charged molecule, causing the negatively
unfolded proteins to migrate through an electric field. This fractionation technique is good for
removing most buffer contaminants (the notable exception being guanidinium as it precipitates
on contact with SDS) that would be incompatible with mass spectrometry and provides a robust
manner in which to prepare complex protein samples whilst at the same time removing any
incompatible buffer components. In the earlier days of proteomics this was a popular technique
as stained SDS PAGE gels provided a means to visualise target bands of interest that could be
excised and digested into proteolytic fragments, often using trypsin, for subsequent analysis
using MALDI-ToF MS.
There are a few draw backs for this fractionation technique, chief amongst them being the
limited resolving power in terms of separation of SDS PAGE, this technique is only effective
for relatively simple protein mixtures or for pure proteins. Over and above the low resolving
power of SDS PAGE, the quantity of protein required for visualisation using staining means that
only high abundance proteins will be identified, making analysis of different gels inconsistent
and difficult. It is also only applicable for whole intact proteins - it can not be used to separate
out tryptic peptides effectively as they are too similar in size and would not separate with any
great resolution before running off the bottom of the gel. Another issue to consider is the
potentially variable nature of peptide extraction from gel slices which could have a serious
effect on downstream label free quantification applications, however this can be negated (to a
degree) through the use of a standardised protocol and loading comparable amounts of protein
onto the SDS PAGE gels to begin with. SDS PAGE is highly orthogonal to other fractionation
strategies as it is based on molecule size, however this technique does have a lower resolving












Figure 2.10: SDS PAGE gel (1DE PAGE)
An example of a typical SDS PAGE gel stained with colloidal Coomassie Blue.
2.4.3.2 2D PAGE
In an attempt to improve the resolving power of the fractionation strategy (SDS PAGE)
employed in early proteomics, two-dimensional (2D) PAGE, also referred to as 2D
electrophoresis (2DE), was used to allow for a two dimensional orthogonal separation of a
protein mixture. In this technique, a sample is loaded onto an iso-electric focusing strip that
separates/fractionates the proteins based on their iso-electric focusing point. The strip containing
the separated proteins is then placed along the top of a PAGE gel, thus separating the proteins
as if they were in a normal SDS PAGE gel in the second dimension. This two-step resolution
allowed for the analysis of more complex samples, however there were still many issues that
prevented this technique from being widely regarded as the best technique for proteomics.
Chief amongst these is the difficulty associated with reproducing quality 2D PAGE gels as
well as the inherent variation that occurs between any two gels making reliable analysis of
differences in protein spots problematic. A number of software spot picking algorithms were
developed to normalise gel images before robotic spot pickers excise spots of interest however
these advancements still have limitations.
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Figure 2.11: 2D PAGE gel (2DE PAGE)
An example of a typical 2D PAGE gel, in this case two gels have been overlaid (left) and then manipulated using
software to align the spots better (right).
2.4.3.3 DIGE
In order to overcome these limitations as well as poor gel to gel reproducibility and to therefore
improve the analysis of different samples using 2D PAGE, differential gel electrophoresis
(DIGE) was developed [176] and has since been referred to as 2D DIGE. In this technique,
the protein samples were labelled with different fluorescent dye probes before being combined
and run on a single gel - thus eliminating the need to analyse different samples on different
2D PAGE gels using normalisation software to help align spots on different gels. With the
cysteine-modifying DIGE labels a large quantity of a sample proteome may be visualised using
as little as micrograms of starting material [177, 178]. Initially only Cy3 (red) and Cy5 (yellow)
dyes were used, however a third dye - Cy2 (blue) - was also later introduced meaning that an
internal standard could be run as well to provide quantitative information. It is worthwhile
noting that the actual colours of these dyes differ between their physical appearance when
compared to the colour that they appear to be when they fluoresce. This ability to multiplex
samples, albeit in a limited capacity, resulted in 2D DIGE becoming a widely accepted and
utilised tool in proteomics at the time. However the relatively low dynamic range of proteins
that are visually identifiable using this technique means that analysis of low-abundance proteins
using PMF is not possible as these proteins are often not present in large enough quantities. The
relatively high cost of the reagents has also helped to hamper the spread of this technology in
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Figure 2.12: 2D DIGE gels
2.4.3.4 Ion Exchange Chromatography
Ion exchange chromatography relies on using a stationary phase (containing a charged
functional group attached to the packing resin) and a polar aqueous mobile phase. The stationary
phase forms ionic bonds with solute molecules, thus cationic columns (negatively charged) bind
positively charged solute molecules and anionic columns (positively charged) bind negatively
charged solute molecules. For this reason, the two forms of ion exchange chromatography are
often referred to as strong cation exchange (SCX) or strong anion exchange (SAX)
chromatography depending on the charge of the stationary phase that is being used. Anion
exchange chromatography can also be performed, often by using the diethylaminoethyl (DEAE)
functional group, and is known as weak anion exchange (WAX) . No matter the type of ion
exchange utilised, the concept remains the same. Once the solute molecules have been bound
they are stripped off the column through competitive binding using a similarly charged polar
molecule in the mobile phase. Thus in cation exchange bound molecules are often released
by increasing the Na+, or some other positively charged molecule, concentration in the mobile
phase and likewise a negatively charged molecule is used to competitively release solute












are prone to becoming insoluble in the presence of high salt concentrations, thus this
fractionation strategy is often employed at the peptide level and not the protein level and due
to it’s downstream issues with mass spectrometry it is often used as the primary step in a
two step fractionation strategy. Mass spectrometers do not tolerate high salt concentrations
as the charged salts tend to ionise far more easily than bigger molecules such as peptides or
proteins, and cause suppression these other molecules when ionisation occurs in the gaseous
phase. A desalting step is required to clean up samples that have been fractionated using ion
exchange chromatography. The strength of this technique lies in the resolving power of ion
chromatography especially as it is highly orthogonal to reverse phase chromatography when it
comes to separating molecules, the drawback of this technique is that it normally has a relatively
high percentage of sample loss.
2.4.3.5 Reverse phase chromatography
Reverse phase (RP) chromatography makes use of a hydrophobic stationary phase (normally
a long chain hydrocarbon attached to a resin) and an organic aqueous/mobile phase. Solute
molecules, such as peptides, adsorb the hydrophobic matrix when in a polar solvent; as the
solvent buffer increases in hydrophobicity, the peptides dissociate from the matrix at the point
at which the interaction of the peptides with the solvent is more favourable than the interaction
of the peptides with the stationary phase. The polar state of the mobile phase can be achieved
using either an acid (such as formic acid) to create a low pH, or a base (such as tri-ethyl
amine, or TEA) to create a high pH. Amino acids contain an amino group (-NH2), a carboxyl
group (-COOH) and in most cases, an R-group (except glycine) attached to the α-carbon.
The R-groups of the amino acids have distinct chemical properties and these properties play
a role in the formation of the chemical micro environment of the peptides that they belong to.
The pKa (the negative log of the dissociation constant, Ka) of the amino (~ pH 9 - 10) and
carboxy groups (~ pH 1.8 - 2.4) are relatively constant across most amino acids, however the
R-groups vary greatly, from ~ pH 4 for the acidic amino acids (aspartic and glutamic acid)
all the way up to ~ pH 13 for the polar, hydrophilic amino acids serine and threonine. As
these functionally different polar environments occur at distinctly different pH’s they result in
the overall polar environment for each peptide to be resolved differently under either a low
pH (for conventional RP chromatography) or a high pH (for high pH RP chromatography).
Consequently, it is possible to obtain two orthogonal means of separation on most peptide or
protein species using a crude high pH RP fractionation step (involving specific quantities of
organic solvent polarised using TEA to create the fractions) followed by the more conventional
acidic pH RP LC fractionation, once the samples have been dried down to remove the original













Figure 2.13: Reverse phase chromatography
Reverse phase chromatography separates molecules based on their hydrophobicity. Hydrophobic molecules adsorb
to the hydrophobic column resin in the presence of a hydrophilic solute and gradually are stripped off the column
resin as the hydrophobicity of the mobile phase increases. At the bottom of the figure is a breakdown of the
chemical profiles of the various amino acids.
Where reverse phase chromatography has a more polar stationary phase compared to the mobile
phase, there is another popular type of chromatography where the mobile phase is more polar
than the stationary phase. This type of chromatography is referred to as hydrophilic interaction
liquid chromatography (HILIC) [179]. This chromatography has number of uses but has been












2.4.3.6 Affinity based chromatography
Due to the broad dynamic range of proteins in most complex biological samples it is conceivable
that a depletion or enrichment step for a particular subset of proteins within that sample would
be an attractive strategy. These techniques could be non-specific (for example, using
precipitation [181, 182]), or targeted in nature (phytate-based rubisco depletion [183], antibody
depletion of albumins [184, 185]). The concept behind these techniques is to either remove
highly abundant proteins so that low abundant proteins will now fall within the dynamic range
of analysis for the mass spectrometer, or to remove the proteins of interest for subsequent
analysis by MS (this is often performed in phosphoproteomics [186–190]). Phosphoproteomics
is focused on the identification and quantification of phosphorylated proteins as well as their
phosphorylation sites (serine, threonine or tyrosine) [148, 191], and it is a field of proteomics
that has seen a large amount of interest develop over the past decade. A common strategy for
enrichment of phospho-serine or phospho-threonine based peptides or proteins is the use of
affinity based chromatography techniques such as immobilized metal affinity chromatography
(IMAC), metal oxide affinity chromatography (MOAC) and strong cation-exchange
chromatography which have been shown to be complementary in nature [192].
IMAC makes use of fixed metal chelators with positively charged co-ordination sites that
interact with the negatively charged groups of the phosphates and carboxylate moieties of the
proteins or peptides of interest. The buffer pH will affect the specificity of the IMAC resin for
phosphopeptides and proteins. IMAC phospho-enrichment can be used at the protein or peptide
level [193–196] following strong cation exchange chromatography. MOAC however does not
require a charging step as the metal ions are part of a solid bead instead of being linked to the
chromatographic support. Consequently, materials such as titanium dioxide (TiO2) are used
widely for the enrichment of phosphopeptides [187, 197, 198]. A further level of control can be
exerted using MOAC by using 2,5-dihydroxybenzoic acid (DHB) and aliphatic hydroxyl acids
to increase the selectivity of TiO2 for phosphopeptides [199, 200].
The analysis of phosphotyrosine based proteins or peptides is performed almost exclusively
using immunoaffinity purification where antibodies that have been raised against specific motifs
are used to enrich these residues from protein or peptide extracts [201–203].
There is a fourth approach that is neither depletion or enrichment specific, the ProteoMiner
approach, which differs slightly in that it attempts to equalize protein populations by depleting
high abundance proteins whilst concurrently enriching low abundance proteins using a diverse
library of hexapeptides bound to chromatographic supports [182, 204]. It is worthwhile noting
that despite manufacturers best attempts, these techniques are not always absolute in their












That is not to say that these techniques should not be used, but the consequences of using these
techniques should be fully understood before a decision is made.
2.4.3.7 Off-gel (iso-electric focussing)
Off-gel fractionation is based on iso-electric focusing. This technique can be performed on
either proteins or peptides. Samples are loaded onto a pH focusing strip along with ampholytes
to maintain the buffering of the system and then placed in an electric field. Sample separation
occurs as a result of the samples having a charge at any pH other than their specific iso-electric
point (pI). The charged samples migrate along the strip in the direction of the pH gradient at
which they no longer have a charge and therefore are unaffected by the electric current. As each
protein or peptide sample has a relatively unique pI, whose range in any particular sample can
be quite broad, it is theoretically possible to fractionate the samples quite well. However, the
degree of fractionation is not extremely high due to limitations in being able to have a large
number of compartments in the off-gel strip and as a result this technique should be used as a
primary fractionation step of a complex sample. Off-gel fractionation is not as compatible with
sample preparation buffers as SDS PAGE is. The final fractions are left in a buffer with a high
salt content and need to be de-salted before any further analysis can be performed on them,
whether it is another fractionation step or analysis on a mass spectrometer.
2.4.3.8 Sub-cellular fractionation
There has been some interesting research into using novel fractionation strategies during the
protein extraction process itself. The advantages behind these techniques is the inherent sub-
cellular localisation information that can be associated with the protein fractions. Of the
multitude of publications in this field, two in particular stand out for the simplicity of the
concepts that they utilise: the first employs a sequential removal of proteins in layers from
the cell itself using a combination of detergents to gradually gain access to the various cellular
compartments [205]; the second makes use of density gradient centrifugation to separate sub-
cellular compounds and vesicles apart into distinct fractions [206].
In the crude sub-cellular fractionation method (CSF), three to four fractions are generated
consisting of 1) the cytosolic protein fraction, 2) the membranous organelles protein fraction,
3) the nuclear membrane protein fraction and 4) the insoluble proteins fraction. It is possible
to combine fraction three and four during the extraction protocol to obtain three fractions in
total. This technique uses different enzymes and detergents to sequentially remove the fractions












pellet in the subsequent buffer. The advantage of this technique is a crude protein fractionation
that also will provide sub-cellular localisation information. However, crossover of proteins does
still occur across fractions and the reproducibility across differing cell types may be difficult
to keep consistent. This approach may provide an excellent way to remove large subsets of
proteins and in doing so shift the dynamic range of the remaining proteins to make another
subset more easily visible - for instance removing the cytosolic proteins, and the consequent
high abundance proteins contained therein, before analysing the nuclear protein subset.
The density gradient centrifugation is slightly more complex but has the added advantage of
providing quantitative information using isotopic mass tags. This approach, known as the
localisation of organelle proteins by isotope tagging (LOPIT), provides spatial information on
identified proteins based on the density of the organelle or protein complex that the proteins
are isolated from during a density gradient centrifugation step. This approach has been shown
to increase the resolution and coverage of identified proteins when compared to other methods
[207], as well as providing an adequate average snapshot of cells in Drosophila melanogaster
[208]. The method relies heavily on developing density gradient organelle maps and an
integrated bio-informatic approach and may require more resources than are available for every
proteomics researcher. However the technique does provide a means of fractionating at the












Figure 2.14: LOPIT organelle fractionation
The LOPIT approach allows for sub-cellular localisation and quantitative information to be extracted for proteins
that are identified by MS/MS. In this example proteins from four fractions corresponding to different gradient
fractions on a self generating iodixanol gradient are digested with trypsin before being labelled with separate
iTRAQ labels and subsequently pooled. The pooled samples are then analysed using MS/MS where relative
differences in quantitation across the four fractions are determined using the reporter element ions (114 - 117) that
are detected. Proteins with a similar localisation on membranes will co-fractionate generating similar quantitation
profiles, likewise it is possible to determine proteins are located amongst organelles of different densities [206].
2.4.4 Middle-out approach
The middle out approach lies somewhere between a protein-centric and a peptide-centric
approach and is characterised by a crude primary fractionation of the sample at the protein
level. The proteins in each of these fractions are then digested and the subsequent proteolytic
peptides are subjected to a more thorough fractionation. The advantages of this mixed approach
mean that highly abundant proteins can be restricted to certain subsets of fractions allowing for
less abundant proteins to be identified. The peptide fractionation still provides a high degree
of sample coverage allowing for the identification of a higher number of total proteins. The














There are a few protein fractionation strategies that are currently employed. The most common
either employ IEF (using the off-gel technique), size exclusion (using 1D PAGE) or use
biological localisation as part of the fractionation strategy (such as in crude sub-cellular
fractionation). Ideally the choice of which protein fractionation technique to use should be
decided based on the type, quantity and source of sample that is being worked upon. Samples
that are difficult to re-solubilise may not combine well with the off-gel fractionator compared
to 1D PAGE. Likewise, if the experimental question that is being considered is closely linked
to cellular localisation of a protein then sub-cellular fractionation may be a more rewarding
starting point that either IEF or 1D PAGE. Ideally the initial protein fractionation should not
be exhaustive as this will exponentially increase the experimental cost as well as machine run
time.
2.4.4.2 Peptide fractionation
The subsequent peptide fractionation strategy could be either a one- or two-step separation and
this choice should be made after considering sample quantity, machine runtime and
experimental cost. It is also worth considering that the higher the number of processing steps
prior to MS/MS the greater the risk for sample loss or contamination. Peptides by their nature
are more robust and soluble and thus should be able to withstand a broader variety of solubility
constraints. It is also pertinent to use a peptide fractionation strategy that is orthogonal to the
protein fractionation strategy.
The ultimate goal of the any shotgun proteomic work flow is to maximise protein coverage
by maximising the number of identifiable peptides. This is achieved through a well thought
out fractionation strategy that will reduce sample complexity during MS/MS. When designing
a shotgun proteomic experiment it is thus important to consider the level of complexity of
the sample, the quantity of sample available to work with and the cost of access to adequate
resources (both financially and in terms of time) before deciding on a final work flow. There is
no one-size fits all strategy and it is important to understand the repercussions of choices that
are made regarding the design of the experiment and the subsequent handling of the sample













2.5.1 Absolute and relative quantitation
Absolute quantitation strategies compare the quantities of individual peptides identified in a
sample against the quantity of a labelled reference standard that has been spiked into the sample.
The reference peptide(s) (usually a synthetic peptide) act as a known absolute value against
which the sample peptides can be compared and their concentration back-calculated to an initial
concentration via a standard curve.
Relative quantitation strategies compare the quantities of individual peptides identified in one
sample with the quantities the same peptides in a separate sample or against other peptides
within the same sample, however at no stage is the comparison normalised to a reference mass
peptide that has been spiked into the sample. This strategy can be employed by using tags or
labels, where a reference sample can be compared against an experimentally altered sample, or
through label-free approaches, where the mass spectra are used to directly determine peptide
abundance in one sample relative to another.
Labelling strategies are crucial for absolute quantitation, whereas relative quantitation can be
performed using labelling or by label free methods. Both techniques have a number of possible
strategies that can be employed.
2.5.2 Labelling strategies
Current label-based proteomic experiments generally employ a number of types of labelling
strategy. The methods vary from integrating labels (either metabolically, chemically or
enzymatically) to isotopic addition of an appropriate label.
2.5.2.1 Metabolically integrated labels
A powerful approach that has emerged in the last decade, employs differential stable isotope
labelling by amino acids in cell culture (SILAC) [209]. This method commonly entails culturing
cells in a medium that contains a stable isotopic form of arginine and lysine (e.g. arginine
bearing six 13C atoms) although there are other amino acids that may be utilised instead.
Consequently, the “heavy” amino acid is incorporated into proteins during cell growth and












produces a “light” set of proteins. SILAC allows “light” and “heavy” proteomes to be
distinguished by MS while avoiding any chemical derivatisation during sample preparation.
Arginine and lysine are used as the distinguishing amino acid as they are guaranteed to form
part of all tryptic peptide fragments. Each peptide comprising a single lysine or arginine,
providing there are no missed cleavages. The method allows for comparative analysis of
proteome perturbations across two different culturing conditions. And furthermore allows the
two cultures to be combined prior to any fractionation. The limiting factor for this strategy is
that it requires cell culture for the label to be integrated and it can only be applied across a few
different conditions and as such is not applicable for experiments that need to be multiplexed
across a high number of conditions.
Figure 2.15: Comparison of stable isotope labelling workflows
The left hand column (A) is an example of a SILAC workflow where proteins are labelled metabolically by
culturing cells in isotopically enriched media (for example, containing 15 N salts, or C-labelled amino acids).
The resulting mass difference that is generated for peptide pairs using this method is variable as it depends on the
amino acid composition. The middle column (B) is an example of an isotope-coded affinity tag (ICAT) workflow,
where proteins are labelled at specific sites with isotopically encoded reagents. This method will generate a mass
difference that is one or multiple times the difference in mass of the encoded reagent that was used. The right
hand column (C) describes a typical enzyme based incorporation of an isotope label workflow whereby isotopic
labelling is introduced using enzyme catalysis that incorporates 18O during proteolysis in 18O enriched water. The
mass difference that is generated by this method is either 4 Da or 2 Da and can make subsequent bio-informatic












2.5.2.2 Chemically added isotopic labels
Isotopic labelling typically involves the attachment of chemical tags that have different isotopic
masses but identical structures to the reactive side chains of amino acids. Gygi et al. developed
the isotope-coded affinity tag (ICAT) approach [210], whereby cysteine residues are specifically
derivatised with a reagent containing either zero or eight deuterium atoms as well as a biotin
group for affinity purification of cystein-derivatised peptides and subsequent MS analysis.
Several variations on this chemical reagent class have since emerged to improve aspects such
as recovery of labelled peptides or chromatographic properties [211–214]. A popular method
that involves the use of cheaper reagents to incorporate a stable isotope dimethyl label has also
been developed [215].
2.5.2.3 Enzymatic
It is possible to introduce a mass shift using serine proteases to catalyse the introduction two 18O
atoms into the carboxyl terminal of peptides in mixtures. Introducing labelled oxygen during the
hydrolysis of proteins was reported more than 25 years ago and the ability of trypsin (and other
serine proteases) to rebind the proteolytic peptides and introduce a second 18O atom through
micro-reverseability was reported in the mid 90s [216, 217]. This is a two-step procedure
that requires proteins to be cleaved initially, before drying down the subsequent peptides. The
dried peptides must then be incubated with trypsin in 18O-enriched water for the label to be
incorporated. This is a global labelling strategy and allows for comparison of two samples
prepared in parallel against each other - similar to how a typical SILAC work flow would be
performed[218, 219].
2.5.2.4 Isobaric approaches
Isobaric labels have identical chemical structures and identical masses - achieved through
judicious placement of multiple isotopes of nitrogen and carbon - so they change the mass
of the labelled product equally such that there is no shift in how the proteins or peptides are
differentiated during MS; however the labels break apart in the collision cell prior to MS/MS
analysis giving rise to different, quantifiable fragment ions, thus allowing for differential
analysis. Most isobaric labels take advantage of the α- or ε-amino group of tryptic peptides and
are activated as N-hydroxysuccinimide (NHS) esters. Two which are capable of multiplexing
up to 8 and 6 samples respectively are the isotope tags for relative and absolute quantification












Figure 2.16: Structure of iTRAQ labels
The chemical structure of the four-plex iTRAQ label set is depicted (A) with the description of the distribution of
the mass balance elements (B). The labels are amine reactive (C) and forms an amide linkage to any peptide amine
(N-terminal or amino group of lysine). Each label has the same mass )145.1 Da) however the reporter elements
are different for each label (114.1 to 117.1) and can be distinguished during MS/MS [220].
2.5.3 Label-free strategies
Label-free quantification approaches aim to correlate the mass spectrometric signal of intact
proteolytic peptides or the number of peptide sequencing events with the relative or absolute
protein quantity directly. The type of label free strategy that can be utilised is directly related
to the mass resolution of the LC-MS data that is generated. Low to moderate mass resolution
LC-MS data can be processed using spectral counting or extracted ion chromatograms. High
mass resolution LC-MS data can use truly label free quantitation strategy that incorporates the
detected m/z elution profile of a particular peptide ion, as detected at the MS1 level, as a function
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MS survey scan Ion intensity of intact peptides
Table 2.2: Differing types of label free quantitation using LC-MS/MS
A list of the broadly utilised quantitation methods that are currently employed, stratified in relation to how the
data is acquired and what data is utilised to calculate the quantitation values. DDA = Data-dependant acquisition.
Tabled sourced from [222].
Tables 2.2 displays the basic quantitation strategies that are currently employed in LC-MS/MS.
Table 2.3 provides a more detailed analysis of the various factors that need to be considered
when wanting to eploy a quantitation strategy. A more in depth description of various label free
strategies follows below.
2.5.3.1 Spectral counting
Spectral counting is a semi-quantitative technique for determining the abundance of a detected
peptide in proportion to the abundance of the total peptide sample. This is essentially achieved
by determining the number of spectra per peptide as a proportion of the total number of peptide
spectra recorded for a given sample. The drawbacks to this approach are that: 1) not all
peptides in the sample ionise efficiently, 2) degenerate peptides can not be effectively counted,
and 3) low numbers of spectral counts could be a function of low abundance, short protein
length, erroneous identification, physicochemical properties affecting peptide observability or
the sample complexity itself. There are a number of spectral counting algorithms that are
currently available in the proteomics field, some of which have attempted to correct for as many
of the listed issues as possible. The most widely utilised algorithms are; the normalised spectral
abundance factor (NSAF), the absolute protein expression method (APEX), the exponentially
modified protein abundance index (emPAI) and the spectral index quantitation (SINQ) method
[224–228]. The NSAF algorithm attempts to adjust the abundance values that are calculated for
a specific peptide according to the length of the protein from which it is derived. The emPAI,
APEX and SINQ methods make use of various ways to utilise a derived index for calculating
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of spectra or peptides identified for a given protein and overall protein abundance in the sample
is used as a basis to calculate the absolute concentration of each protein within the sample.
2.5.3.2 Extracted ion chromatograms (XIC)
When using XICs for semi-quantitatively tracking peptide abundance in a sample, a peptide
must be identified at least once. The the m/z ratio and retention time (TR) of the identified
peptide is then used to extract an ion chromatogram of the MS precursor ion. The ion
chromatogram can be integrated to ascertain a measure of quantitation [229, 230]. The drawback
to this method is the reproducibility of chromatography across multiple runs which will directly
affect the TR of the peptide being used for extraction of the ion chromatogram [231]. For
both spectral counting and XICs there is no estimation for error rates. The quantitation is also
complicated by the stochastic nature of the MS/MS sampling process, especially when it comes
to low abundance peptides.
2.5.3.3 Label-Free Quantification of Multidimensional LC-MS Data
For more accurate label free quantification, the LC-MS data needs to be acquired at a high mass
resolution at the MS1 level. Machines equipped with the new generation of ToF or OrbiTrap
mass analysers are normally used for this method as they have high resolution power and mass
precision - often in the low parts per million (ppm) mass unit range. Peptide signals are detected
at the MS1 level and distinguished from noise by their characteristic isotopic pattern. These
patterns are then tracked across the TR dimension and used to construct a chromatographic
elution profile of the monoisotopic peptide mass. The total ion current of the peptide signal is
then integrated and used as a quantitative measurement of the original peptide mass. Extracted
peptide signals can be mapped across multiple LC-MS runs using co-ordinates on the m/z and
TR dimension. The efficiency of the tracking is dependant on the mass resolution of the MS1
level. It has been shown that this process can be linear across three to four orders of magnitude
after normalising the data concerned to remove any systematic artefacts in the peptide intensity
values between LC-MS measurements.
An algorithm that is often used to estimate protein abundances across a number of samples
in either a label free or SILAC dependent manner for LC-MS/MS experiments is the intensity
based absolute quantification (iBAQ), this algorithm is often utilised in the MaxQuant software
suite [232]. In this algorithm, absolute protein amounts are calculated as the sum of all peptide












The Top3 algorithm was proposed by Silva et al. and is essentially an algorithm that calculates
the abundance of each protein based upon the average intensity of its three best ionizing peptides
[234]. This algorithm can theoretically be applied to any number of the best ionising peptides
and is therefore sometimes referred to as the TopN method. A recent comparison of various
label free quantitative algorithms showed that only the Top3 method is directly proportional to
protein abundance over the full quantification range and consequently is the preferred method
in the absence of reference protein [235].
2.6 Targeted proteomics
Targeted proteomics differs from shotgun proteomics in that the mass spectrometer is
programmed to analyse precursor ion sequences in MS until a precursor ion which has been
included on a list of watched peptides is identified at which point the precursor ion is selected
for fragmentation and further analysis by MS/MS. This approach can be performed using two
major techniques, the first involves building a peptide atlas of candidate precursor ions so that
subsequent machine run time may be minimised without lowering the number of identifiable
peptides significantly and the second utilises already existing repositories, such as PeptideAtlas,
to provide these precursor ions and their expected transition masses.
2.6.1 Directed approaches
The directed approach has been developed so that large scale quantitative analysis of relatively
complex samples can be performed, especially with respect to longitudinal time course studies,
without the associated extended machine run time and resources that would be required in
order to achieve this intensive analysis. This technique is often performed on LTQ-Orbitrap
instruments as they have the capacity to trap precursor ions before selecting appropriate ions
for subsequent MS/MS analysis. Essentially this process requires an initial set of runs to be
performed to acquire a set of precursor ions that can be used to effectively identify proteins
likely to be in the sample of interest. Once the atlas database is sufficient in size, a limited
number of unique precursor ions, as well as their subsequent transition ions, can be identified
per protein and an inclusion list can be formed. The inclusion list ensures that the mass
spectrometer does not waste duty time analysing potentially redundant peptides and does not
waste time analysing vast numbers of peptides belonging to only one protein but instead will
analyse peptides that form part of the inclusion list before analysing other peptides that are












this approach can prove to be hugely effective for long term experiments involving very specific
samples from the same source organism. The power of this technique has been rather elegantly
used to track drug perturbations in moderately complex organisms over multiple time points
with some fascinating results [236]. By reducing machine runtime without compromising the
number of proteins that can be identified and quantified, this technique provides the opportunity
to analyse many more time points to delve deeper into longitudinal changes in proteomic
profiles. An added strength is that every run can be used to further develop the size of the













Figure 2.17: Outline of a directed proteomic approach
The directed approach involves two phases, an initial discovery phase and a secondary scoring phase. In
the discovery phase the peptide samples from the different cell states are mixed together and analysed
using data-dependent acquisition 1D LC-MS/MS. Comprehensive proteome coverage is achieved by sequential
sequencing of all detectable pre-cursor ions using directed LC-MS/MS analysis coupled to database searching.
The resultant identified peptide sequences are then stored in a 1D Peptide Atlas database along with some other
key features (ion signal intensity, retention time and m/z ratio). The best five proteotypic peptides (PTPs) are then
identified for each protein and stored in an inclusion list. In the second phase the LC-MS/MS is focused on the
PTPs that are in the inclusion list as well as a set of heavy labelled reference peptides which can be used to calculate
quantitation values using label-free approaches [236, 237].
2.6.2 Selected reaction monitoring
Selected reaction monitoring (SRM), also often referred to as multiple reaction monitoring
(MRM), is normally performed on a triple quadrupole machine as it requires three phases. In the












candidate peptides that have already been identified by the researcher running the experiment
to be of value. These candidate peptides must conform to a few rules such as they should
ionise easily, be specific to the protein of interest and should be reproducible through sample
preparation. The second phase occurs when the selected precursor ion is subjected to
fragmentation in the second quadrupole producing a series of fragment ions. The third phase
makes use of specific fragment ions, once again that the researcher has deemed to be of interest,
that are unique to the precursor ion to confirm the identity of the precursor ion and thus the
identity of the protein that the precursor ion belongs to. This technique contains two selection
steps and for this reason has a higher dynamic range (normally in the order of five magnitudes)
compared to shotgun proteomic techniques (normally in the region of four orders of magnitude).
It is sensitive due to the non-scanning mode and has a wide dynamic range, all of which combine
to make this an excellent technique for quantitative proteomics.
Figure 2.18: A basic SRM analogy
In a typical SRM experiment, the first quadrupole (Q1) will select a peptide which will then be fragmented in the
second quadrupole (q2). The third quadrupole (Q3) then selects a specific fragment of the fragmented precursor
ion.
Absolute quantitation in proteomics requires internal standards against which a comparison
of the measured component of interest can be performed. This is often achieved in SRM
analysis using isotopically labelled synthetic peptides that are added to the sample prior to the
LC-MS. Alternatively label-free relative quantitation can be achieved through comparison of
the normalised peak intensities between different samples (e.g. disease and control). However
the limiting factor is the sample complexity as only a few hundred, at the most, transitions
can be monitored for any given LC-MS run and given the dynamic range of these instruments
compared (105) to the dynamic range that exists in biologically complex samples (1012) it is
clear that sample preparation is crucial for a successful analysis.
A couple of the key specifics of this technique when applied to proteomics, as opposed to small












precursor ions produce fragments with higher m/z values than the precursor ions, requiring the
instrument to have an extended mass range; 2) the experimental design needs to be performed
prior to SRM analysis in order to be able to identify proteotypic peptides of interest (from which
protein identification can be inferred) as well as their fragment ions, this process needs to take
into account the complex nature of the sample being analysed.
2.7 Discovery to validation
As has been discussed in this review it is clear that proteomics is a diverse field of study and
has many techniques that will be used when a specific task needs to be performed, covering
everything from discovery to validation of candidate biomarkers.
2.7.1 Proteomics pipeline
There have been many discussions and demonstrations regarding the application of proteomics
to drug discovery for big pharma companies. Invariably the discovery phase requires the
identification of as many proteins as possible using a minimal number of biological samples
and ultimately leads to the validation phase where a small number of proteins are monitored
across a larger number of biological samples.
Figure 2.19: Typical proteomics pipeline
Row A describes the current pipeline from discovery to validation that has been implemented for many drugs in big
pharma companies to date. Row B describes a possible alternative workflow as well as the application proteomics












The advantages of proteomics are the high throughput manner of the techniques and the relative
cost per data point, especially when compared to other non ”omic” based biological assays.
2.7.2 Proteomics question
With the varied proteomic techniques and applications that have been developed it is crucial to
understand which techniques should be used for the proteomic question that is to be interrogated.
Thus having a clear understanding of the key differences in shotgun and directed approaches is
fundamental for any keen proteomic researcher. If the biological question involves attempting to
understand how drugs can perturb a biological pathway for a particular system, then a discovery
approach would be best suited. However if the biological question is to validate whether a
particular protein can be used as a biomarker for identifying a disease outcome then a directed
approach would be a better solution. As technology develops and mass spectrometers improve
the need for quality sample preparation in order to maximise the dynamic range that is analysed
will diminish slightly, however currently sample preparation is one of the most critical steps in
performing a successful proteomic experiment - provided the correct technique is chosen for
the biological question concerned.
The aim for this thesis was to determine ex vivo, using PBMCs, the molecular basis of the
differences in the immune responses to M.tb that occur in vivo between TB-IRIS and TBART
patients. The main outcomes being to:
1. Identify a potential protein biomarker for the IRIS condition
2. Provide the basis for a better understanding of the molecular origin of TB-IRIS
3. Serve as the basis for development of more targeted suppression of TB-IRIS.
Thus, a high throughput proteomic approach was utilised as this approach provides the best
opportunity to analyse the changes in the proteomic profile at the broadest possible level that
occur within these PBMCs when challenged by H37Rv antigen and/or treated with
dexamethasone. In order to increase proteomic coverage in the most cost effective manner,
a middle out fractionation strategy has been employed in conjunction with a quantitative label
free LC-MS/MS approach. Due to cost and sample scarcity considerations patient samples have
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3.1 Patient recruitment
Blood samples were drawn from patients that were admitted to Brooklyn Chest Hospital in
Stanberry Road, Ysterplaat, Cape Town after informed consent was obtained. Patients were
enrolled into a broad ranging study and assessed at defined intervals for the development of
paradoxical TB-IRIS and other clinical events using the consensus clinical case definition [96].
Within this study, bloods were drawn from enrolled patients pre-ART initiation, on the day of
ART initiation, within three days of enrollment, and then subsequently at one, two, three, four,
eight and 12 weeks after initiation of ART. Patients were then clinically diagnosed as either
having developed paradoxical TB-IRIS or as TBART responders by Dr Graeme Meintjes. Dr
Meintjes was in charge of patient recruitment as well as determining if a patient satisfied the
criteria required to participate in the study (listed below), Rene Goliath was the nurse in charge
of securing patient blood samples. The experimental analyses undertaken for this thesis was
performed on bloods obtained in week three of this process, Figure 3.1. This study was nested
within a larger study entitled “Prospective cohort study of hospitalised HIV-TB co-infected
patients at Brooklyn Chest Hospital” that has been granted ethical clearance by the University
of Cape Town Research Ethics Committee (REC 049/2009)). Recruitment criteria for the study
were as follows; all the inclusion criteria are required and if any of the exclusion criteria are
met then the patients were excluded.
Inclusion criteria:
1. Patients diagnosed with TB on the basis of microbiological investigation or highly
suggestive clinical and radiological features
2. Patients who reported symptomatic improvement after commencement of TB treatment
3. Patients who were HIV-infected and qualified for anti-retroviral treatment (ART),
as defined within South African Department of Health guidelines
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Exclusion criteria:
1. Patients with previous ART experience (excluding anti-retroviral for PMTCT)
2. Patients infected with rifampicin resistant TB
3. Patients younger than 18 years old
4. Pregnant patients
5. Patients who were confused or unable to understand the ICF
6. Patients with a haemoglobin count of less than 6.5 g / dL
Figure 3.1: Cohort recruitment
3.2 PBMC preparation
Blood samples were drawn into Sodium-heparin vacutainers and were processed in a Bio-safety
Level 2 (BSL 2) facility within 8 hours of being drawn, using a standard Ficoll/Histopaque
density gradient centrifugation protocol, briefly described below:
Between 10 mL and 15 mL of patient sample blood was mixed with an equal volume of
Dulbecco’s Phosphate Buffered Saline (PBS, Sigma cat. no. D8537) in a 50 mL Falcon tube.
The resultant PBS/blood mixture (between 20 mL and 30 mL) was carefully layered onto 10 mL
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centrifuged at 700 x g for 20 minutes at room temperature (brakes off). The characteristically
thin and milky white middle phase (normally approximately 5mL in volume), containing the
PBMCs, was removed and added to 10 mL of RPMI-1640 (Sigma cat. no. R8758) in a new
Falcon tube. Once completed this volume was topped up to 30 mL using RPMI-1640. The cells
were then pelleted at 600 x g for 10 minutes at room temperature (brakes on). The supernatant
was discarded and the cells were re-suspended in 10 mL RPMI-1640 and a 20 µL aliquot was
removed for cell counting (described in section 3.2.1). The cells were spun down at 600 x g
for 10 minutes at room temperature (brakes on) and the pellet was re-suspended in 400 µL of
RPMI-1640, after which, 500 µL of cell freeze solution, comprised of 20 % DMSO and 80 %
FCS, was added dropwise. The solution was then transferred to a Nunc vial and placed in a Mr
Frosty™ (Thermo Scientific cat. no. 5100-0001) at -80 °C overnight, before being transferred
to a liquid nitrogen tank for long term storage.
3.2.1 Cell counting
Cell counting was performed using a standard Fast-Re d 102™ counting chamber microscope
slide (Hycor Biomedical cat. no. 1482207):
These standard counting chamber slides consist of 10 counting chambers per slide. Each
chamber contains ten 4 x 4 grids which are used to count the number of cells within each
block’s perimeter. The volume above each 4 x 4 grid is 0.1 µL. Cells counts were performed
using the 20 µL aliquot that was removed in the PBMC extraction described above which was
added to 20 µL of 0.4 % trypan blue (Sigma cat. no. T8154), forming a 1:1 dilution. The
counting chamber in the slide was loaded using 10 µL of this solution. Counts were determined
using two rows of the chamber, containing eight blocks per row. The total number of cells, in the
10 mL RPMI-1640 PBMC solution from which they were removed, is obtained by multiplying
the total number of cells counted across two rows by the dilution factor when using the trypan
blue and then working back from the volume above the blocks counted (0.1 µL) to the volume
of the RPMI-1640 PBMC sample solution (10 mL). Formula 3.1 was used to determine the
concentration of PBMCs in the sample solution.
Algorithm 3.1 Number of cells in RPMI-1640 PBMC solution
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3.3 PBMC culture: general conditions
The frozen PBMCs were processed in batches of no more than four samples at a time. Cells
were defrosted from liquid nitrogen storage by rapidly bringing their temperature to 37 °C using
an incubator. The media was then exchanged for one that was dimethylsulfoxide (DMSO)
free by centrifuging and replacing the supernatant with RPMI-1640 containing 10 % fetal calf
serum (FCS), otherwise referred to as R-10. The cells were placed an incubator at 37 °C
overnight under 5 % CO2 atmosphere. The following day the cells were pelleted (600 x g,
10 minutes, room temperature), re-suspended in R-10 and counted (as previously described
in Section 3.2.1). Post counting, the cells were pelleted and re-suspended in R-10 to a final
concentration of 2 x 106 PBMCs/mL, then plated at a final quantity of 100 000 PBMCs / well
in sterile 96 well round bottom cell culture plates with lids (Costar, Corning, Cambridge, MA,
USA - Cat no. 3595). This was done in order to minimise sample loss during protein and
RNA extraction protocols. All PBMC cultures for this study were performed in the presence of
HAART. The HAART cocktail used for cell culture was a combination of three anti-retrovirals,
namely; lamivudine (3TC), efavirenz and zidovudine (AZT), all of which were solubilised
appropriately and combined into a stock solution. The various cell culture conditions are shown
below in Table 3.3 for the qPCR work and in Table 3.7 for the proteomics work.
ARV concentrations were selected based on two previous publications specifically dealing with
these three drugs, either in various combinations with one another, or individually [239, 240].
Based on these publications it was decided to use the following culture concentrations for
efavirenz, 3TC and AZT respectively: 115 nM, 9 µM and 5 µM,which are considered close
approximations to the maximum serum concentrations of these drugs in vivo.






H37Rv 250 000 CFUs/mL
Table 3.1: Final condition-specific reagent concentrations per well
The concentration of dexamethasone was determined as follows. It has been shown that
rifampicin affects the bioavailibility of prednisolone in vivo [241] and the Cmax for prednisolone
in the presence of rifampicin was found to be in a range of between 100 ng/mL to 1000 ng/mL
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metabolise drugs in the body - either through increased clearance of co-administered drugs or
by inhibition of interaction with the p450 enzymes [242, 243]. Dexamethasone is metabolised
by CYP3A4 and as such dosage for patients receiving dexamethasone whilst being treated with
rifampicin should be increased [244]. Dexamethasone is the stable analogue of prednisolone,
which is the pro-drug of prednisone. According to the South African Medicines Formulary
dexamethasone is thought to be approximately 6.7 times stronger than prednisone or
prednisolone [245]. Thus, mathematically, the comparative effective range for dexamethasone
is between 14.9 ng/mL and 149.25 ng/mL as described in the study by McAllister [241]. A
separate study specifically involving the effects of dexamethasone on PBMCs ex vivo was
performed using a concentration of 13 ng/mL [246]. It was therefore decided to use a
concentration of 15 ng/mL of dexamethasone for the ex vivo PBMC cell culture work in order
to mimic as closely as possible the expected in vivo concentrations in TB-IRIS and TBART
patients who by definition are on rifampicin treatment.
When determining the antigen load for re-stimulation of the cultured PBMCs it was decided
to use a theoretical multiplicity of infection (MOI) for the M.tb antigen (strain H37Rv). It
was decided to use a theoretical MOI of 5:1 (antigen:target) as this would ensure that most of
the macrophages would be exposed to at least one bacilli whilst concurrently ensuring that the
system was not overwhelmed with too much antigen. The base assumption being that of the
100 000 PBMCs per well, approximately 10 000, or 10 %, of the population could be expected
to be macrophages. Thus with an MOI of 5:1 it was decided to use 50 000 colony forming
units (CFUs) of heat killed H37Rv for this study. Heat killed H37Rv was obtained by heating a
solution of a known concentration of M.tb to 80 °C for 4 hours.
Cells were cultured in a final volume of 200 µL in R-10. Each well contained 100 000 PBMCs
as well as appropriate concentrations of anti-retrovirals (ARVs) and if required Dexamethasone
and/or heat-killed H37Rv. Individual stock solutions (Table 3.2) for the different conditions
were prepared such that each well contained 50 µL PBMC stock solution, 50 µL condition
specific stock solution and 100 µL of R-10. The final culture concentrations in each well for
the individual reagents can be seen in Table 3.1.
Condition Conditional stock solution volumes (µL)ARVs Dexamethasone H37Rv R-10 Total vol.
+ Dex / + H37Rv 3 20 20 7 50
+ Dex / - H37Rv 3 20 - 27 50
- Dex / +H37Rv 3 - 20 27 50
- Dex / - H37Rv 3 - - 47 50
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After culturing, viable cells were counted (as per Section 3.2.1) to ensure no bias in cell
quantities per sample in downstream analysis. An analysis was also performed to determine the
potential for selective depletion of monocytes through adhesion to the cell wall. Cell recoveries
were compared testing the effectiveness of using ice cold 5 mM EDTA versus ice cold PBS.
There were no measurable differences (using cell counts of recovered cells compared to seeding
amounts) for either so it was decided to use ice cold PBS when rinsing out culture wells.
3.4 Quantitative real-time PCR range-finding
experiment
Before the proteomic experiment could be performed, the optimal culture time for proteomic
analysis needed to be determined. However it was deemed too costly to determine the optimal
time point by LC-MS/MS so it was decided that the best method to use would be quantitative
real-time PCR (qPCR), specifically looking at the variation in expression profiles of a number
of genes across four pre-determined time points. qPCR is a robust technique that allows for
the quantitation of a gene product based on the cycle time required for that gene product to be
detected at a particular threshold. qPCR can be used to determine either relative or absolute
expression levels particular target genes, depending on the experimental design. The basis for
determining the quantity of the gene copy number is based on the principle that each PCR cycle
doubles the quantity of a particular gene product and so at any given cycle number, the amount
of product formed is directly related to the quantity of the gene available for replication at the
start of the PCR experiment. The changes in expression levels can therefore be empirically
determined as an absolute value (providing a standard curve for a known product is used) or
in relative terms across samples (e.g. the same sample but at differing time points). For the
purposes of this work, relative quantitation of a set of target gene expression levels was sufficient
as the purpose of the experiment was to determine which of the four potential culture time points
would be best suited for the proteomic work flow.
The first set of cell cultures were set up for a qPCR range-finding experiment (Table 3.3) to
determine the optimal time point for a proteomic investigation. The qPCR experiment involved
using five TB-IRIS patient samples and five TBART patient samples cultured individually under
four conditions (plus and minus re-stimulation with heat-killed M.tb H37Rv; plus and minus
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Condition 0 hours 6 hours 20 hours 44 hours
+ Dex / + H37Rv
+ Dex / - H37Rv
- Dex / + H37Rv
- Dex / - H37Rv
Table 3.3: Culture conditions for qPCR experiment.
Five TB-IRIS samples and five TBART samples were cultured individually in the presence (+ H37Rv) and absence
(- H37Rv) of restimulation with heat-killed TB antigens (H37Rv) as well as in the presence (+ Dex) and absence
(- Dex) of Dexamethasone.
For clarity, Table 3.4 defines what culture conditions have been used and how they have been
abbreviated when referenced in this thesis.
Patient label Dataset labels Culture conditions
TB-IRIS or
TBART
MM (minus / minus)
Minus dexamethasone / Minus
re-stimulation with H37RV
MP (minus / plus)
Minus dexamethasone / Plus
re-stimulation with H37RV
PP (plus / plus)
Plus dexamethasone / Plus
re-stimulation with H37RV
Table 3.4: Culture conditions and corresponding data labels
3.4.1 RNA extraction
PBMCs cultured under each condition and for each length of time were processed individually
in parallel. The cells were washed twice in PBS (volume times) and then pooled post culturing
according to common time point and condition and TB-IRIS or TBART origin, yielding a total
of 32 pools. Each pool contained approximately 500 000 cells from which RNA was extracted
immediately. A pooling strategy was adopted for both the qPCR and the subsequent proteomic
work as a combination of the scarcity in available sample as well as the exponential increase
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Figure 3.2: Basic workflow of sample culturing for qPCR experiment
The culture workflow indicated above was conducted for five TB-IRIS patient samples and five TBART patient
samples, resulting in 32 pooled samples (16 TB-IRIS and 16 TBART) across 4 time points that were then used to
extract RNA for the qPCR time-ranging experiment.
RNA was extracted from the pooled cells using a standard QIAzol (Qiagen, Hilden, Germany
- Cat. no. 79306) extraction protocol as described by the guidelines provided with the reagent
(http://www.qiagen.com/literature/render.aspx?id=375). As per the reagent
protocol: 5 - 10 x 106 cells can be extracted in 1 mL QIAzol. Previous cell cultures resulted in
500 000 PBMCs per condition being generated for RNA extraction. Thus 200 µL QIAzol was
added to each pool of 500 000 PBMCs in a 1,5 mL tube and gently triturated. To this, 40 µL of
chloroform was added and the eppendorf was gently inverted to mix before being incubated on
ice for 10 minutes. Insoluble debris was removed by centrifuging the sample at 10 000 x g at 4
°C for 10 minutes. The aqueous phase was transferred to a new 1.5 mL tube before adding 100
µL isopropanol, to precipitate the RNA, and was incubated at -20 °C overnight. The following
day the RNA was pelleted at 8 000 x g at 4 °C for 30 minutes. The supernatant was discarded
and the RNA pellet was washed in 200 µL 75 % ethanol. The RNA was pelleted once more by
centrifuging at 8 000 x g at 4 °C for 20 minutes before being re-suspended in 30 µL RNAse free
water. The RNA was quantified using a Nanodrop™ (A260 / A230 and A260 / A280) and then
stored at -80 °C. To improve the yield and stability of RNA during the extraction protocol, the
area and equipment that where utilised for the extractions were cleaned using RNAse AWAY™
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3.4.2 Quantitative real-time PCR
Quantitative real-time PCR, sometimes referred to as RT-PCR, was performed on the extracted
RNA using a one step RNA-Ct kit (Applied Biosystems, Foster City, CA, USA - Cat. no.
4393463) on a Roche LightCycler™ 400 qPCR machine. The RNA was defrosted and diluted
to a final concentration of approximately 2.4 ng/mL ensuring that each well in the 384 well
qPCR plate contained 10 µg of RNA. The basic components of each well per plate was based
on Table 3.5.
Reaction component Volume (µL) / Reaction
TaqMan® RT enzyme mix (40x) 0.25
TaqMan® RT-PCR mix (2x) 5
TaqMan® PDAR probe (20x) 0.5
Sample RNA template 4.25
Total 10
Table 3.5: Reagent volumes per well for each qPCR plate
The qPCR plates were prepared using a QIAgility robotic plater (Qiagen, Hilden, Germany) and
the corresponding software (Version 4.11.0). For each mRNA to be quantified, total RNA was
plated in triplicate for each time point, condition and sample type (TB-IRIS and TBART). The
expression of the following genes were successfully analysed: IL 8, IL 12, IFN-γ and TNF-α .
The qPCR machine cycling conditions were as per Table 3.6. The constitutively expressed
GAPDH gene was used as a reference house-keeping gene for this study and expression of the
target gene was normalised to this reference gene in all the samples studied [247].
Step Temp (°C) Duration Cycles
Reverse transcription step 48 15 min Hold
Enzyme activation 95 10 min Hold
Denature 95 15 sec
40
Anneal / Extend 60 1 min
Table 3.6: qPCR machine cycling conditions
The qPCR plate was laid out as per Figure 3.3, the probes were donated from the Wilkinson
lab based at the Institute for Infectious Diseases and Molecular Medicine (IIDMM). Probes for
the following genes were obtained: IL 2, IL 6, IL 8, IL 12, IFN-γ , TNF-α and GAPDH. The
genes were spread across 2 consecutive plates that were plated and run on the LightCycler™
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on a separate plate for the 20 hour time point for IL 2, IL 6, IL 8, IL 12, TNF-α , IFN-γ and
GAPDH after analysis of the first qPCR run showed inconsistent results for this time point.
Figure 3.3: Basic setup for qPCR plate
The basic plate setup for the qPCR experiment. Rows A to N contained gene probes for test genes and the final
two rows (O &P) contained gene probes for a reference house keeping gene (GAPDH). Each gene was tested using
RNA isolated from four distinct time point samples. Each time point was further broken down into four culture
conditions. D = Dexamethasone, T = H37Rv, + = cultured in the presence of, - = cultured in the absence of.
3.4.3 qPCR data analysis
The threshold cycle (Ct) required to reach a specified, common PCR product yield was
determined in triplicate for each target gene (IL 8, IL 12, IFN-γ , TNF-α) as well as for the
reference gene (GAPDH) in each of the 32 samples. For each pooled sample the target gene
triplicate Ct data was normalised for total RNA quantity by subtracting the mean Ct number for
GAPDH from the mean Ct number for the specific target gene (Ct ’target gene’ - Ct GAPDH),
giving a normalised mean Ct value (∆Ct) for all the target genes.
Before comparing external perturbation induced variation in gene transcription levels per time
point across TB-IRIS and TBART groups, genes were standardised against their non-perturbed
baseline condition (- Dex / - H37Rv); at the same time point. This was achieved by subtracting
the normalised ∆Ct target gene for the baseline condition (- Dex / - H37Rv) from the normalised
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∆∆Ct (TB-IRIS; 6 hour; IFN-γ; + / +) is obtained by subtracting ∆Ct (TB-IRIS; 6 hour; IFN-γ;
- / -) from ∆Ct (TB-IRIS; 6 hour; IFN-γ; + / +).
After normalisation and baseline subtraction was performed, the difference in expression levels
between the TB-IRIS and TBART groups was determined for each of the three non-baseline
conditions (+ Dex / + H37Rv, + Dex / - H37Rv and - Dex / + H37Rv) at a given time point
by subtracting ∆∆Ct TBART sample target gene from the corresponding ∆∆Ct TB-IRIS sample
target gene for each time point resulting in a ∆∆∆Ct value for the target gene at a specific time
point for a specific condition.
Due to the exponential nature of PCR amplification, the ∆∆Ct values relate to the difference
in absolute mRNA quantities according to the relationship 2-∆∆Ct. For simplicity, the analysis
of trends was performed using the ∆∆Ct values themselves, however it should be noted that
a negative ∆∆Ct value indicates an increase in transcription levels and a positive ∆∆Ct value
indicates a decrease in transcription levels.
3.5 Proteomic experiment
3.5.1 Method development
Prior to defrosting TB-IRIS and TBART patient PBMCs for culturing in preparation for the drug
and re-stimulation perturbation experiment illustrated in Figure 3.5, freshly isolated PBMCs
obtained from volunteers were used to test method development as outlined below. A number
of cell lysis and protein extraction buffers were tested to determine which buffer would provide
the highest and most diverse yield of proteins from a sample of PBMCs. There were three
broad passages of method development, each of which was directly related to the type of mass
spectrometer that was used for that passage of work.
3.5.1.1 MALDI ToF/ToF workflow
Extraction optimisation: The original mass spectrometer that was available for this study
was a 4800 MALDI-ToF/ToF (Applied Biosystems) that was available through the Centre
for Proteomic and Genomic Research (CPGR). The original approach that was used involved
iTRAQ reagents. Consequently there was a need to ensure that buffers containing primary
amines (the most common primary amine based buffers being Tris base and ammonium











3 Materials and Methods
The initial extraction protocol that was used, was derived from the work of Skopeliti et al. [248].
This involved cell lysis using a 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS) based lysis buffer adapted by replacing 50 mM Tris-Cl pH 8 with 100 mM tri-ethyl
ammonium bicarbonate (TEAB) as the buffering solvent. Figure 3.4 is a simplified outline of
the protocol and brief description of the workflow described by Skopeliti et al.
Figure 3.4: Simplified protein extraction protocol described by Skopeliti et al.
The altered lysis buffer used for initial protein extractions consisted of 100 mM TEAB
containing 2 % CHAPS, 15 mg/mL DTT, 2 mM MgCl2, 200 U/mL benzonase and a protease
inhibitor cocktail (Roche cat. no. 05892970001). Proteins were extracted in 100 µL lysis
buffer as per the protocol in figure 3.4. Protein yields from 1 x 106 PBMCs were typically
between 60 - 80 µg. A number of extractions were performed and the protein pelleted however,
based on the standard operating procedures implemented by the CPGR, tryptic digest had to be
performed by employees only. Consequently, pelleted proteins were transferred to the CPGR
for re-solubilisation, tryptic digestion and MS analysis. The issue of protein re-solubilisation
for tryptic digestion led the CPGR to develop a new extraction protocol.
Briefly: Between 5 x 105 and 2 x 106cells were lysed in 50 µL lysis buffer consisting of 500
mM TEAB containing 0.05 % deoxycholate (DOC), 1 % n-octyl 3-D glucopyranoside (OGP)
and 4 M guanidine-HCl. The lysate was sonicated in a sonicating water bath until the cells
dissolved, insoluble debris was removed by centrifugation. The proteins were precipitated out of
the supernatant using 4 volumes of ice cold acetone at - 20 °C overnight. The protein precipitate
was pelleted and the supernatant removed. The pelleted proteins were then dissolved in 20 µL
of dissolution buffer consisting of 500 mM TEAB, 6 M guanidine-HCl. The DOC protocol led
to an increase in the amount of total protein extracted. Using the DOC extraction protocol on
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Tryptic digestion: The protocol for tryptic digestion that was performed by the CPGR is as
follows. An aliquot of 5 µL of sample at a concentration of 20 μg / µL was placed into 1,5 ml
centrifuge tube. The volume was adjusted to 10 μl by adding 5 µL 50 mM TEAB. The sample
was reduced by adding in 1 µL 100 mM TCEP and incubated for 1 hour at 60˚C. The sample
was allowed to cool down to room temperature before alkylating by adding 1 µL of 100 mM
S-methylmethanethiosulphonate (MMTS) - prepared in 2-propanol - and incubated for 15 min
at room temperature. The sample volume was adjusted to 45 μl using 50 mM TEAB. Digestion
was performed by adding 5 μl 50 mM TEAB containing 5 μg of trypsin to the sample which
was incubated at 37˚C for 18 hours. After incubation, samples were dried down by speedivac
in preparation for MS analysis using the MALDI-ToF/ToF.
Nano-LC and plate spotting: All nLC mass spectrometry experiments were performed
on a Dionex Ultimate 3000 connected to a robotic plate. For liquid chromatography, separation
was performed on a LC Packings column (15 cm, 75 µm ID, 3 µm, C18 ) that was fitted with a
C18 trap column (5 mm, ID 300 µm) at a flow rate of 300 nL / min. The gradient used was as
follows: 5 % solvent B for 5 minutes, followed by 5-15 % solvent B in 5 minutes, followed by
15 - 60 % solvent B in 85 minutes, followed by 60 - 90 % solvent B in 10 minutes and kept at
90% solvent B for 10 minutes. Solvent A was 0.15 % tri-fluroacetic acid (TFA) in 98 % water,
and solvent B was 0.12 % TFA in 80 % acetonitrile (ACN).
MALDI-ToF analysis: The mass spectrometer was operated in data-dependent mode to
automatically switch between MALDI-ToF-MS and ToF/ToF-MS/MS acquisition. Data was
acquired using the 4000 Series Explorer software package. The matrix used for the MALDI
plates was α-Cyano-4-hydroxycinnamic acid. A fixed laser intensity of 4500 Hz was used and
a total of 600 shots per spectrum was set for MS mode. The number of sub-shots per spectrum
was set to 60 in MS mode. The laser search pattern was set to random with no bias towards the
centre or edge of the spots. Timed ion selection was enabled and the precursor ion scan MS
spectra (m/z 800 – 3000) were acquired in the MALDI-ToF with resolution R = 17 000 - 22 000.
The weakest pre-cursors were selected first, with a minimum signal to noise (S/N) threshold
of 35, for collision induced dissociation. Fraction-to-fraction precursor mass tolerance was
set at 100 ppm. Internal calibrants (angiotensin 1, m/z 1296.685; glu-1-fibrinopeptide, m/z
1570.677; neurotensin, m/z 1672.925; ACTH clip 19-39, m/z 2465.198) enabled accurate mass
measurement in both the MS and MS/MS modes. The MS reflector was operated in positive
mode. For MS/MS, 800 shots per spectrum and 40 shots per sub-spectrum were set. Ion
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However the results obtained from the MALDI-ToF/ToF remained unsatisfactory despite the
improved extraction protocol.
3.5.1.2 Q-ToF workflow
At this point in time, an opportunity for hands on experience with an Agilent 6530 Q-ToF,
acquired by the Department of Molecular and Cellular Biology at the University of Cape Town,
arose. This led to the development of a workflow directed towards this instrument. The DOC
extraction was utilised but tryptic digestion and peptide fractionation required optimisation.
Trypsin digestion: Proteins extracted using the DOC protocol were reduced by adding 1
µL 105 mM and incubating at 60 °C for 1 hour. The sample was gently mixed and quickly
spun down before alkylation using 1 µL of 84 mM tris(2-carboxyethyl)phosphine (TCEP) for
30 minutes at room temperature in the dark. After reduction and alkylation 38 µL of 500 mM
TEAB was added, to reduce the guanidine concentration, and briefly mixed and spun down
before adding in trypsin at a ratio of 25:1 (protein:trypsin). The sample was then left in a wet
chamber at 37 °C overnight. The tryptic digest was stopped the after 18 hours by adjusting the
pH to below pH 4 using an appropriate volume of dilute formic acid (FA). The tryptic digest was
desalted using PepClean™ C-18 spin columns (Thermo Scientific, cat. no. 89870) as per the
manufacturer’s instructions. The desalted peptides were dried down in a speedivac and stored
at - 80 °C.
A second method of sample preparation and specifically trypsin digestion was also tested. The
second method of sample preparation involved using filter aided sample preparation (FASP).
Proteins extracted using the DOC method and pelleted by acetone precipitation were re-
solubilised in 4 % sodium do-decyl sulfonate (SDS), 100 mM di-thiothreitol (DTT - Sigma cat.
no. D9779) in water. The protein suspension was incubated at 95 °C for 20 minutes [249]. A
200 µg fraction, as quantified by Bradford reagent (Fermentas cat. no. R1271), of reduced total
protein was then added to a 30 kDa molecular weight cut-off (MWCO) spin filter (Nanosep cat.
no. OD030C33) and concentrated down to approximately 30 µL by centrifugation. The decision
to use the 30 kDa MWCO spin filters instead of a smaller cut-off size spin filter was based on
the elegant work performed by Wiśniewski et al [249], which showed that the slightly higher
MWCO filters were better for washing off detergent but did not negatively affect the number of
small molecular weight proteins (less than 30 kDa) that were identified. The 30 µL retentate was
alkylated by adding 500 µL of UA buffer (8 M urea, 0.1 M Tris-Cl pH 8.5) containing 50 mM
iodoacetamide (hereafter referred to as IAA), and incubated at 20 °C for 20 minutes. Unreacted
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retentate and reducing the volume by centrifugation; this was repeated three times. The urea
concentration was then reduced to a trypsin compatible level by diluting the spin filter retentate
with 500 µL ABC (50 mM Ammonium Bicarbonate) and then re-concentrating the protein, by
centrifugation to a final retentate volume of approximately 30 µL; this was repeated three times.
Two micrograms (2 µg) of sequencing grade trypsin (Promega cat. no. V5111) was dissolved
in 40 µL of ABC and was then added to the retentate, giving a final protein:trypsin ratio of
100:1. The spin filter was incubated in a wet chamber at 37 °C overnight, then transferred to a
new 1.5 mL tube and the tryptic peptides were separated from undigested protein and trypsin
by centrifugation at 10 000 x g at 20 °C for 10 minutes through the 30 kDa MWCO membrane.
Peptide fractionation: To increase proteome coverage, fractionation strategies at the peptide
level were tested to see which strategy would yield the highest number of protein identifications.
The first fractionation technique employed was the 3100 OFFGEL Fractionator (Agilent
Technologies, Santa Clara, California, Illinois, U.S.A). Optimisation of this technique was
performed using the smaller 12 cm strip with a focusing range of pH 4 - 7. Approximately 300
µg of protein was obtained from 3 x 106 PBMCs using the DOC protein extraction method and
digested using the first trypsin protocol described above. The desalted peptides were then loaded
onto the 3100 OFFGEL apparatus as per the manufacturers protocol (http://www.chem.
agilent.com/Library/usermanuals/Public/G3100-90113_OFFGEL_Fractionator.pdf
), and run overnight using the standard “OG12PE01” program.
The second fractionation technique that was tested was high pH reverse phase chromatography.
This strategy was optimised using a DOC extraction performed on 1.6 x 106 PBMCs resulting
in approximately 130 µg of protein. The resultant protein pellet was run through the FASP
process and digested with trypsin, as described above, before being desalted on a C-18 spin
column and dried down in a speedivac. The peptides were then solubilised in 5 % ACN, 1.25
% TEA ( ~ pH 10) and run through a purpose manufactured C-18 micro-column. This column
was manufactured from a typical SDS PAGE gel loading pipette tip that was twisted to form a
fret and then packed with C-18 resin obtained from a Supelco C-18 Discovery column (Supelco
cat no. 52601-U). The micro column was prepared for the peptide sample by washing it with
approximately 15 column volumes (CV) of 50 % ACN,1.25 % TEA, before being conditioned
with approximately 15 CVs of 5 % ACN, 1.25 % TEA. The peptide sample was re-suspended
in 40 L of 5 % ACN, 1.25 % TEA and loaded onto the column. The flow through was kept
and reloaded onto the column. The column was washed with approximately 5 - 8 CVs of 5
% ACN, 1.25 % TEA. Five stepwise fractions of increasing organic solvent concentration (10
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onto the column and the flow through collected. The flow through from the sample loading was
combined with the 80% ACN fraction, the samples were dried down in a speedivac.
Q-ToF analysis: The 12 pI fractions from the OFFGEL Fractionator were collected and
desalted before being run on an Agilent 6530 Q-ToF mass spectrometer (Agilent Technologies,
Santa Clara, California, Illinois, U.S.A). The Agilent Q-ToF incorporates a n-LC chip-cube
system where the LC column is contained on a chip that also contains the ESI needle for
the mass spectrometer. All nLC mass spectrometry experiments was performed on an Agilent
1290 Infinity nLC CHIP-cube system connected to an Agilent 6530 Q-ToF mass spectrometer
(Agilent Technologies, Santa Clara, California, Illinois, U.S.A) equipped with a nanospray ESI
source. Liquid chromatography was performed on a Zorbax 300 SB-C18 column housed in a
0.075 x 150 mm chip, containing a 160 nL enrichment column and with a 5 µm particle size
(Agilent Technologies cat. no. G4240-62010), at a flow rate of 300 nL / min. The gradient
used was as follows: 3 % solvent B at 0 minutes, followed by 5 % in 0.1 minutes, followed by
8 % in 2 minutes, followed by 35 % solvent B in 60 minutes, followed by 40 % in 67 minutes,
followed by 90 % in 67.1 minutes and 90 % solvent B for 4 minutes, before dropping to 3 %
solvent B for 20 minutes. Solvent A was 0.1 % FA, 3 % ACN in water, and solvent B was 0.1%
FA, 3 % water in ACN.
The mass spectrometer was operated in data-dependent mode. Ionization mode was set to
positive electrospray and the scanning range for MS spectra was set at 275 - 2000 m/z (MS)
and 50 - 2000 m/z (MS/MS). A maximum of 10 precursors per cycle was allowed and the rate
of acquisition was set to 8 Hz (MS) and 3 Hz (MS/MS). The collision energy for the CID was
set at -4.8+3.6 V (precursor m/z / 100). In data-dependent LC-MS/MS experiments, dynamic
exclusion was used with a 60 s exclusion duration excluded after 1 spectra, the isolation width
was set to medium(4m/z) in MS/MS mode. Mass spectrometry conditions were 1.85 kV, with
the drying gas temperature set to 325 °C. A reference mass of trace amounts of the calibrant
HP-922 (922.0097 m/z) were continuously inserted into the ionisation region.
Despite the number of protein identifications increasing in comparison to the MALDI-ToF/ToF
results, the number of proteins identified were still very low. The stability of the ESI nanospray
appeared to be inconsistent. Agilent has recently replaced the CHIP-cube system and the
majority of the ESI source aperture components, at their own cost, in an attempt to increase
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3.5.1.3 LTQ-Orbitrap workflow
An LTQ-OrbiTrap became available and it was decided to test the high pH fractions that were
originally intended for the Q-ToF on the OrbiTrap instead. The desalted and dried down peptide
fractions were sent to Dr Salome Smit in the Central Analytical Facility, at the University of
Stellenbosch. All nLC mass spectrometry experiments were performed on a Thermo Scientific
EASY-nLC II connected to an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific,
Bremen, Germany) equipped with a ESI source. For liquid chromatography, separation was
performed on a EASY-pre-column (2 cm, ID 100 μm, 5 μm, C18), followed by an EASY-column
(10 cm, ID 75 μm, 3 μm, C18) at a flow rate of 300 nL / min. The gradient used was as follows:
5-15 % solvent B in 5 minutes, followed by 15 - 40 % solvent B in 80 minutes, followed by 40
- 60 % solvent B in 10 minutes, followed by 60 - 80 % solvent B in 5 minutes and kept at 80
% solvent B for 10 minutes. Solvent A was 0.1 % FA in water, and solvent B was 0.1% FA in
ACN.
The mass spectrometer was operated in data-dependent mode to automatically switch between
Orbitrap-MS and LTQ-MS/MS acquisition. Data was acquired using the Xcaliber software
package. The precursor ion scan MS spectra (m/z 400 – 2000) were acquired in the Orbitrap
with resolution R = 60 000 with the number of accumulated ions being 1 x 106. The 20 most
intense ions were isolated and fragmented in the linear ion trap (number of accumulated ions 1.5
x 104) using collision induced dissociation. The lock mass option (polydimethylcyclosiloxane;
m/z 445.120025) enabled accurate mass measurement in both the MS and MS/MS modes. In
data-dependent LC-MS/MS experiments, dynamic exclusion was used with a 60 s exclusion
duration. Mass spectrometry conditions were 1.8 kV, capillary temperature of 250 °C, with no
sheath and auxiliary gas flow. The ion selection threshold was 500 counts for MS/MS and an
activation Q-value of 0.25 and activation time of 10 ms were also applied for MS/MS.
Middle out optimisation: Based on the positive results obtained using the bottom up
method, it was decided to try and improve proteomic coverage by introducing an initial crude
protein fractionation step followed by individual and parallel trypsin digestion of the protein
fractions and subsequent separate fractionation of the resultant peptides. Two protein
fractionation methods were tested. The first was crude sub-cellular fractionation and the second
was phosphoprotein enrichment.
Crude sub-cellular fractionation (CSF) involves sequentially extracting location specific proteins
from cells using a series of detergent based buffers that gradually strip the various membrane
layers off of animal cells and was performed as described by Holden et al. [205]. This protocol
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individually and in parallel and run on a standard 10 % glycine-SDS-PAGE Laemmli. The
cytosolic fraction was obtained by lysing 3 x 106 cells in a 1.5 mL tube using 400 µL buffer 1
containing 50 mM HEPES pH 7.4, 150 mM NaCl, 25 µg / mL digitonin (Sigma cat. no. D141)
and incubated at 4 °C for 10 minutes whilst gently being rotated end over end. The insoluble
material was pelleted by centrifugation at 2 000 x g at 4 °C for 10 minutes. The supernatant
containing cytosolic proteins was removed and the pellet was washed with 1 mL ice cold PBS
and pelleted again and the PBS removed. The pellet was re-suspended in 400µL of buffer 2
containing 150 mM NaCl, 50 mM HEPES pH 7.4, 1 % NP40 and incubated for 30 minutes
on ice (the suspension was gently agitated every 10 minutes). Insoluble debris was pelleted by
centrifugation at 7 000 x g at 4 °C for 10 minutes, before the supernatant was removed and
kept aside as the membranous organelle fraction. The remaining pellet was washed with PBS
and re-pelleted by centrifuging at 7 000 x g at 4 °C for 10 minutes. The insoluble debris was
re-suspended in 320 µL ice cold buffer 3 containing 150 mM NaCl, 50 mM HEPES pH 7.4, 0.5
% DOC, 0.1 % SDS, benzonase (1 U / mL) and incubated at 4 °C for 1 hour whilst gently being
rotated end over end. Post incubation, 40 µL of 10 % SDS and 40 µL of 1 M DTT were added
to the suspension. The tube was vortexed and placed in a heating block for 20 minutes at 95 °C.
Any insoluble debris was pelleted by centrifugation at 10 000 x g at 4 °C for 10 minutes. The
supernatant was removed and kept as the third nuclear membrane and insoluble protein fraction.
The 3 separate fractions (cytosolic, membranous orgenelles and nuclear membrane/insoluble
proteins) that were obtained were aliquoted into 4 fractions as soon as they were isolated. The
first was used for quantitation by Bradford assay, the second was tested for compatibility with
the FASP process, the third was run on a gel and the fourth was stored at - 80 °C.
The complexity of any protein sample can be derived from numerous factors, including the
number of unique proteins in the sample as well as any post-translational modifications of those
proteins. One of the most common PTMs that occurs to proteins is the phosphorylation at either
the serine, threonine or tyrosine residues. Phosphorylation has been shown to play a key role
in cellular signalling in a number of pathways, from apoptosis to immune mediated cellular
signalling. Phosphorylation is among the most widespread post-translational modifications in
nature, and it has been estimated that more than 30% of the proteins in a given mammalian cell
at some point during their expression are phosphorylated [250]. However due to their charged
nature and relatively low abundance, phosphoprotein derived peptides are very difficult to detect
in a complex peptide sample. For this reason a phosphoprotein enrichment could be very useful
as it would allow a focus in subsequent analysis on phosphoproteins. Phosphoproteins can be
isolated from a complex protein mixture via the negatively charged phosphate groups (PO42-).
Phospho-enrichment was performed, using a CHAPS based buffer, as per the protocol provided
(http://www.qiagen.com/literature/render.aspx? id=23717) in the Phosphoprotein Purification
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were defrosted and re-suspended in 3 mL of phosphoprotein lysis buffer (0.25 % CHAPS,
benzonase, 25 mM MES pH 6.0, 1 M NaCl) and incubated at 4 °C for 30 minutes. Post-
incubation, insoluble debris was pelleted by centrifugation at 10 000 x g for 30 minutes at 4 °C.
The supernatant was loaded onto the pre-prepared phospho-enrichment column and the flow
through was re-loaded onto the column. This step and the subsequent steps were performed
at room temperature. After re-loading, the flow through was reserved as a phospho-depleted
fraction. The column was washed using 6 mL of phosphoprotein lysis buffer. The phospho-
enriched fraction was eluted by adding 2 mL of phosphoprotein elution buffer (50 mM K2PO4
pH 7.5 , 50 mM NaCl) to the column and collecting the flow through. The 2 separate fractions
(phospho-enriched and phospho-depleted) that were obtained were aliquoted into 4 fractions as
soon as they were isolated. The first was used for quantitation by Bradford assay, the second
was tested for compatibility with the FASP process, the third was run on a gel and the fourth
was stored at - 80 °C.
3.5.2 Cell culture and pooling strategy
Once the proteomic method development yielded positive results using the OrbiTrap, the second
cell culture experiment for the proteomic study of TB-IRIS and TBART PBMCs was conducted
(Table 3.7). The culturing involved 30 TB-IRIS and 30 TBART patient samples. These samples
were cultured, as described in table 3.7, at one time point using the same four conditions as those
used for the qPCR time-ranging experiment. The time point was determined by the outcome of
the qPCR time-ranging experiment.
Condition Time point
+ Dex / + H37Rv (+ / +) 20 hour
+ Dex / - H37Rv (+ / -) 20 hour
- Dex / + H37Rv (- / +) 20 hour
- Dex / - H37Rv (- / -) 20 hour
Table 3.7: Culture conditions for proteomics workflow
Samples were defrosted in batches of four, from either TB-IRIS or TBART samples. The
cultured PBMCs were processed sequentially in batches of four from their removal from liquid
nitrogen storage through to culturing and pooled during PBS washing post culturing. Each
condition at the single time point was pooled, i.e. four TBART samples were defrosted and
cultured under four separate conditions. The samples were pooled for each condition post-
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Figure 3.5: Basic workflow for sample culturing for proteomic experiment
A second biological repeat of 6 TB-IRIS patient samples was performed after the insoluble
pellets for the 30 TB-IRIS pooled patient samples were misplaced. This meant that subsequent
proteomic analysis was performed using the pooled sample of 6 TB-IRIS patients and the pooled
sample of 30 TBART patients.
3.5.3 Protein extraction and fractionation
Both the TB-IRIS and TBART samples were processed individually and in parallel to produce
two crude fractions during protein extraction. Due to resource restrictions (notably access to
enough machine time and the high cost of machine time), it was decided to perform protein
extraction and subsequent mass spectrometry analysis on 3 of the 4 TB-IRIS samples (+ Dex /
+ H37Rv; - Dex / + H37Rv; - Dex / - H37Rv), and on 2 of the 4 TBART samples (- Dex / +
H37Rv; - Dex / - H37Rv).
3.5.3.1 Phospho-enrichment:
Phospho-enriched and phospho-depleted protein fractions were obtained from pooled samples
of 30 TB-IRIS and 30 TBART patients using the protocol described in subsection 3.5.1.3.
The pooled sample of PBMCs, containing approximately 3 x 106 cells, for both TB-IRIS and
TBART patient were processed individually and in parallel.
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3.5.3.2 SDS PAGE
A third protein fraction was obtained by re-solubilising the insoluble cellular debris that was
pelleted after the phospho-enrichment extraction, described in subsection 3.5.1.3, using standard
1 x sample application (SAB) buffer - commonly used in Laemmli gels [175] - composed of
40 mM Tris-HCl (pH 6.8), 2 % SDS, 2 mM β -mercaptoethanol, 4 % glycerol, 0.01 % w/v
bromophenol blue. This was performed on the pellets of the pooled sample of 30 TBART
patient samples and on a biological repeat of 6 pooled TB-IRIS patient samples. The SDS
re-solubilisation was performed using 100 µL , for the pooled TBART samples and 20 µL
1 x SAB for the pooled TB-IRIS samples. Re-solubilised samples were heated to 95 °C for
10 minutes before being spun down and loaded onto a standard 10 % glycine-SDS-PAGE
Laemmli gel. The TBART samples were loaded in duplicate lanes on a 1 mm thick 10 %
glycine-SDS-PAGE Laemmli and the TB-IRIS samples were loaded onto a separate 1 mm thick
10 % glycine-SDS-PAGE Laemmli gel. Both gels were prepared from the same stock solutions
in parallel and run separately at 20 mA for 90 minutes.
3.5.4 Protein digestion
Peptides for the phospho-enriched extractions were obtained by using an adaption of the filter
aided sample preparation (FASP) method[251]. The FASP process was performed on only the
phospho-enriched fractions for both the TB-IRIS and TBART patient samples. The phospho-
enriched samples were reduced by adding DTT to a final concentration of 100 mM and boiling
at 95 °C for 20 minutes, before being loaded onto the 30 kDa MWCO spin filters and the
protocol was continued as described in sub-section 3.5.1.2.
In gel trypsin digestion: The individual lanes from the glycine-SDS PAGE gels were cut
into 5 separate equal sized slices. Each gel slice was cut into smaller cubes. The cubes from
each gel slice were pooled into 5 separate fractions that were processed individually in parallel.
The fractions were washed twice with 300 µL water followed by 300 µL of a 50% (v/v)
acetonitrile solution for 10 min. The acetonitrile was replaced with 300 µL 50 mM ammonium
bicarbonate and incubated for 10 minutes, and repeated twice more. All the gel fractions were
then incubated in 300 µL 100% acetonitrile until they turned white, after which the gel pieces
were dried in vacuo. The proteins were reduced with 120 µL 10 mM DTT for 1 hour at 57
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followed by 300 µL 50% acetonitrile, before the proteins were alkylated in 120 µL 55 mM
iodoacetamide for 1 hour in the dark at room temperature. Following alkylation the gel pieces
were washed with 300µL 50 mM ammonium bicarbonate for 10 minutes followed by 300µL
50% acetonitrile for 20 minutes, before being dried in vacuo. In-gel protein digestion was then
carried out by immersing the gel slices in 100 μL of a 10 ng/μL trypsin solution and incubating
at 37 °C overnight. The resulting tryptic peptides were extracted from the gel slices twice with
100µL 70% acetonitrile, 0.1% FA for 30 minutes, and then dried in a speedivac and stored at -20
°C. The dried peptides were re-solubilised in 5% acetonitrile, 0.1% formic acid in preparation
for mass spectrometry.
3.6 Mass spectrometry
Mass spectrometry was outsourced to the Central Analytical Facility based at Stellenbosch
University in the Western Cape, South Africa. In the case of the phospho-enriched and phospho-
depleted fractions, the samples were prepared to the point of a purified and desalted peptide
digest that was dried down before being transferred to the facility. The insoluble debris fraction
samples were transferred to the facility as complete Laemmli gels that had already been stained
with colloidal Coomasie Blue (CCB). The Laemmli gels were processed as described in
Subsection 3.5.4.
3.7 Data analysis
The RAW data files generated by the mass spectrometer were converted into MS2 files using the
MakeMS2 program (http://proteome.gs.washington.edu/software/makems2/). Once
converted the MS2 files were then analysed using Crux [159]. The main parameters for this
particular study were firstly, an FDR of 5 % as determined by Crux using a q-value score of 0.05
or less. The q-value of an individual hypothesis test is the minimum FDR at which the test may
be called significant. Secondly, only uniquely mapped peptides (one peptide mapping to one
protein only) for protein identifications were used. Crux is not proficient at assigning proteins
from degenerate peptides (one peptide mapping to multiple proteins) with high confidence.
Other than these two parameters, the standard default settings for the Crux algorithm were used
(the parameter file is attached in the Appendix section). Due to the difficulties that Crux has
pertaining to degenerate peptides, the final protein assignments based on the identified peptides
from the Crux algorithm was performed using the Trans-Proteomic Pipeline (TPP). The TPP
algorithm performs far better at assigning proteins from degenerate peptides. The databases that
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database contains no splice variants; secondly, SwissProt Global Proteome Human Organism
9606 - this database contains splice variants; and thirdly, the IPI database (version 3.5).
The Crux search was performed using was the University of Cape Town ICTS-HPC cluster. The
output from Crux was then parsed through TPP for protein assignment of the identified peptides
using Protein Prophet. The basic data processing workflow can be seen in Figure 3.6.
Figure 3.6: Proteomic data processing pipeline
Data processing for proteomic analysis: the RAW data file output of the mass spectrometer was converted into an
MS2 file which was then used by Crux to undergo PSM. The identified peptide lists that are generated are then












4.1 PBMC culture optimisation
Prior to any proteomic or qPCR experiments being performed, it was important to verify whether
or not any of the M.tb antigen (H37Rv) or the drugs (ARVs or dexamethasone) that were used
during the ex vivo culturing process resulted in any negative or abnormal side effects such as
induced cellular apoptosis or decreased cell viability amongst others. To confirm this, PBMCs
from three healthy donors were isolated and cultured in the presence and absence of ARVs.
The cultures were performed in duplicate and the mean PBMC numbers were compared as
the percentage of living cells remaining versus the increasing length of exposure to the ARVs













Figure 4.1: ARV cytotoxicity study
The average percentage viability of PBMCs from three healthy donors, cultured in duplicate. The averages are for
PBMC viability cultured in the presence of: 115 nM Efavirenz (turquoise), 5 µM AZT (red), 9 µM 3TC (blue),
all three ARVs combined (purple) and a control of de-ionised H2O.
Cellular viability was not significantly affected by any of the individual ARVs or any
administered combinations, as the cell viability remained above 80 % for up to 44 hours culturing
and dipped nominally below 80 % at 52 hours of culturing, Figure 4.1.
A similar experiment was repeated to test the effect of dexamethasone and H37Rv on their
own and in combination with ARVs (Figure 4.2). This experiment was performed on PBMCs
isolated from the same three healthy donors previously used for the ARV cytotoxicity
experiment, in duplicate with the mean of these repeats being plotted in Figure 4.2. The cell
culture time point was not extended beyond 49 hours as a result of the cellular viability dropping












Figure 4.2: Dexamethasone and heat killed H37Rv cytotoxicity study
The average percentage viability of PBMCs from three healthy donors, cultured in duplicate. The averages are
for PBMC viability cultured in the presence of: HAART combination and 15 ng / mL dexamethasone and 50 000
CFUs heat killed H37Rv (red), HAART combination and 15 ng / mL dexamethasone (green), HAART combination
and 50 000 CFUs heat killed H37Rv (turquoise), and a control of de-ionised H2O (cyan).
Culturing PBMCs in the presence of various combinations of the drugs (ARVs or
dexamethasone) or antigen (H37Rv) had a negligible effect in terms of cell viability in
comparison to the control and therefore should not cause any significant changes in a global
proteomic comparison since there is no intrinsic bias associated with decreased cell viability on
addition of drug or antigen to the culture wells (Figure 4.2).
4.2 qPCR work
Given that TB-IRIS is known to be an inflammatory syndrome characterised by hyper-
cytokinemia [252], it was decided to analyse the quantities of the following genes: IL 8, IL 12,
IFN-γ and TNF-α , as a simplistic indicator of differences in inflammatory protein expression
patterns within each time point for each condition. The analysis was performed in triplicate
for each gene at each of the four chosen time points (0, 6, 20 44 hours). The changes in the
expression levels were determined as per the ∆∆∆Ct method described in the Methods chapter
(Subsection 3.4.3). The difference in gene expression profiles were plotted per time point and
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Figure 4.3: qPCR results - intra-condition analysis
Four time points (0, 6, 20 and 44 hours) were analysed for the difference in expression of four genes (IFN γ , TNF
α , IL 8 and IL 12) according to the ∆∆∆Ct method described in the Methods chapter (Subsection 3.4.3).
The selection criteria for the optimal time point to utilise for the LC-MS/MS based proteomics
analysis were based on the following: 1) The expression profile of the analysed genes needed
to display high levels of variation - as an indication of an inflammatory response that was not
biased one way or another (e.g. a skewed Th1 or Th2 response), 2) A high level of expression
of the genes - thus likely indicating a measurable response for this time point. In Figure 4.3 the
0 hour time point is the baseline effect against which the other time points were analysed. The
6 and 44 hour time points both have strong intra-time point trends, with the 6 and 44 hour time
points having relatively higher levels of expression (in terms of scale of expression), although
the expression profiles are biased in one direction for each time point respectively. The 20 hour
time point has a mixed expression profile with a relatively strong scale of expression for the
analysed genes, thus being the likely time point to best study the apparent dysregulation of the












4.3 Protein extraction method development:
4.3.1 MALDI-ToF/ToF workflow:
In order to establish a viable sample preparation method for MALDI ToF/ToF analysis, initial
focus was on a CHAPS based protocol (Methods chapter, Subsection 3.5.1.1). An extraction
volume of 100 µL of a 2 % CHAPS based lysis buffer was used for 1 x 106 PBMCs after initial
attempts using larger volumes of this lysis buffer (up to 1 mL) yielded poor recovery results (the
concentration of extracted proteins in the larger extraction volumes was too low and was close
to the lower limits of detection for the Bradford assay). The efficiency of the smaller volumes
of the extraction buffer were then visually inspected using a standard 10 % glycine-SDS-PAGE
Laemmli gel (Figure 4.4). Yields using this extraction protocol were generally consistent and
extractions from 500 000 PBMCs resulted in approximately 60 - 80 µg of crude total protein,
as quantified by the Bradford assay, and was consistent with previously published yields [248].
Figure 4.4: Initial iTRAQ compatible protein extractions
The gel pictured was used to run extracts from two different donor samples (lanes 1 and 2) that were extracted
using the CHAPS based protocol described by Skopeliti et al. [248], both lanes contain approximately 10 µg as
determined by Bradford reagent. Lane 3 is a molecular weight marker.
4.3.2 ESI Q-ToF workflow:
The 2 % CHAPS based lysis buffer that was initially used in the MALDI ToF/ToF workflow
was carried over to the ESI-MS workflow. However, the 2 % CHAPS based lysis buffer was
incompatible with downstream iTRAQ labelling - due to it containing Tris which is effectively a
primary amine and interferes with the iTRAQ chemistry - thus the proteins had to be precipitated












be compatible with trypsin for efficient enzymatic digestion prior to labelling. The following
iTRAQ compatible re-solubilisation buffers were attempted:
The first buffer tried was 500 mM TEAB as this is an ideal buffer for trypsin digestion (~ pH
8.5) and is compatible with the iTRAQ chemistry. However, this buffer failed to re-solubilise a
large number of proteins, leaving behind a large protein pellet.
The second buffer evaluated was 8 M urea in 500 mM TEAB. Post-resuspension, the urea
concentration was then diluted to 2 M using 500 mM TEAB. This approach still left behind
a small insoluble pellet and also increased the risk of carbamylated proteins being generated
during the workflow. A similar approach was attempted using 6 M guanidine-HCl in 500
mM TEAB which was subsequently diluted down to 1 M using 500 mM TEAB. Although
removing the risk of carbamination, this approach did not perform better in terms of protein
re-solubilisation.
We then hypothesised that the 2 % CHAPS (Methods chapter, Subsection 3.5.1.1) based buffer
used for the protein extraction may be selective (not producing a complete and representative
protein extraction) and that difficulties with downstream re-solubilisation may be attributable
to its properties. A new method was tested, substituting a DOC (Methods chapter, Subsection
3.5.1.1) based buffer for the CHAPS based buffer.
To test whether or not the DOC extraction was selective it was tested against lysing a PBMC
pellet in standard 1 x Laemmli SAB. The two extractions were performed on 500 000 PBMCs,
each isolated from the same donor: the first set was processed using the DOC extraction method
and the second set was processed by lysing the cells directly in a 1 x Laemmli SAB. Insoluble
debris was removed from both samples and the supernatant from both extractions were then run












Figure 4.5: Comparison of completeness of extraction
The gel was run and first stained in colloidal Coomassie Blue (lanes 4 - 6) and then stained using the more sensitive
silver stain (lanes 1 -3). Each lane contains the following: 1 and 6) Approximately 10 µg of DOC extract, 2 and
5) Approximately 10 µg of SDS/Laemmli extract, 3 and 4) Molecular weight marker - lanes 1 - 3 have been silver
stained, lanes 4 - 6 have been stained using Colloidal Coomassie Blue.
It was then decided to evaluate whether the DOC protein extraction protocol was compatible
with a standard trypsin digestion protocol for iTRAQ labelling and was capable of producing a
large number of well digested peptides that could be easily detected along a broad range when
run on a simple gradient through a C-18 reverse phase column on a n-LC system. This was done
by performing a test DOC extraction on approximately 1 x 106 PBMCs, followed by acetone
precipitation of the extracted soluble proteins.
Once precipitated the protein pellet was transferred to the CPGR for tryptic digest and n-LC
analysis. This was performed as follows: the protein pellet was re-suspended as per Methods
chapter (Subsection 3.5.1.1), for the DOC protocol and reduced in 5 mM TCEP at 57 °C for
1 hour, then alkylated (20 mM iodoacetamide, room temperature, 45 minutes in the dark) and
finally digested by adding in trypsin at a ratio of 1:50 (trypsin:total protein) and incubated at 48
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Figure 4.6: Nano-LC digest trace
The UV 214 trace (red line) of a typical protein digest from the DOC method. In this particular instance
approximately 5 µg of peptide was loaded onto a Dionex UltiMate® 3000 Nano LC system and run over 120
minutes at a flow rate of 0.300 µL / minute. The solvent gradient (blue line) is for the percentage of solvent buffer
B. Solvent buffer B was 95 % ACN, 0.125 % tri-fluoro-acetic acid (TFA) in H2O.
The success of the tryptic digestion in the protein product extracted using the DOC method led
to further method development and optimisation on the fractionation strategies that would be
employed on these samples.
4.4 Peptide Fractionation strategies:
In order to tease apart complex proteomic samples for more comprehensive LC-MS/MS













Protein extracted from PBMCs via the DOC protocol was digested with trypsin and desalted as
above. An aliquot of the tryptic peptides was removed before loading 300 µg onto the Agilent
3100 OFFGEL fractionator. The resultant MS spectra of the whole peptide lysate can be seen
in comparison to two of the OFFGEL fractions in Figure 4.7.
Figure 4.7: Effectiveness of Off-gel fractionation on crude PBMC protein extract
The effectiveness of Off-gel fractionation of proteins extracted from PBMCs was tested using an Agilent 3100
Off-gel Fractionator. Approximately 300 µg of protein was digested using trypsin, the peptide mixture was
desalted before being run on the fractionator. The resultant fractions were desalted and then run on a Agilent
6530 Q-ToF (two of these Off-gel fractions are displayed as the red and black total ion current chromatograms
- bottom and middle respectively). An aliquot of the original protein extraction was removed prior to Off-gel
fractionation and the whole peptide mixture was run as a control on the same mass spectrometer (blue total ion
current - top).
The lack of protein identifications in the combined Off-gel fractionated samples (less than
20) when compared to the whole peptide mixture (over 100) and the apparent overall loss of
complexity in the recovered fractions excluded this method from further experimental












4.4.2 High pH C-18 reverse phase fractionation:
Given the poor performance of the Off-gel fractionation, it was decided to evaluate high pH
reverse phase separation as an alternative. Approximately 50 µg of tryptic peptide was loaded
onto a self-manufactured reverse phase tip column containing approximately 8 µg of C-18 resin.
A manual step gradient (10, 15, 20, 25, 80 %) was applied and individual fractions collected
and analysed by LC-MS/MS at Stellenbosch University where Dr Salome Smit performed the
subsequent MS analysis (described in the Methods chapter, Subsection 3.5.1.3). The fractions
were run using a 90 minute n-LC gradient and the results were processed using Crux version
1.37. The parameters for the search were a q-value of 0.05 and degenerate peptides were






F1: 5 % ACN 170 492 611
F2: 10 % ACN 211 266 758
F3: 15 %ACN 162 365 589
F4: 20 % ACN 178 375 393
F5: 80 % ACN 107 204 293
Total non-redundant proteins 447 1011 1591
Total redundant proteins 828 1763 2645
% Redundancy 53.99 57.35 60.15
Table 4.1: Initial high pH RP protein numbers
The total number of proteins identified in each fraction (F1 - F5) are shown per database from which they were
obtained. The total number of non-redundant proteins is the total number of unique proteins summed across all
fractions. The total redundant proteins is the sum of each fraction together, including overlapping proteins. The
percentage redundancy is a measure of the percentage of proteins that are unique and do not overlap across the
different fractions. Organism 9606 in the UniProt databases is Homo sapiens. The difference between the two
UniProt database in Table 4.1 is that the GP database is the global proteome and contains splice variants and other
protein modifications, whereas the non-GP database essentially contains one protein per gene. The IPI database is
a meta-database that is formed from a number of other databases including UniProtKB, Ensembl, RefSeq, HinvDB
and VEGA and contains splice variants and isoforms although it has recently ceased curation.
Although results varied greatly depending on the database used, they indicated that the high pH
reverse phase separation protocol combined with the DOC extraction method was successful












4.5 Protein fractionation strategies:
Concurrent work by other members of our lab showed promising results using a “middle out”
approach (a limited protein fractionation step followed by a more extensive peptide fractionation
of the protein fraction-derived proteolytic peptides before MS analysis). This led to the testing
of two approaches for protein fractionation that could then be processed using the FASP protocol
described in the Methods chapter (Subsection 3.5.1.2). For ease of comparison, the fractionated
proteins were analysed on a standard 10 % glycine-SDS-PAGE Laemmli gel.
4.5.1 Crude sub-cellular fractionation:
Briefly, cytoplasmic proteins (fraction 1) were extracted after permeabilising the cell membrane
using digitonin, allowing the cytoplasmic proteins to diffuse out into the supernatant. Following
centrifugation, the supernatant was remove and the pellet was then re-suspended in an NP40
based buffer which solubilised the membranous organelles and their proteins (fraction 2). The
remaining cellular debris was pelleted by centrifugation and re-suspended in E-RIPA buffer
(containing 1 % SDS) to give the nuclear/insoluble protein fraction (fraction 3). An SDS-PAGE
gel was then used to compare the differences and similarities of the protein complement in













Figure 4.8: Crude sub-cellular fractionation
The gel above contains the CSF fractions (lanes 2 -7) extracted from two separate aliquots of 3 x 106 PBMCs,
as well as a DOC extraction (lane 9) from 1.6 x 106 PBMCs. All PBMCs were from the same donor.
The individual lanes contain: Molecular weight marker (1 & 8), cytoplasmic proteins fraction (lanes 2 & 5),
membranous-organelle protein fraction (lanes 3 & 6), nuclear & insoluble protein fraction (lanes 4 & 7) and the
DOC extraction (lane 9). The CSF samples from the first extraction (lanes 2 - 4) were processed using the FASP
protocol using a starting volume of 400 µL of starting material for all three fractions. The CSF samples from
the second extraction (lanes 5 - 7) were processed using the FASP protocol from a starting volume of 225 µL of
starting material for all three fractions. These volumes equated to approximately equal quantities of protein for
each fraction being loaded onto a 30 kDa MWCO spin filter at the initiation of FASP (~ 200 µg - as determined
by Bradford reagent). After the FASP process was completed up to the step prior to trypsin digestion, an equal
volume aliquot (~ 20 µL) was removed from the spin filter retentate and run on a gel. The DOC extraction was
not processed using the FASP protocol and approximately 10 µg of protein was loaded as determined by Bradford
reagent. The gel was then stained using colloidal Coomassie Blue.
4.5.2 Phosphoprotein enrichment:
Phosphoproteins are often enriched using chromatography based on IMAC or TiO2 resins. To
test the effectiveness of this method, an extraction was performed on a duplicate set of 3 x 106
PBMCs: one set was extracted in 1.5 mL 0.25 % CHAPS based lysis buffer and the other in
3 mL 0.25 % CHAPS based lysis buffer (Methods chapter, Subsection 3.5.1.3), both samples
were then enriched for phosphoproteins on a proprietary column according to the manufacturers
guidelines (http://www.qiagen.com/literature/render.aspx?id=23717). The
phospho-enriched and phospho-depleted fractions were then processed using the FASP protocol
described in the Methods chapter (subsection 3.5.1.2). An aliquot was removed prior to tryptic
digestion and run on a 10 % glycine-SDS-PAGE gel (Figure 4.9) to estimate the amount of
overlap between the two fractions, as well as compare them to the DOC extraction protocol that
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Figure 4.9: Phospho-protein extraction (Silver stained and CCB)
In Figure 4.9, Gel A contains the phospho-depleted (PD) fractions and the phospho-enriched (PE) that were
extracted from two separate aliquots of 3 x 106 PBMCs. All PBMCs were extracted from the same donor.
The extractions were performed as per the kit protocol with the only difference being that the first extraction
was performed in 3 mL CHAPS extraction buffer and the second extraction was performed in 1.5 mL CHAPS
extraction buffer. The individual lanes contain: Molecular weight marker (1), PD 1.5 mL (2) PD 3 mL (3) PE 1.5
mL (4) PE 3 mL (5). The 3 mL sample (PD and PE) was processed for FASP using a total volume of 250 µL of
starting material. The 1.5 mL sample (PD and PE) was processed using a starting volume of 450 µL of starting
material. These volumes equated to approximately equal quantities of protein for each fraction being loaded onto
a 30 kDa MWCO spin filter at the initiation of FASP (~ 200 µg - as determined by Bradford reagent). After the
FASP process was completed up to the step prior to trypsin digestion, an equal volume aliquot (~ 20 µL) was
removed from the spin filter retentate and run on an SDS-PAGE gel. Staining was performed using a silver stain
kit. Gel B, contains exactly the same samples as gel A in the same lanes but was stained using colloidal Coomassie
Blue.
4.5.3 Improved discovery strategy for shotgun proteomics:
A closer inspection of Figures 4.8 and 4.9 show some interesting details and characteristics.
In Figure 4.8 it can be seen that the reproducibility of the extraction is inconsistent across the
two extractions (green boxes) as well between the individual fractions of the two extractions
(red boxes): for example, high abundant proteins occur in all the fractions and certain bands
are present in one fraction but not in the same fraction for the repeat extraction. It appears that
the membranous-organelle protein fraction (fraction 2) had a far lower total protein quantity
than fractions 1 and 3 (cytoplasmic and nuclear/insoluble respectively). This would introduce
another variable in terms of workflow processing as this fraction would probably not need
peptide fractionation post tryptic digest, whereas the other two fractions would. By contrast,
from Figure 4.9 it appears that the volume used for the extraction has a bearing on the outcome
of the subsequent phospho-enrichment. A lower extraction volume (1.5 mL) appears to favour
















favour enrichment of the phosphoproteins (PE fraction). The 3 mL PE fraction also appeared
to have a high number of proteins across a large molecular weight range, with only four highly
abundant proteins visible (blue boxes). Based on these observations, as well as the fact that it
would be inherently appealing to enrich for proteins that are involved in signalling pathways in
order to gain insight regarding the differential response of the TB-IRIS and TBART samples
to the various experimental conditions, it was decided that the best option would be to use the
phosphoprotein enrichment rather than of the crude sub-cellular fractionation.
4.5.3.1 Protocol finalisation
Following on from the decision to use phospho-enrichment, the subsequent proteomic work
was performed on TB-IRIS and TBART samples as opposed to healthy donors as the need
to optimise a protocol or workflow had now been completed. Pooled culture samples for the
relevant time point and culture conditions for both TB-IRIS and TBART samples were extracted
using the phospho-enrichment 0.25 % CHAPS based lysis buffer. The insoluble proteins were
pelleted by centrifugation and the soluble proteins were loaded onto the phospho-enrichment
column, whilst the flow through was collected and kept aside for analysis as the phospho-
depleted fraction. The phospho-enriched fraction was obtained by eluting the bound
phosphoproteins.
4.5.3.2 Initial phospho-depleted results
As part of this phospho-enrichment approach, the phospho-depleted fraction could be further
fractionated to tease apart the higher quantity and complexity of the non-phosphorylated.
Initially, this was attempted by performing a manual high pH RP fractionation on the flow
through of the phospho-enrichment column. The flow through from the phospho-enrichment
column was thus collected and concentrated on a 10 kDa MWCO spin filter before being
processed as before (Sub-section 4.4.2). The crude fractions from the high pH reverse phase
column (five per sample) were collected and analysed by LC-MS/MS an Orbitrap Velos mass
spectrometer. Disappointingly, four out of five fractions identified between five and 25 proteins
per fraction, with the fifth fraction identifying 88 proteins. Based on this outcome, it was













4.5.3.3 Secondary phospho-depleted results
Previous high pH reverse phase fractionation (Subsection 4.4.2) had been shown to be robust
and provide high recovery of sample. However, based on the low numbers seen in the initial
phospho-depleted results using the flow though from the column during the phospho-enrichment
protocol, it was decided to determine how much protein remained as part of the insoluble pellet
that was recovered during the phospho-protein extraction after the lysis of the PBMCs using
the 0.25 % CHAPS based buffer. The insoluble protein pellets from the various samples during
the phospho-protein extraction were re-solubilised in 50 µL 1 x SAB buffer and incubated at
95 °C for 20 minutes. A 10 µL aliquot was then run on a standard 10 % glycine-SDS-PAGE
Laemmli gel. A large number of proteins were visible on this gel so a second gel was then run
maximising sample loading.
Figure 4.10: TBART phospho-depleted gel
Figure 4.10 above, is of the insoluble protein pellets from the phospho-protein extraction of the TBART samples,
run on a standard 10 % glycine-SDS-PAGE gel. The 1mm thick gel was run for 90 minutes at 20 mA and stained
using CCB. Lane 1 was the molecular weight marker. Lanes 2 and 3 were duplicates of the TBART - Dex / - heat
killed H37Rv (MM), lanes 3 and 4 were duplicates of the TBART - Dex / + heat killed H37Rv (MP) samples. All
lanes were loaded using 20 µL aliquots of the insoluble protein pellet re-solubilised in 50 µL 1 x SAB and heated
to 95 °C for 20 minutes.












Figure 4.11: TB-IRIS phospho-depleted gel
Insoluble protein pellets from the phospho-protein extraction of the TB-IRIS samples, run on a 10 %
glycine-SDS-PAGE gel. The 1mm thick gel was run for 90 minutes at 20 mA and stained using aquastain
(AcquaScience, cat. no. AS0001000) . Lane 1 was the molecular weight marker. Lane 2 was the TB-IRIS +
Dex / + heat killed H37Rv (PP) sample, lane 3 was the TB-IRIS - Dex / + heat killed H37Rv (MP) sample and lane
4 was the TB-IRIS - Dex / - heat killed H37Rv (MM) sample. All lanes were loaded using the 20 µL aliquot of 1
x SAB that was used to re-solubilise the pellet by heating to 95 °C for 20 minutes.
Each lane of each gel was cut into five fractions and each gel slice was then subjected to in-gel
tryptic digestion according to the method described in the Methods chapter (Subsection 3.5.4).
The TBART samples, Figure 4.10, had enough sample for duplicate lanes to be combined
together. The TB-IRIS samples, Figure 4.11, had enough sample for one lane per sample to
be run. Following extraction of the resultant tryptic peptides from the gel slices, each set of
peptides were analysed by LC-MS/MS on an Orbitrap Velos mass spectrometer.
4.6 Data processing for downstream software analysis
The RAW data for each proteomic experiment described above was processed at the time of
acquisition using the basic workflow outlined in the Methods chapter (Section 3.7). However,
in order to obtain an accurate measure of the protein numbers for each method and to obtain
a relative perspective on the number of proteins identified in each method, whilst allowing for
updates in software and databases the RAW data for each method was subsequently re-processed
using an identical workflow and parameters (algorithm version, databases, thresholds etc.). The













The Barista algorithm was used to identify proteins from the various experiments [253]. Due to
the nature of the pairwise analysis it was decided to use a q-value of ≤ 0.05 as the threshold in
downstream analysis since the probability of specific proteins being false positives in both sets
of data would be lower than the q-value for a single dataset and could thus be included in the
analysis.
Sample Group Culture condition UniProt Organism
9606 Global
Proteome q ≤ 0.05
UniProt Organism
9606 Global






















Table 4.2: Non-redundant protein numbers per sample group
Protein numbers indicated above are the total number of non-redundant proteins identified per sample group.
The “ALL” groups are the non-redundant numbers for the constituent culture condition protein lists. All
protein numbers are calculated with a Barista q-value ≤ 0.05 (column one) and ≤ 0.01 (column two) . PD =
phospho-depleted, PE = phospho-enriched, PDE = phospho-depleted + phospho-enriched.
In Table 4.2, the phospho-enriched (PE) data is from the 0.25 % CHAPS lysis followed by
on-column phospho-enrichment, followed by tryptic digestion and analysis by LC-MS/MS.
The phospho-depleted (PD) data is from the re-solubilisation of the insoluble protein pellet that
remained after the CHAPS based lysis for the phospho-enrichment protocol that was
subsequently fractionated using SDS PAGE before undergoing in-gel tryptic digestion and
then analysed by LC-MS/MS. The different fractions were merged at the spectra level using
the Barista algorithm. These two datasets were then combined at the protein level into a












the analysis of the flow through from the phospho-enrichment column was excluded due to the
poor number of identifications and inconsistent quality.
4.6.2 Protein quantification
Protein quantification was performed using normalised spectral abundance factor (NSAF)
values that were obtained from the spectral data during protein identification. It has been shown
that the the number of spectra that identify a protein correlate to the quantity of the protein
that is present in the sample [254], and since small proteins tend to have fewer spectral counts
than large proteins, spectral count normalisation is often used to minimise quantitative errors.
A normalisation approach using NSAF values was proposed by Zybailov et al. [224], whereby
the NSAF for a protein k is a normalised spectral count taking into consideration the spectral
counts and protein length of all proteins identified in the experiment. The relative abundance of













5.1 Data set pairing
Datasets were analysed in a pairwise manner to increase the overall number of identified proteins
that were used for further downstream analysis. Datasets were paired within their corresponding
patient groups (TB-IRIS or TBART) and contained one test condition (MP or PP) paired against
the baseline condition (MM) for that respective patient group, giving a ratio fold change
representing the paired dataset. Protein identifications were performed using a q-value of ≤
0.05 as the cost/benefit ratio for using this slightly less stringent q-value was such that there
was just under a 20 % gain in protein identifications for both the TB-IRIS and TBART data
at a cost of the number of false positives increasing by four percent. The probability that any
specific false positives would be found by chance in both paired datasets also serves to reduce
the number of false positives that would likely be seen in the common proteins in each paired
datasets. The lack of replicates also means that there is not enough power behind the statistics
when analysing changes in protein expression profiles at the protein level and consequently the
majority of the analysis is performed at the pathway level. This is not to say that potentially
interesting trends may be identified at the protein level, however it is not possible to state with
confidence if these trends are significant or not.
The paired groups and their corresponding number of proteins (based on the quantified proteins
common to both datasets in Table 4.2) are listed in Table 5.1.
Paired conditions Common proteins
TB-IRIS MP TB-IRIS MM 320
TB-IRIS PP TB-IRIS MM 337
TBART MP TBART MM 391
Table 5.1: Pairwise protein datasets for downstream IPA analysis
For each paired condition, commonly identified proteins with NSAF values (Barista quantitation values) were













Despite there being a noticeable difference in the numbers of proteins identified in the TB-IRIS
PDE MM dataset compared to the TBART PDE MM dataset - 467 versus 698 - (Table 4.2),
it appears from the subsequent qualitative data analysis that this has not skewed the results by
limiting one of the baseline datasets in the IPA analysis. Indeed, looking at Table 5.1 shows
that the number of paired proteins per dataset is approximately similar. A further analysis of
the distribution of canonical pathways, Figure 5.12, indicates that only 12 % (15 / 125) of the
identified canonical pathways are unique to the to the TBART MP-MM paired dataset.
5.2 Systems analysis using Ingenuity Pathway
Analysis data
Ratios for the fold change of the common proteins found in each individual paired datasets
were uploaded into Ingenuity Pathway Analysis (IPA) software where they were analysed
using default program parameters after being log transformed. The only changes to the default
conditions were to limit the analysis to Homo sapiens based parameters, excluding mouse and
rat parameters. A Core Analysis and a Biomarker Analysis were performed as standard for
each paired dataset that was uploaded. Comparison of Core and Biomarker analyses for certain
combinations of the paired datasets were also performed. The level of analysis can broadly
be interpreted at the protein level as well as at the pathway level and the results of these are
presented hereafter.
5.2.1 Intra-condition protein level analysis
In IPA, the Core analysis function ranks the top candidates that have been identified across
a number of fields. Table 5.2 shows the predicted fold changes in protein abundance for the
highest ranked candidates (by degree of change) across the paired datasets described in Table
5.1. Fold changes were obtained from the ratio, x, of the normalised spectral abundance factor
(NSAF) values for proteins common to both datasets where if x < 1 then it is converted by the


























































































Table 5.2: IPA core analysis predicted protein changes: up-regulated
The values represent the predicted up-regulation fold change in the corresponding proteins. TBART MP/MM = the
ratio of the fold change values determined by the NSAF values for specific proteins from the TBART MP dataset
divided by the NSAF values for the corresponding proteins in the TBART MM dataset, TB-IRIS MP/MM = the
ratio of the fold change values determined by the NSAF values for specific proteins from the TB-IRIS MP dataset
divided by the NSAF values for the corresponding proteins in the TB-IRIS MM dataset, TB-IRIS PP/MM = the
ratio of the fold change values determined by the NSAF values for specific proteins from the TB-IRIS PP dataset
divided by the NSAF values for the corresponding proteins in the TB-IRIS MM dataset. * indicates proteins that






























































































Table 5.3: IPA core analysis predicted protein changes: down-regulated
The values represent the predicted down-regulation fold change in the corresponding proteins. TBART MP/MM
= the ratio of the fold change values determined by the NSAF values for specific proteins from the TBART MP
dataset divided by the NSAF values for the corresponding proteins in the TBART MM dataset, TB-IRIS MP/MM
= the ratio of the fold change values determined by the NSAF values for specific proteins from the TB-IRIS MP
dataset divided by the NSAF values for the corresponding proteins in the TB-IRIS MM dataset, TB-IRIS PP/MM
= the ratio of the fold change values determined by the NSAF values for specific proteins from the TB-IRIS PP
dataset divided by the NSAF values for the corresponding proteins in the TB-IRIS MM dataset. * indicates proteins
that do not exceed the threshold limit in Figure 5.1 and Figure 5.2.
A second, more visual analysis of the changes in the protein expression profiles of the two
disease states (TBART and TB-IRIS) was performed using the log of the ratios of the changes
in individual protein NSAF expression values that were plotted using the R scripting language
on a Cartesian plane. A threshold of two times the standard deviation was employed to eliminate
normal random error or variation in the measurements and hence distinguish them from causal
variation. Standard deviation represents how much variation exists from the average mean, or
expected value in a dataset. A low standard deviation indicates that the data points tend to be












spread out over a large range of values.
Figure 5.1: Protein expression profile distribution of TBART MP samples
The ratios of the quantile-normalised quantitation values for the TBART MP and TBART MM datasets were log2
transformed and plotted on a set of axis. Proteins that did not have significant (more than two times the standard
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Figure 5.2: Protein expression profile distribution of TB-IRIS MP samples
The ratios of the quantile-normalised quantitation values for the IRIS MP and IRIS MM datasets were log2
transformed and plotted on a set of axis. Proteins that did not have significant (more than two times the standard
deviation of the mean) changes in their ratios were excluded (pink band) leaving only proteins of interest labelled.
The effect of dexamethasone on the protein expression profile of TB-IRIS patient derived
PBMCs in the presence of H37Rv antigen was also plotted.
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Figure 5.3: Protein expression profile distribution of TB-IRIS PP samples
The ratios of the quantile-normalised quantitation values for the IRIS PP and IRIS MM datasets were log2
transformed and plotted on a Cartesian plane. Proteins that did not have significant (more than two times the
standard deviation of the mean) changes in their ratios were excluded (pink band) leaving only proteins of interest
labelled.
There are a number of interesting proteins that apparently have significant changes in abundance
but without repeat measurements of expression values it is difficult to maintain statistical
confidence in these absolute values. Regardless, this analysis does provide a few proteins of
interest that may prove worthwhile for analysis in future studies.





































Table 5.2 and Table 5.3 does not reveal any significant involvement of these proteins in any
inflammatory based pathways. The exception being that of integrin linked kinase (ILK), a
plasma-membrane protein that plays a key role in integrin signalling that is up-regulated in the
TB-IRIS PP/MM dataset. Although the lack of any other proteins relating to inflammatory
responses or cell-to-cell communications makes it difficult to ascertain the significance of this
finding. In fact, the vast majority of the proteins from those tables have very little if any overlap
in related pathways to which they belong.
IPA has the capacity to interrogate data against known or putative biomarkers as well as to
identify potential biomarkers through their presence or absence across directly compared
datasets. A biomarker analysis using IPA was performed for all three conditions and Table
5.4 shows the outcome.
Condition Gene Name Protein details
TBART MP/MM
HLA-DRB1 MHC II, DR beta 1
ITGB Integrin beta 2, complement component
receptor 3 and 4 subunit
PRKCD Protein kinase C, d lta
PTPN6 Protein tyrosine hosphatase, non-receptor
type 6
TB-IRIS PP/MM
ARRB1 Arrestin, beta 1
CD36 CD36 molecule, thrombospondin receptor
All three
MPO Myeloperoxidase
STAT1 Signal transducer and activator oftranscription
1, 91 kDa
Table 5.4: IPA biomarker analysis
Biomarker analysis using IPA software for the three patient derived PBMC datasets was performed, specifically
looking for biomarkers within human cells related to inflammatory or immunological dysfunction. No unique
biomarkers were found for the TB-IRIS MP/MM datasets, however there were two biomarkers common to all
three datasets that were observed.
5.2.2 Intra-condition biological pathway level analysis
Analysis of the distribution of p-values for the datasets across various biological functions












Figure 5.4: Overview of differences in biological functions
It is immediately clear from Figure 5.4 that major differences in the biological functions exist
between each of the three conditions that were analysed. For example, it seems intuitive
that inflammatory responses should be more highly represented in the TB-IRIS than TBART
samples and that the dexamethasone treated TB-IRIS samples should be intermediate between
the two. It is less obvious though why differences might exist between TB-IRIS and TBART
samples in “cell function and maintenance” or “cell-to-cell signalling and interaction”. A more
probing analysis of the composition of the differences in these biological functions and their
composite pathways, using the activation z-score values, reveals some interesting differences
between the TB-IRIS MP/MM, TB-IRIS PP/MM and TBART MP/MM datasets. These
differences have been tabulated in Figure 5.6.
Within IPA, the z-score algorithm is used as a means to calculate the activation state of a
pathway. The z-score prediction is based on relationships, referred to as edges, in the molecular
pathway. The edges must; 1) Represent experimentally observed gene expression or Upstream
events, 2) Be associated with a direction of change that is either activating or inhibiting (as












5.5, given the observed differential regulation of a gene (up or down), the z-score determines
the activation state of an upstream regulator by the regulation direction associated with the
relationship from the upstream regulator to the gene. If the z-score is ≥ 2 then the pathway
activity is predicted to increase, while if the z-score is ≤ - 2 then the pathway activity is
predicted to decrease, with values between 2 and -2 are not assigned predictions in activation
state.
Figure 5.5: How the z-score is calculated
The activation z-score identifies upstream regulators that can explain changes in expression of the gene or protein
for the observed dataset, and predicts the activation state of the upstream regulators. IPA assigns the red colour to
up-regulated products and green to down-regulated products.
A biological function is only predicted to increase or decrease if the z-score meets the minimum
statistically relevant thresholds described. The z-score is thus notably different from a p-value in
that it used to predict activity of a pathway and not just identify pathways that show enrichment
















Figure 5.6: Delving deeper into biological functions
Significant z-score values for specific biological functions belonging to multiple biological pathways (highlighted
in the key provided as part D). The number of molecules refers to the number of molecules in this dataset that are
being used to categorise the the specific biological function as well as determine the z-score. The p-value is the
significance level of over-representation of the molecules associated with the specific biological function.
An assessment of the differences in biological functions (using the z-score) is one of many
macro-level analyses that can be performed to analyse differences in biological dataset trends.
The second macro-level analysis that was performed entailed the analysis of the canonical
pathways of the three datasets using the p-value as a measure of over-representation. The













dataset and a related function is due to random association. The smaller the p-value, the
less likely that the association is random and the more significant the association. In general,
p-values < 0.05 indicate a statistically significant, non-random association. The p-value of
overlap is calculated in IPA by the Fisher’s Exact Test.
An analysis of non-significant activation scores for the TB-IRIS MP/MM dataset also revels a
number of biological functions that have been activated, Table 5.5.
TB-IRIS MP/MM
Focused Biological Pathway Z-score p-value # Proteins
Activation of blood cells 0.649 3.97E-06 30
Activation of phagocytes 0.856 2.98E-04 15
Activation of T lymphocytes 0.941 1.51E-02 11
Activation of mononuclear leukocytes 1.056 1.07E-02 15
Phagocytosis of granulocytes 1.000 2.13E-03 4
Phagocytosis of myeloid cells 1.067 1.78E-03 5
Table 5.5: Non-significant TB-IRIS analysis
Activation scores of other immunological and inflammatory based biological functions for the TB-IRIS MP/MM
dataset that did not achieve a significant activation z-score. This illustrates the varied and non-focussed nature of
the TB-IRIS MP/MM dataset.
5.2.3 Inter-condition Canonical Pathways Analysis: TBART vs
TB-IRIS
The Ingenuity Pathway suite of software was used to visualise, by way of a stacked bar chart,
the over-representation values of various canonical pathways, including the number of up-
and down-regulated proteins within that particular pathway. The TB-IRIS MP/MM, TBART
PP/MM and TB-IRIS MP/MM datasets (Figure 5.7) show a number of interesting trends in the












Figure 5.7: IPA generated stacked bar chart of TB-IRIS MP/MM dataset
Listed are 20 of the most relevant canonical pathways across the three datasets. The -log10 of the p-value
of over-representation is represented on the right axis scale for each diagram and the percentage coverage of
experimentally observed proteins relative to the total number of proteins in that pathway is on the left axis. The
bold numbers at the end of each bar represents the total number of proteins involved in the pathway in the reference
database. A = TBART MP/MM dataset, B = TB-IRIS PP/MM dataset, C = TB-IRIS MP/MP dataset. The bar chart
represents percentage coverage of each pathway, separated into up- (red) or down- (green) regulated protein sets.












Changes in canonical pathway over-representation profiles across the TB-IRIS and TBART
samples were also analysed, using only proteins common to both paired datasets and then
adjusting these values using the log[ratio of changes between paired datasets].
Figure 5.8: Over-representation analysis of canonical pathways
The -log[p-value] for common and significantly over-represented canonical pathways was plotted on a Cartesian
plane, with the x-axis representing TB-IRIS values and the y-axis TBART values. The dotted line represents the
null hypothesis that the over-representation for a given pathway is equal for both TB-IRIS and TBART samples.
The pink band sets a threshold of change in the p-value of 0.01 from this null hypothesis line for both sets of data,
thus highlighting those canonical pathways that exceed this level of significance.
Figure 5.8 clearly indicates that a number of canonical pathways have been significantly over-
represented for both patient datasets when analysed using Ingenuity Pathway Analysis software.
Significant differences found in these pathway associated p-values (represented as -log[p-value])
between the datasets can be used to determine which of the pathways are more highly













Figure 5.9: Differential analysis of significantly over-represented canonical pathways
The ∆ -log[p-value] was determined by subtracting the -log[p-value] for TB-IRIS from the -log[p-value] for
TBART associated canonical pathways for the pathways highlighted in Figure 5.8. A positive ∆ -log[p-value]
indicate a greater over-representation of the associated pathway in TBART patient derived data, whereas a negative
∆ -log[p-value] indicate a greater over-representation of the associated pathway in TB-IRIS patient derived data.
Based upon this analysis, it is clear that there are a number of canonical pathways that are
significantly over-represented for the TBART derived PBMCs when compared against the
TB-IRIS derived PBMCs. Interestingly many of these canonical pathways are connected in
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organisation, motility, function, recruitment, signalling and maintenance.
5.2.4 Pathway analyses of the effect of dexamethasone
To determine the effect of dexamethasone on the changes in canonical pathway over-
representation profiles, common proteins from paired ratio datasets (TBART MP/MM vs TB-
IRIS PP/MM; TB-IRIS PP/MM vs TB-IRIS MP/MM) were plotted.
Figure 5.10: Canonical pathway analysis of effect of dexamethasone
The -log[p-value] for common and significantly over-represented canonical pathways was plotted on a Cartesian
plane. The dotted line represents the null hypothesis that the over-representation for a given pathway is equal
for both TB-IRIS and TBART samples. The pink band sets a threshold of change in the p-value of 0.01 from
this null hypothesis line for both sets of data, thus highlighting those canonical pathways that exceed this level of
significance. Graph A (left) represents TBART MP vs TB-IRIS PP and graph B (right) represents TB-IRIS PP vs
TB-IRIS MP.
A comparison of the changes in significantly over-represented canonical pathways in the













Figure 5.11: Effect of dexamethasone on canonical pathway profiles
Box 1 represents canonical pathways that were significantly over-represented in TBART MP/MM dataset when
compared against the TB-IRIS MP/MM but which are absent when the TBART MP/MM dataset was compared
against the TB-IRIS PP/MM dataset (Figure 5.8). Box 2 represents canonical pathways that were significantly
over-represented in TB-IRIS PP/MM dataset in comparison to the TB-IRIS MP/MM dataset (Figure 5.10).
5.2.5 Analysis of unique pathways
Pathways that were significantly over-represented for three pairwise datasets (TB-IRIS PP-MM,
TB-IRIS MP-MM, TBART MP-MM) were also analysed using a Venn diagram (Figure 5.12) to












Figure 5.12: Venn diagram of canonical pathway analysis
Venn diagram of significantly over-represented canonical pathways (p-value ≤ 0.05) for the three pairwise datasets.
Red circle = TB-IRIS PP-MM, blue circle = TB-IRIS MP-MM, green circle = TBART MP-MM. Numbers
represent the number of pathways that are shared by the corresponding datasets or are unique to one dataset.
Table 5.6, lists the individual pathways that are unique across the datasets and as such would
have been removed from the previous paired dataset analysis as that was based on significantly
over-represented canonical pathways that were common to both sets of data.
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Prostate Cancer Signalling 1.45
TB-IRIS MP-MM
Amyloid Processing 1.62
Antiproliferative Role of Somatostatin Receptor 2 1.33
Apoptosis Signalling 1.35
Cardiac β -adrenergic Signalling 1.57
Colorectal Cancer Metastasis Signalling 1.85
DNA Double-Strand Break Repair by Non-Homologous End Joining 1.43
Dopamine Receptor Signalling 1.59
Endothelin-1 Signalling 1.52
HIF1α Signalling 1.64
Hypoxia Signalling in the Cardiovascular System 1.94
IL-1 Signalling 1.30
Metabolism of Xenobiotics by Cytochrome P450 1.37
Sphingosine-1-phosphate Signalling 1.45
Tumoricidal Function of Hepatic Natural Killer Cells 1.82
TBART MP-MM
Aminosugars Metabolism 1.37
Amyotrophic Lateral Sclerosis Signalling 1.33
Bile Acid Biosynthesis 1.37
Calcium-induced T Lymphocyte Apoptosis 1.70
Fructose and Mannose Metabolism 1.37
Galactose Metabolism 1.62
Glyoxylate and Dicarboxylate Metabolism 2.00
Mechanisms of Viral Exit from Host Cells 3.19
nNOS Signalling in Neurons 1.46
Pentose Phosphate Pathway 1.37
Primary Immunodeficiency Signalling 1.43
Tight Junction Signalling 1.66
Tryptophan Metabolism 1.55
Table 5.6: Unique canonical pathways from IPA analysis












It is clear from clinical and immunological data that inflammatory responses to the M.tb
pathogen differ in vivo between TB-IRIS and TBART patients. This study was therefore
undertaken to develop a broader understanding of the proteomic phenotypes of TB-IRIS and
TBART patient derived PBMCs to better understand at a sub-cellular level the development
TB-IRIS. PBMCs were selected to model this difference in vitro, using changes in the proteomic
expression profiles of these cells in response to M.tb to study underlying mechanistic differences
as well as to identify potential biomarkers. PBMCs in cell culture represent a well defined
model and analysis of their proteome seems likely to reveal a greater degree of complexity than
previous immunology studies, built upon the analysis of a limited number of secreted or cell
surface marker proteins, have been able to do.
The results of this study provide some fascinating insights regarding the possible mechanisms
associated with the development of TB-IRIS, as well as regarding the physiological changes
that are induced in TB-IRIS PBMCs by treatment with dexamethasone. Due to the nature of
the experimental design, in particular the limiting supply of patient samples and the need to
pool samples post-culturing it was not possible to perform biological replicates here; indeed
there was not even enough sample for technical replicates. A discussion at the pathway level
of analysis therefore appears a more robust approach than that of a protein level analysis
in terms of the differences between the expression profiles of TBART and TB-IRIS derived
PBMCs. The focus on pathway analysis makes it difficult to identify with great certainty definite
biomarkers, but it does provide a platform from which to further study and validate potential
biomarkers. The strength of this approach and subsequent data analysis lies in the identification
of differences in sub-cellular pathways that have been utilised in response to the dual infections
of HIV and TB.
Extraction conundrum: It is important to remember the complexity of the nature of protein
extraction. Mass spectrometry based high throughput proteomics inherently requires a protein
extraction protocol that is robust, easily repeatable and does not result in a bias towards certain












a trade off that needs to be made during the protein extraction and processing steps. This trade
off comes from the need to use relatively harsh lysis buffers to ensure that as complete a protein
compliment is extracted in as small a volume as possible. The lysis buffer must also cause the
least amount of chemical or other modifications possible (for example the accidental removal
of phosphate groups). However these lysis buffers often contain detergents and other reagents
that are incompatible with either the enzymatic digestion process or with the LC or mass
spectrometer itself. Harsher detergents may yield greater concentrations of proteins but will
result in a need for more processing, and subsequent sample loss, before they can be analysed
by LC-MS. Not using detergents may result in a poor protein yield that requires little processing
before digestion or LC-MS. There is no simple one method for all occasions in proteomics and
researchers should always ensure that they understand the research question that the experiment
is attempting to answer. Thus it is important to note that an analysis of the proteome at the
pathway level should be especially informative on the nature of the sample preparation and the
quality of the extraction protocols that have been used.
6.1 Pathway level analysis
The differences at the macro-level of biological functions that were detailed in Figure 5.4
provides a clear indication that there are quantitative differences in the activation and expression
profiles of the TB-IRIS and TBART PBMCs. However it is from Figure 5.6 that the qualitative
differences can be most easily assessed.
Of particular interest is that there appears to be a decrease in the communication of blood cells
in the TB-IRIS MP/MM condition. Despite registering signs of an immune response, deduced
from the increased activity in the formation of cellular protrusions and movement of PBMCs
and the overall strong overrepresentation of inflammatory response pathways (Figure 5.4), it
appears these TB-IRIS PBMCs do not exhibit signs of having a co-ordinated immune response
to any measurable degree since they are lacking activation of a number of any distinct innate
or adaptive responses. There were a number of immune responses that were identified with
a z-score below two (i.e. not activated) and it is plausible that these cells lack a co-ordinated
response to the high antigen load that would be present in typical TB-IRIS patients.
By contrast it appears that treatment of TB-IRIS PBMCs with dexamethasone (the TB-IRIS
PP/MM dataset) results in a greater number of biological pathways related to an innate immune
response being activated, pathways relating to neutrophils, phagocytes, antigen presenting cells












responses or suppressing other immune responses to the extent that a focussed immune response
is apparently produced is as yet unclear.
The correlation between the ability of TBART patients to effectively cope with the dual
infections of HIV and TB in combination with appropriate treatment could be based on an
effective adaptive immune response. The evidence for this can be observed in the fact that
PBMCs for the TBART MP/MM dataset exhibit signs of an activated pathway for the adhesion
of monocytes and a proliferative T-cell response. This suggests that these cells are capable of
recruiting monocytes and activating these an adaptive immune response. These TBART PBMCs
also exhibit evidence of having better cellular organisation and it may be that with this improved
cellular organisation there is an improved capacity for these cells to form functional granulomas
and effectively contain the often excessive M.tb antigen load at dispersed sites of disease.
6.1.1 The differing patient responses: TBART vs TB-IRIS
Over representation analysis of identified proteins common to both TBART and TB-IRIS patient
derived PBMCs within the context of specific canonical pathways is perhaps a more robust
means of analysing differences between these two patient groups who have been shown to
display distinctly different patterns of disease progression and responses to treatment in vivo.
A closer inspection of the results of the expression profiles in Figure 5.9 reveals that the
TBART patient derived PBMCs had consistently higher levels of expression in certain canonical
pathways when compared to the TB-IRIS derived patient PBMCs when re-stimulated with
H37Rv. Most notable of thes pathways were the RhoA signalling pathway, regulation of
actin-based motility by Rho pathway, Fcγ receptor-mediated phagocytosis in macrophages
and monocytes pathway, integrin signalling pathway, actin cytoskeleton signalling pathway,
signalling by Rho Family GTPases pathway, RhoGDI signalling pathway, EIF2
signalling pathway, Rac signalling pathway, actin nucleation by ARP/WASP complex pathway,
leukocyte extravasation signalling pathway & the antigen presentation pathway.
Many of these pathways are very closely related and often overlap in terms of pathway
regulation or directly flow from one into the other; Figure 6.1 illustrates this for the proteins
identified in the TBART MP/MM dataset.
The common factor linking all of these is the role of the actin cytoskeleton in the maintenance
and functioning of these cells, notably with respects to: extra-cellular mediated signalling and
recruitment of other lymphocytes and leukocytes, cellular motility, engulfing foreign particles,
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remaining antigens. All of these functions are crucial when combating infections, particularly
TB where the capacity to engulf foreign particles or form functional granulomas is of great
importance and diminished by dual infection with HIV.
6.1.1.1 Actin cytoskeleton organisation
This key cellular structure (specifically the actin cytoskeleton) can be thought of as a dynamic
filament network and is a key structural component of the cell, mediating many biological
functions that are dependant on cellular structure such as: cell motility, phagocytosis, antigen
presentation, signalling and apoptosis. There are three distinct branches in the actin cytoskeleton
organisation pathway and they are activated by various classes of transmembrane receptors,
such as integrin receptors, receptor tyrosine kinase or G protein-coupled receptors.
6.1.1.2 Cellular motility
Cellular movement is a result of adhesion, loss of attachment and subsequent re-adhesion of
filopodia and lamellipodia structural elements of the cell in a cyclical manner and is perhaps
the most relevant of the actin cytoskeleton related cellular functions. It is primarily regulated
through the Rho family of small GTPases - notably RhoA, Rac and cell division cycle 42
protein (Cdc42). RhoA is implicated in the formation of actin stress fibres, focal adhesion
and actinomyosin assembly. RhoA binds and activates Rho kinase (ROCK), which has several
downstream cytoskeletal targets including; increasing myosin light chain (MYL)
phosphorylation by directly phosphorylating MYL and inhibiting the myosin light chain
phosphatase (MLCP) leading to actinomyosin assembly. ROCK also phosphorylates LIM-
kinase (LIMK), which subsequently phosphorylates the actin depolymerising protein, cofilin
(CFL), inhibiting its function and resulting in stabilisation of actin. While RhoA causes the
formation of stress fibres, stimulation of Rac, through the activation of WAVE and the actin-
related protein (ARP) 2/3-actin complex, induces the formation of lamellipodia and activation
of Cdc42 leads to the formation of filopodia, through the binding of N-WASP.
These cellular activities need to be tightly controlled and this is achieved, both spatially and
temporally, through the nucleation of new actin filaments and the elongation of existing
filaments using key regulators of the Wiskott-Aldrich Syndrome Protein (WASP) family, such
as N-WASP and up to three variants of SCAR/WAVE (WAVE 1, 2, 3). Nucleation of new actin
filaments is spatially controlled by the ARP2/3 complex which is an important regulator of actin












actin filaments at the leading edge of cells - pushing the plasma membrane forward and causing
protrusions.
The regulation of cellular motility is integrated and regulated through a number of key canonical
pathways, namely: Actin Nucleation by ARP/WASP Complex, Rac signalling, Regulation of
Actin-based Motility by Rho, RhoA signalling, RhoGDI signalling and Signalling by Rho
Family GTPases. All of these canonical pathways are significantly more over-represented in
the TBART MP/MM dataset than in the TB-IRIS MP/MM dataset, suggesting that the TBART
derived PBMCs have a better capacity to co-ordinate and execute the required regulation of this
important biological function. It conceivable that PBMCs belonging to the TBART patients
are more capable of being mobilised to sites of infection and once there are able to elicit a
proliferative T-cell response, unlike what has been observed for the TB-IRIS derived PBMCs.
6.1.1.3 Phagocytosis
The capacity to engulf extra-cellular compounds for consumption (in the case of nutrients),
destruction (in the case of pathogens) or clearance from the extra-cellular space (in the case of
antigens) is an important function of lymphocytes and monocytes. The process of phagocytosis
is complicated and normally refers to a number of events that have been grouped together, for
example: particle binding, receptor clustering, actin nucleation, pseudopod extension,
membrane recycling and phagosome closure. The Fcγ receptors (FcγR) of the immunoglobulin
superfamily are well characterized phagocytic receptors in macrophages and monocytes. The
receptors signal via immunoreceptor based tyrosine activation motifs (ITAM) when they are
activated. When IgG opsonised particles bind to the FcγR and activate it there is resultant
tyrosine
phosphorylation of the associated ITAM, creating a binding site for the SRC kinase members
like LYN and HCK and the spleen tyrosine kinase (SYK). As previously mentioned, actin
assembly and organisation is a crucial step in phagocytosis (especially early in the process)
and is triggered by G proteins like Rac and Cdc42 through the activation of the ARP 2/3
complex amongst others. Local polymerization of actin filaments is crucial for the formation
and protrusion of pseudopodia that eventually internalize the opsinised particle and this is
controlled be a large molecular complex containing WASP that is recruited to the newly formed
phagosome and plays a crucial role in actin polymerization and pseudopod extension.
From Figures 6.2 - 6.4 it is clear that the TBART-MP/MM dataset has a greater degree of
activation of this pathway compared to the TB-IRIS MP/MM and PP/MM datasets. This ability
to clear antigen effectively therefore appears to be one of the key differences between the
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identified proteins from the TBART MP/MM dataset in the Fcγ receptor-mediated phagocytic
pathway with other canonical pathways that are important in actin cytoskeleton organisation, it
becomes obvious that there are a number of key proteins (Table 6.1) that act as regulators for









Table 6.1: Key proteins integrated in the multiple canonical pathways
The proteins in the above table are key regulators of the “Fcγ Receptor-mediated phagocytosis in Macrophages and
Monocytes” canonical as well as key regulators in key canonical pathways that have been identified as significant
in Figure 5.8. The connections column denotes within how many of these key pathways these pathways play a
regulatory role.
It is also interesting to note that a recent gene expression study on correlates of pathogenesis-
driven gene expression signatures in TB observed an up-regulation of the FcγR1 gene as a
hallmark of active TB [255]. This perhaps, suggests that TBART derived PBMCs are responding
to TB antigen in a similar manner to an HIV negative patient, whilst TB-IRIS derived PBMCs
are somehow responding aberrantly.
6.1.1.4 Antigen presentation
The actin cytoskeleton has a key role to play in the presentation of internally produced antigens
and is thus a critical component of the host cell’s defence against phagocytosed pathogens.
The canonical pathway associated with this mechanism is known as the antigen presentation
pathway and is intricately linked to the presentation of both internal foreign particles (e.g.
proteins or lipids) or endogenously derived antigens. In the case of intra-cellular antigens, such
as those derived from tumour cell proteins, this is achieved using the major histocompatibility
complex (MHC) Class I system. The MHC Class II system is associated with the presentation
of extra-cellular pathogen derived antigens that have been generated through phagocytosis of
the pathogen and degradation of the organism in the lysozome before transporting antigenic










































































































































































































canonical pathway is significantly over-represented in the TBART MP/MM dataset compared
to the TB-IRIS MP/MM dataset. A functional antigen presentation process will often result in
the activation of an adaptive immune response against the responsible antigen and its source;
interestingly, only the TBART PBMCs showed any form of co-ordinated adaptive immune
response, as seen in Figure 5.6.
6.1.1.5 Extra-cellular signalling and leukocyte recruitment
The capacity of leukocytes to communicate with the extra-cellular matrix (ECM) that surrounds
them is critical for the functioning of these cells as it informs them of what is happening
outside of their immediate environment as well as provides an opportunity to communicate any
important information about their own internal workings, or failings in the case of intra-cellular
infections, to the cells in their immediate environment. Integrin signalling is central to this
function and provides the mechanism for these cells to communicate with the ECM. A direct
consequence of effective integrin signalling would be the recruitment of leukocytes to sites of
inflammation as well as the activation of an adaptive immune response. The TBART PBMCs
showed significant over-representation in integrin signalling and the leukocyte extravasation
canonical pathways (which is the process whereby leukocytes migrate from blood to tissue
during inflammation) compared to the TB-IRIS PBMC datasets, suggesting that these cells
were able to effectively communicate with the ECM and recruit more leukocytes to the site of
disease.
6.1.1.6 Apoptosis
Apoptosis is a process that most cells undergo at some point in time. There exist a number of
mechanisms that can induce apoptosis and many of these are dependent on the health of the
cell concerned. Properly functioning cells are capable of inducing apoptosis when required, for
instance if infected with a pathogen or if there is dysregulation in the mitochondrial functioning
of the cell such as occurs in many cancers. The eukaryotic initiation factor-2 (eIF2) canonical
pathway is involved in the synthesis of proteins within the cell and is intricately linked to
cell growth and proliferation, intracellular and second messenger signalling, as well as cellular
stress and injury responses. Phosphorylation of the eIF2-α subunit ceases protein production
and leads to cell apoptosis. This particular canonical pathway was significantly upregulated
in the TB-IRIS PBMCs compared to the TBART PBMCs, suggesting these cells are more
prone to undergo cellular apoptosis. The root cause of this apoptosis is not clear but it may












cells are derived from severely immunocompromised patients at a critical point during their
infection, three weeks after HAART initiation, and are likely to be very fragile), or that these
cells are unable to effectively deal with the dual infection and are being overrun, resulting in
their apoptosis. Regardless of molecular origin though, it is interesting that the TBART derived
PBMCs did not have as significant an over-representation of apoptotic pathways as the TB-IRIS
patient derived PBMCs.
6.1.2 The effect of dexamethasone
The effect of the dexamethasone treatment would be expected a priori to resemble what has
already been published with regards to corticosteroids (essentially a broad spectrum suppression
of the host immune response)[246, 256–259]. When analysing the differences in canonical
pathway over-representation of the TB-IRIS PP and TB-IRIS MP datasets, the assumption is
that the only difference in these datasets should be induced by the addition of dexamethasone.
A comparative analysis of the TBART MP dataset with respect to the TB-IRIS PP and TB-IRIS
MP datasets then represents a further effort to understand whether dexamethasone resolves a
TB-IRIS phenotype to a TBART phenotype, or whether it has some other effect.
It is interesting to note the significantly over-represented canonical pathways that are identified
in the TBART MP/MM vs TB-IRIS MP/MM comparison (Figure 5.8) but which are absent
in the TBART MP/MM vs TB-IRIS PP/MM comparison (Figure 5.10); these patterns are
listed in Box 1, Figure 5.11. A more detailed analysis behind the disappearance of these
pathways is needed: if these pathways are still present but have a smaller difference between the
-log[p-values] for pathway over-representation, it would suggest that the effect of the
dexamethasone is to induce a more significant response in the associated pathway; however
if the pathway becomes absent (has no significant over-representation because not enough
proteins belonging to the pathway have been identified) then it is possible that the effect of
the dexamethasone is to suppress the associated pathway. Of the six canonical pathways listed
in Box 1 of Figure 5.11, four are seen to have an increased degree of over-representation - the
two exceptions being the citrate cycle and the antigen presentation pathway.
Similarly, an analysis of the changes in significance of over-representation for the TB-IRIS
PP/MM and TB-IRIS MP/MM datasets provides some insight into the differences induced
by treatment with dexamethasone. From Box 2, Figure 5.11, it is clear that many of the
pathways that are more highly over-represented in the TBART MP/MM dataset comparable
to TB-IRIS MP/MM dataset are also more highly over-represented for the TB-IRIS PP/MM












dexamethasone results in induction of a number of pathways that are responsible for the correct
functioning of TB-IRIS patient derived PBMCs in response to TB antigen - although it appears
that it is not to the same extent as in the TBART MP/MM dataset. A notable exception is the
protein ubiquitination canonical pathway which shows a greater degree of over-representation
in the TB-IRIS PP/MM dataset when compared to the TB-IRIS MP/MM dataset and is not
represented at any level of significance for the TBART MP/MM dataset.
6.1.3 Unique canonical pathways
There were a number of canonical pathways that were identified above the threshold level of
significance (p ≤ 0.05) in only one of the datasets and consequently was excluded from the more
detailed analyses and comparisons. The lack of replicate data means that inferring too much
from these pathways is hazardous. In the field of proteomics, the failure to identify all proteins
present in any one experiment might be due to a number of variables (sample complexity,
equipment sensitivity and equipment accuracy being some of the many variables) that make
it difficult to state with absolute certainty that if a protein has not been identified in a complex
sample then it does not exist in that sample. A pathway level analysis alleviates this risk to an
extend in that if a few proteins from a pathway are not identified but a number of others are, the
pathway will still have a high degree of over-representation.
With this in mind, Table 5.6 represents those canonical pathways that were uniquely identified
to any one dataset and which had a level of significance of over-representation. This Table was
derived from a Venn diagram analysis of significantly over-represented canonical pathways in
all three datasets (Figure 5.12). Encouragingly, more than half of the identified pathways (68
/ 125) were common to all 3 datasets and less than 12 % (maximum of 15 / 125) were unique
to any one dataset. Of the unique canonical pathways, the majority have a level of significance
that is marginal, except for three in particular, namely: the “Glyoxylate and Dicarboxylate
Metabolism” and “Mechanisms of Viral Exit from Host Cells” in the TBART MP/MM dataset
as well as the “Hypoxia Signalling in the Cardiovascular System” within the TB-IRIS MP/MM
dataset. The mechanism of viral exit may seem counter-intuitive initially as the majority of
the data suggests that the TBART patient derived PBMCs have lymphocytes that are more
capable of cellular maintenance and structure and as such have improved cellular functioning.
Furthermore, given that the PBMCs were cultured in the presence of ARVs, viral replication
- and hence viral exit from host cells - should have been blocked in all samples. Further












6.2 Protein level analysis
A brief discussion pertaining to individual strongly differentially expressed identified proteins
is merited. However, this discussion must be viewed in the context of the caveats that have
been previously mentioned, chief among them being the absence of experimental repeats thus
meaning that absolute fold changes observed should be treated with a little caution.
The methodology used in generating these results mean these comparisons are strictly within
each patient group (TBART or TB-IRIS) when compared against their baseline expression
profiles (i.e. test conditions compared to baseline PBMCs that have been cultured in the absence
of dexamethasone and absence of re-stimulation by heat killed H37Rv).
6.2.1 Protein profiles of TBART and TB-IRIS cultured PBMCs
When looking at the proteins for the TBART MP/MM and TB-IRIS MP/MM datasets there
are a few interesting trends that appear. For both the fold change data (Tables 5.2 & 5.3)
and the log[ratio] data (Figures 5.1 & 5.2) the protein Thioredoxin domain-containing protein
5 (TXNDC5) appears to be up-regulated in the TBART MP/MM dataset whilst being down-
regulated for the TB-IRIS MP/MM dataset. TXNDC5 is thought to be located in the lumen
of the endoplasmic reticulum and has been shown to be associated with the obstruction of
apoptotic pathways in human umbilical vein endothelial cells [260]. The opposing expression
profile for the TBART MP/PP and TB-IRIS MP/MM datasets adds to the evidence suggesting
that TB-IRIS PBMCs are more likely to undergo apoptosis and consequently exacerbate the
dysfunctional immune response seen in TB-IRIS patients. Other proteins identified in these lists
have been shown to have prominent roles in some important canonical pathways such as integrin
signalling, RhoGDI signalling, Fcγ Receptor-mediated phagocytosis and Rac signalling; these
pathways have been considered previously (Subsection 6.1.1) so these individual pathways will
not be discussed further here.
6.2.2 Changes in protein expression in response to dexamethasone
The list of proteins with the greatest changes in expression levels for the TB-IRIS MP/MM
and TB-IRIS PP/MM datasets have a two proteins that are shared (PDIA4 and INF2). Protein
disulfide-isomerase A4 catalyses the arrangement of disulphide bonds in proteins and inverted
formin-2 (INF2) is thought to have a role in the severing of actin filaments and accelerates their












membrane-associated small GTPase and has been shown to be an important regulatory protein
for a number of cellular processes. There also appear to be a greater number of proteins from
the TB-IRIS PP/MM dataset that are associated with similar canonical pathways as those found
in the TBART MP/MM dataset, although this is not exclusively so.
6.3 Conclusion
6.3.1 The molecular origin of TB-IRIS
Previous work in mouse fibroblasts has shown the importance of the actin cytoskeleton in
the functioning, maintenance and motility of these cells. The dynamic nature of the actin
cytoskeleton in response to external stimuli can be seen in Figure 6.6.
Figure 6.6: Time lapse sequence of GFP-actin stained ruffles in mouse fibroblast
The sequence of pictures are a set of still shots that have been acquired from a time-lapse video and shows live-cell
imaging of an actin-GFP expressing mouse fibroblast responding to platelet-derived growth factor (PDGF) with
circular dorsal ruffles. Circular dorsal ruffles are dynamic, F-actin-enriched plasma membrane structures that
transiently occur on the dorsal surface of fibroblasts in response to mitogenic stimuli such as PDGF. These dynamic
structures form within minutes of stimulation and generally disappear within 30 minutes. The proposed functions
of these dorsal ruffles include the internalization of growth factor receptors, macropinocytosis/fluid phase uptake,
and cytoskeletal rearrangements required for cell movement. Note that ruffles expand into circles that eventually












It is clear from Figure 5.8 that there are differences in the in vitro canonical pathway expression
profiles of TB-IRIS and TBART patient derived PBMCs when re-stimulated with heat killed
H37Rv. Many of the pathways that are positively associated to the TBART PBMCs are involved
in the organisational maintenance of the actin cytoskeleton and consequently the cellular
structure of these cells. Correct cellular organisation of the actin cytoskeleton is critical for
motility, maintenance, signalling and proper biological functioning, thus it is plausible that
the lack of this cellular organisation within TB-IRIS patient derived PBMCs in vitro could be
associated with the dysfunctional immune response that is the primary characteristic of TB-IRIS
patients in vivo.
The differences in the activation scores of specific biological functions (Figure 5.6), are also
indicative of fundamental differences in the type of immune response that these patient derived
PBMCs are undergoing. TB-IRIS MP PBMCs appear to have a number of pathways activated,
but few reach the statistically significant threshold scores of -2 ≥ x ≥ 2, suggesting that there is
a lack of co-ordination in how these cells are responding to re-stimulation with TB antigen.
Thus, despite the overall immune response being vigourous, it appears to be ineffective in
dealing with the root cause of the problem. Perhaps the most illuminating activation score is the
interaction of blood cells, which decreases significantly, strongly supporting the hypothesis
that these cells lack a co-ordinated immune response of any sorts. By treating these cells
with dexamethasone (the TB-IRIS PP/MM dataset) it appears that the response tends towards
becoming a co-ordinated innate response - h wever the exact molecular mechanism by which
this is achieved is not immediately clear. It may be that the dexamethasone dampens some of the
numerous inflammatory responses that the untreated cells activate in the presence of TB antigen,
leading to the innate responses becoming seemingly more up-regulated; or it may be that the
dexamethasone stimulates the innate pathways directly and thus achieving the same apparent
result. For the TBART patient derived PBMCs there is a clear activation of T-cell response
functions which suggests that these patients have a innate capacity to contain and clear the TB
antigen using an adaptive immune response, which is in contrast to the TB-IRIS patients.
Most of the canonical pathways that were positively associated with the TB-IRIS patient derived
PBMCs have been shown to have a strong link to cellular apoptosis. Whether this is due to
cellular fatigue or immunologically functional fatigue (which is a hallmark of HIV, especially
if a patient has been has been infected for a long time) or is as a consequence of a dysregulated
immune response is as yet unclear.
The difference in incubation times prior to the development of clinical symptoms for
“paradoxical” TB-IRIS patients post HAART initiation may be rooted in the failure of TB-IRIS
patient derived PBMCs to organise their cytoskeletal structure. Thus, resulting in the decline












granulomas and leading to an aberrant inflammatory response to potentially higher loads of
systemic antigenic compounds.
6.3.2 The mechanism of action of dexamethasone
The initial hypotheses on the mechanism of action for dexamethasone as a treatment for
TB-IRIS patient derived PBMCs was that the dexamethasone somehow affected the cell
morphology and phenotype of the PBMCs and caused these cells to behave more like TBART
patient derived PBMCs.
The over-representation of canonical pathway expression profiles of these three datasets
suggests that treatment TB-IRIS derived PBMCs with dexamethasone i vitro does induce
a change in the canonical pathway expression profile that has a number of similarities with
the proteins identified in the TBART MP/MM dataset. The degree of this overlap is difficult
to quantify however since there are a greater number of pathways that overlap between the
TB-IRIS MP/MM and TB-IRIS PP/MM datasets whilst only a few key pathways change. It
may be that the suppression of the inflammatory response that is a consequence of treatment
with a corticosteroid may result in the PBMCs being provided an environment in which they
are able to partly better maintain their cellular cytoskeletal structure, with this resulting in a
slightly improved response to the infections with TB and HIV. It is plausible that despite an
opportunity to improve cellular structure in these patients through concurrent dexamethasone
treatment, the fundamental immune dysregulation would result in these patients suffering an
inflammatory relapse if they were to stop corticosteroid treatment before sufficient antigen
clearance had occurred. This theory could explain the approximately 20 % of TB-IRIS patients
on prednisone who in fact have halted their corticosteroid treatment and promptly suffered from
severe
inflammatory relapse.
6.3.3 Identification of possible biomarkers
As previously stated, the nature of the experimental design has made it difficult to identify
biomarkers with any statistical confidence, yet there were a number of proteins whose
expression profiles proved to be interesting. Not surprisingly the majority of these appeared
within the regulatory pathways related to the functioning of the actin cytoskeleton or related
to Fcγ receptor-mediated phagocytosis. Identifying a biomarker suffers from a number of












be completely absent in the test or control group, only present in the test or control group or
have a change in expression levels (either up or down) in the test versus control group. Thus it is
important to establish the nature of the biomarker before being able to speculate with confidence
about potential biomarkers. Some of the biomarkers identified in Table 5.4 are associated with
antigen presentation and receptor signalling and may provide an interesting starting point for












Previous and current literature suggests that TB-IRIS is somehow connected to the dysregulation
of the Th1/Th2 (Figure 7.1) response system as well as to differences in the ability to elicit a
primed innate response resulting in a co-ordinated adaptive immune response[262, 263].
Figure 7.1: Th1/Th2 response mechanism
A simplistic overview of the components of the Th1/Th2 response mechanism that is prevalent in the host defense
against pathogenic infections such as M.tb. A balanced response would see an increase in the Th1 activators to
control an infection and then followed by the restriction of this response through an increase in the Th2 activators
once the infection is under control.
These hypotheses have been founded mainly on cytokine data, which has previously been the
dominant source of evidence in this field of study. The new data generated the present study
using high throughput proteomics has shown that PBMCs derived from TB-IRIS and TBART
patients behave differently and often in a manner that is consistent with current hypotheses -
yet the large amount of new data has led to new hypotheses centering on the differing nature of
the inflammatory response and antigen processing that TBART and TB-IRIS patients appear to












Figure 7.2: A model of TB-IRIS
The TB-IRIS model depicted here is adapted from Barber et al [263], who proposes that there is an uncoupling
of the innate and adaptive immune responses during M.tb infection, resulting in excessive inflammation. (A) A
normal response = Macrophages require two signals to become fully activated. Firstly, the innate host response
recognises microbial products by pattern recognition receptors, which prime the cells for further activation leading
to the second response involving interaction with IFNγ-producing CD4+ T cells, thus leading to fully activated
macrophages and the production of high levels of pro-inflammatory mediators such as TNF and IL-6. (B) T-cell
deficient response = the host infected macrophage cells become primed by microbial products but never become
fully activated and execute their pro-inflammatory effector functions. This leads to an increase in pathogen load and
results in an exaggerated T cell response after the immune system reconstitutes. (C) Our adapted model showing
the differences between the TBART and TB-IRIS patients whereby it appears the TBART patients are able to
elicit a priming innate response leading to an adaptive immune response in a well co-ordinated manner, however
the TB-IRIS patients elicit strong but uncoordinated innate immune responses that do not result in an effective












Critically these differences appear to be CD4 T-cell independent, unlike the Barer model.
Instead, the data generated here suggests that either there is some intrinsic defect in monocytes/
NK cells in TB-IRIS patients or, perhaps more likely, that there is a difference in the activation
of these cells in TB-IRIS patients. The present data also suggests a possible role for B-cell
deficiencies in TB-IRIS patients since the Fcγ receptor pathways appear to be down regulated
compared to TBART patients.
Fresh perspectives using high throughput proteomics have led to new questions and it would
be of significant interest to isolate and identify the differing proteomic profiles of specific
sub-populations of PBMCs (e.g. B cells, T cells etc.) so as to ascertain which of these cell
populations are the key role players in the differing immune responses for both the TBART
and TB-IRIS patients as well as to provide a more fine tuned analysis of the qualitative nature
of this response at a mechanistic level. Thus future work should focus o initially repeating
this work using a more reliable method of quantitation as well a greater number of replicates
before delving deeper into the differing nature of the immune response and antigen processing
that exists between these two disease states using high throughput proteomic techniques. This
would no doubt be made easier if the efficiency of the protein extraction protocol could be
improved upon. Transcriptomic analysis would also be a possible avenue for future research
depending on what resources were available to the researcher in question.
Another avenue of research that would be of immense value would be to analyse the progression
of the immune responses for both disease states using high throughput techniques so as to be
able to track the aetiology and progress on of pathology from prior to initiation of ARVs through
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# Which isotopes to use in calculating fragment ion mass.
# <string>=average|mono. Default=mono.
# Parameter file only. Used by crux-search-for-matches and crux-predict-peptide-ions.
fragment-mass=mono
# Print to stdout additional information about the spectrum.
# Avaliable only for crux-get-ms2-spectrum. Does not affect contents of the output file.
stats=false
# Specifies the operator that is used to compare an entry in the specified column to the value
# given on the command line.
# (eq|gt|gte|lt|lte|neq). Default: eq.
# Available for crux extract-rows
comparison=eq
# Minimum number of points for estimating the Weibull parameters.
# Default=4000.
# Available for crux search-for-xlinks
min-weibull-points=4000
# Number of consecutive MS1 scans over which a peptide must be observed to be considered
# real. Gaps in persistence are allowed when setting –gap-tolerance. Default = 3.
# Available for crux bullseye
scan-tolerance=3
# Predict the given number of isotope peaks (0|1|2). Default=0.













# Window type to use for selecting decoy peptides from precursor mz.
# <string>=mass|mz|ppm. Default=mass.
# Available for crux search-for-matches
precursor-window-type-decoy=mass
# The ion series to predict (b,y,by,bya). Default=’by’ (both b and y ions).
# Only available for crux-predict-peptide-ions. Set automatically to ’by’ for searching.
primary-ions=by
# Perform parsimony analysis on the proteins and report a parsimony rank column in
# output file. Default=none. Can be
# <string>=none|simple|greedy
# Available for spectral-counts.
parsimony=none
# Which isotopes to use in calculating peptide mass.
# <string>=average|mono. Default=average.
# Used from command line or parameter file by crux-create-index and
# crux-generate-peptides. Parameter file only for crux-search-for-matches.
isotopic-mass=mono
# Include self-loop peptides in the database. Default=T.
# Available for crux search-for-xlinks program.
xlink-include-selfloops=true
# Quantification at protein or peptide level (PROTEIN,PEPTIDE).
# Default=PROTEIN.
# Available for spectral-counts and either NSAF and SIN.
quant-level=protein
# Window type to use for selecting candidate peptides.
# <string>=mass|mz|ppm. Default=mass.
# Available for search-for-matches, search-for-xlinks.
precursor-window-type=mass
# Search peptides within +/- ’precursor-window’ of the spectrum mass.
# Definition of precursor window depends upon precursor-window-type.
# Default=3.0.













# Set the precision for masses and m/z written to sqt and .txt files.
# Default=4
# Available from parameter file for all commands.
mass-precision=4
# Specify rules for in silico digestion of proteins. See HTML documentation for syntax.
# Default is trypsin.
# Overrides the enzyme option. Two lists of residues are given enclosed in square brackets or
# curly braces and separated by a |. The first list contains residues required/prohibited before
# the cleavage site and the second list is residues after the cleavage site. If the residues are
# required for digestion, they are in square brackets, ’[’ and ’]’. If the residues prevent digestion,
# then they are enclosed in curly braces, ’{’ and ’}’. Use X to indicate all residues. For example,
# trypsin cuts after R or K but not before P which is represented as [RK]|{P}. AspN cuts
# after any residue but only before D which is represented as [X]|[D].
custom-enzyme=__NULL_STR
# Predict flanking peaks for b and y ions (T,F). Default=F.
# Only available for crux-predict-peptide-ion.
flanking=false
# Include peaks +/- 1da around b/y ions in theoretical spectrum.
# sequest-search and search-for-xlinks default=T. search-for-matches default=F.
# Available in the paramter file for all search commands.
use-flanking-peaks=true
# Change the mass of all amino acids ’A’ by the given amount.
# For parameter file only. Default=no mass change.
A=0.000000
# Change the mass of all amino acids ’C’ by the given amount.
# For parameter file only. Default=+57.0214637206.
C=57.021464
# Change the mass of all amino acids ’D’ by the given amount.
# For parameter file only. Default=no mass change.
D=0.000000
# Change the mass of all amino acids ’E’ by the given amount.












# Specify the width of the bins used to discretize the m/z axis. Also used as tolerance for
# assigning ions. Default=1.0005079 for monoisotopic mass or 1.0011413 for average mass.
# Available for crux-search-for-matches and xlink-assign-ions.
mz-bin-width=1.000508
# Change the mass of all amino acids ’F’ by the given amount.
# For parameter file only. Default=no mass change.
F=0.000000
# Change the mass of all amino acids ’G’ by the given amount.
# For parameter file only. Default=no mass change.
G=0.000000
# Change the mass of all amino acids ’H’ by the given amount.
# For parameter file only. Default=no mass change.
H=0.000000
# Change the mass of all amino acids ’I’ by the given amount.
# For parameter file only. Default=no mass change.
I=0.000000
# Change the mass of all amino acids ’K’ by the given amount.
# For parameter file only. Default=no mass change.
K=0.000000
# Change the mass of all amino acids ’L’ by the given amount.
# For parameter file only. Default=no mass change.
L=0.000000
# Change the mass of all amino acids ’M’ by the given amount.
# For parameter file only. Default=no mass change.
M=0.000000
# Change the mass of all amino acids ’N’ by the given amount.
# For parameter file only. Default=no mass change.
N=0.000000
# Change the mass of all amino acids ’P’ by the given amount.












# Change the mass of all amino acids ’Q’ by the given amount.
# For parameter file only. Default=no mass change.
Q=0.000000
# Change the mass of all amino acids ’R’ by the given amount.
# For parameter file only. Default=no mass change.
R=0.000000
# Change the mass of all amino acids ’S’ by the given amount.
# For parameter file only. Default=no mass change.
S=0.000000
# Change the mass of all amino acids ’T’ by the given amount.
# For parameter file only. Default=no mass change.
T=0.000000
# Change the mass of all amino acids ’V’ by the given amount.
# For parameter file only. Default=no mass change.
V=0.000000
# Change the mass of all amino acids ’W’ by the given amount.
# For parameter file only. Default=no mass change.
W=0.000000
# Change the mass of all amino acids ’Y’ by the given amount.
# For parameter file only. Default=no mass change.
Y=0.000000
# Print version number and quit.
# Available for all crux programs. On command line use ’–version T’.
version=false
# Set the resolution of the observed spectra at m/z 400. Used in conjunction with –instrument
# The default is 100000.
# Available for crux hardklor
resolution=100000.000000
# The format to write the output spectra to. By default, the spectra will be output in the same
# format as the MS/MS input.












# The minimum length of peptides to consider. Default=6.
# Used from the command line or parameter file by crux-create-index and crux-generate-peptides.
# Parameter file only for crux-search-for-matches.
min-length=6
# Predict the precursor ions, and all associated ions (neutral-losses, multiple charge states)
# consistent with the other specified options. (T,F) Default=F.
# Only available for crux-predict-peptide-ions.
precursor-ions=false
# Degree of digestion used to generate peptides.
# <string>=full-digest|partial-digest. Either both ends or one end of a peptide must conform to
# enzyme specificity rules. Default=full-digest.
# Used in conjunction with enzyme option when enzyme is not set to ’no-enzyme’. Available
# from command line or parameter file for crux-generate-peptides and crux create-index.
# Available from parameter file for crux search-for-matches. Digestion rules are as follows:
# enzyme name [cuts after one of these residues][but not before one of these residues].
# trypsin [RK][P], elastase [ALIV][P], chymotrypsin [FWY][P].
digestion=full-digest
# Replace existing files (T) or exit if attempting to overwrite (F).
# Default=F.
# Available for all crux programs. Applies to parameter file as well as index, search, and analysis
# output files.
overwrite=T
# Choose the algorithm for analyzing combinations of multiple peptide or protein isotope
# distributions. (basic | fewest-peptides | fast-fewest-peptides | fewest-peptides-choice |
# fast-fewest-peptides-choice) Default=fast-fewest-peptides.
# Available for crux hardklor
hardklor-algorithm=fast-fewest-peptides
# Set additional options with values in the given file.
# Available for all crux programs. Any options specified on the command line will override
# values in the parameter file.
parameter-file=/opt/exp_soft/medbio/program_options/crux_1_37/parameters/mono_
target_peptide-shuffle.txt
# The minimum number of peaks a spectrum must have for it to be searched. Default=20.












# Predict peaks with the given maximum number of nh3 neutral loss modifications. Default=0.
# Only available for crux-predict-peptide-ions.
nh3=0
# Type of analysis to make on the match results: (RAW|NSAF|dNSAF|SIN|EMPAI). Default=NSAF.
# Available for spectral-counts. RAW is raw counts, NSAF is Normalized Spectral Abundance
# Factor, dNSAF is Distributed Spectral Abundance Factor, SIN is Spectral Index Normalized
# and EMPAI is Exponentially Modified Protein Abundance
Index measure=NSAF
# Number of psms per spectrum to score with xcorr after preliminary scoring with Sp.
# Set to 0 to score all psms with xcorr. Default=500.
# Used by crux-search-for-matches. For positive values, the Sp (preliminary) score acts as a
# filter; only high scoring psms go on to be scored with xcorr. This saves some time. If set to 0,
# all psms are scored with both scores.
max-rank-preliminary=2000
# The maximum number of modifications that can be applied to a single peptide.
# Default=no limit.
# Available from parameter file for crux-search-for-matches.
max-mods=255
# Set the tolerance (+/-ppm) for finding persistent peptides. Default = 10.0.
# Available for crux bullseye
persist-tolerance=10.000000
# Spectrum charge states to search. <string>=1|2|3|all. Default=all.
# Used by crux-search-for-matches to limit the charge states considered in the search. With ’all’
# every spectrum will be searched and spectra with multiple charge states will be searched
# once at each charge state. With 1, 2 ,or 3 only spectra with that that charge will be searched.
spectrum-charge=all
# MS2 file corresponding to the psm file. Required for SIN.
# Available for spectral-counts with measure=SIN.
input-ms2=__NULL_STR
# Show search progress by printing every n spectra searched.
# Default=10.













# Restrict analysis to only a small window in each segment ( (min-max) in m/z).
# The user must specify the starting and ending m/z values between which the analysis will be
# performed. By default the whole spectrum is analyzed.
# Available for crux hardklor
mz-window=__NULL_STR
# Use MSToolkit to parse spectra. Default=F.
# Available for crux-search-for-matches
use-mstoolkit=false
# Set the signal-to-noise threshold. Any integer or decimal value greater than or equal to 0.0
# is valid. The default value is 1.0.
# Available for crux hardklor
signal-to-noise=1.000000
# The estimated percent of target scores that are drawn from the null distribution.
# Used by compute-q-values, percolator and q-ranker
pi-zero=1.000000
# Reports peptide intensities as the distribution area. Default false.
# Available for crux hardklor
distribution-area=false
# Prefix added to output file names. Default=none.
# Used by crux search-for-matches, crux sequest-search, crux percolator
# crux compute-q-values, and crux q-ranker.
fileroot=__NULL_STR
# If true, Hardklor will calculate the local noise levels across the spectrum using –sn-window,
# then select a floor of this set of noise levels to apply to the whole spectrum.
# Available for crux hardklor
static-sn=true
# Sort in ascending order. Otherwise, descending. Default: True.
# Available for sort-by-column
ascending=true
# Compute the Sp score for all candidate peptides. Default=F












# Set the correlation threshold [0,1.0] to accept a predicted isotope distribution. Default=0.85
# Available for crux hardklor
corr=0.850000
# The maximum mass of peptides to consider. Default=8000.
# Available from command line or parameter file for crux bullseye
bullseye-max-mass=8000.000000
# If the target and decoy searches were run separately, rather than using a concatenated database,
# then Q-ranker will assume that the database search results provided as a required argument
# are from the target database search. This option then allows the user to specify the location of
# the decoy search results. Like the required arguments, these search results can be provided as
# a single file, a list of files or a directory. However, the choice (file, list or directory) must be
# consistent for the MS2 files and the target and decoy SQT files. Also, if the MS2 and SQT
# files are provided in directories, then Q-ranker will use the MS2 filename (foo.ms2) to identify
# corresponding target and decoy SQT files with names like foo*.target.sqt and foo*.decoy.sqt.
# This naming convention allows the target and decoy SQT files to reside in the same directory.
# Available for q-ranker and barista.
separate-searches=__NULL_STR
# Set level of output to stderr (0-100). Default=30.
# Available for all crux programs. Each level prints the following messages, including all those
# at lower verbosity levels: 0-fatal errors, 10-non-fatal errors, 20-warnings, 30-information on
# the progress of execution, 40-more progress information, 50-debug info, 60-detailed
# debug info.
verbosity=30
# Specify the location of the left edge of the first bin used to discretize the m/z axis. Default=0.68
# Available for crux-search-for-matches.
mz-bin-offset=0.680000
# Create an ASCII version of the peptide list. Default=F.
# Creates an ASCII file in the output directory containing one peptide per line.
peptide-list=false
# Choose the charge state determination method. (B|F|P|Q|S). Default=Q.
# Available for crux hardklor
cdm=Q











# Available from command line or parameter file for crux bullseye
bullseye-min-mass=600.000000
# Print the theoretical spectrum
# Available for xlink-predict-peptide-ions (Default=F).
print-theoretical-spectrum=false
# Use MGF file format for parsing files
# Available for search-for-xlinks program (Default=F).
use-mgf=false
# Set the tolerance (+/-units) around the retention time over which a peptide can be matched to
# the MS/MS spectrum. The unit of time is whatever unit is used in your data file (usually
# minutes). Default = 0.5.
# Available for crux bullseye
retention-tolerance=0.500000
# Set the maximum charge state to look for when analyzing a spectrum.
# Default=5.
# Available for crux hardklor
max-charge=5
# Number of decoy peptides to search for every target peptide searched.Only valid for fasta
# searches when –decoys is not none. Default=0.
# Use –decoy-location to control where they are returned (which file(s)) and –decoys to
# control how targets are randomized.
# Available for search-for-matches and sequest-search when searching a fasta file.
num-decoys-per-target=1
# Search only select spectra specified as a single scan number or as a range as in x-y.
# Default=search all.
# The search range x-y is inclusive of x and y.
scan-number=__NULL_STR
# The maximum number of modified amino acids that can appear in one peptide.
# Each aa can be modified multiple times. Default=no limit.
# Available from parameter file for search-for-matches.
max-aas-modified=255
# Include peptides with up to n missed cleavage sites. Default=0.











# Parameter file only for crux-search-for-matches. When used with
# enzyme=<trypsin|elastase|chymotrpysin> includes peptides containing one or more potential
# cleavage sites.
missed-cleavages=0
# Output filename for complete list of decoy p-values.
# Default=’search.decoy.p.txt’
# Only available for crux search-for-matches. The location of this file is controlled by –output-dir.
search-decoy-pvalue-file=search.decoy.p.txt
# Search decoy-peptides within +/- ’mass-window-decoy’ of the spectrum mass.
# Default=20.0.
# Available for crux search-for-xlinks.
precursor-window-decoy=20.000000
# Set the depth of combinatorial analysis. Default 3.
# Available for crux hardklor
depth=3
# Re-run a previous Q-ranker analysis using a previously computed set of lookup tables.
# Available for q-ranker and barista.
re-run=__NULL_STR
# Specify "no base" averagine. Only modified averagine models will be used in the analysis.
# Default = F
# Available for crux hardklor
no-base=false
# Print the header line of the tsv file. Default=T.
# Available for crux extract-columns and extract-rows
header=true
# Minimum mass of spectra to be searched. Default=0.
# Available for crux-search-for-matches.
spectrum-min-mass=0.000000
# Folder to which results will be written. Default=’crux-output’.














# Include dead-end peptides in the database. Default=T.
# Available for crux search-for-xlinks program.
xlink-include-deadends=true
# Gap size tolerance when checking for peptides across consecutive MS1 scans.
# Used in conjunction with –scan-tolerance. Default = 1.
# Available for crux bullseye
gap-tolerance=1
# Type of instrument (fticr|orbi|tof|qit) on which the data was collected.
# Used in conjuction with –resolution. The default is fticr.
# Available for crux hardklor
instrument=fticr
# The maximum length of peptides to consider. Default=50.
# Available from command line or parameter file for crux-create-index and
# crux-generate-peptides. Parameter file only for crux-search-for-matches.
max-length=50
# Set a filter for mzXML files. Default=none
# Available for crux hardklor
mzxml-filter=none
# Generate peptides only once, even if they appear in more than one protein (T,F). Default=F.
# Available from command line or parameter file for crux-genereate-peptides.
# Returns one line per peptide when true or one line per peptide per protein occurence when
# false.
unique-peptides=true
# Q-ranker analysis begins with a pre-processsing step that creates a set of lookup tables
# which are then used during training. Normally, these lookup tables are deleted at the
# end of the Q-ranker analysis, but setting this option to T prevents the deletion of these tables.
# Subsequently, the Q-ranker analysis can be repeated more efficiently by specifying the
# –re-run option. Default = F.
# Available for q-ranker and barista.
skip-cleanup=false
# Predict ions up to max charge state (1,2,...,6) or up to the charge state of the peptide (peptide).
# If the max-ion-charge is greater than the charge state of the peptide, then the max is the











# Available for predict-peptide-ions and search-for-xlinks. Set to ’peptide’ for search.
max-ion-charge=peptide
# The maximum mass of peptides to consider. Default=7200.
# Available from command line or parameter file for crux-create-index and
# crux-generate-peptides.Parameter file only for crux-search-for-matches.
max-mass=7200.000000
# Ignore peptides that persist for this length. The unit of time is whatever unit is used in
# your data file (usually minutes). These peptides are considered contaminants. Default = 2.0.
# Available for crux bullseye
max-persist=2.000000
# The minimum mass of peptides to consider. Default=200.
# Available from command line or parameter file for crux-create-index and
# crux-generate-peptides. Parameter file only for crux-search-for-matches.
min-mass=200.000000
# Set the maximum number of peptides or proteins that are estimated from the peaks found in a
# spectrum segment. The default value is 10.
# Available for crux hardklor
max-p=10
# Set the precision for scores written to sqt and text files. Default=8.
# Available from parameter file for crux search-for-matches, percolator, and compute-q-values.
precision=8
# Specify location of decoy search results.
# <string>=target-file|one-decoy-file|separate-decoy-files.
# Default=separate-decoy-files.
# Applies when decoys is not none. Use ’target-file’ to mix target and decoy search results in
# one file. ’one-decoy-file’ will return target results in one file and all decoys in another.
# ’separate-decoy-files’ will create as many decoy files as num-decoys-per-target.
decoy-location=target-file
# The p-value or q-value threshold. Default=0.01.
# Available for spectral-counts. All PSMs with q-value higher than this will be ignored.
threshold=0.010000
# Set the tolerance (+/-ppm) for exact match searches. Default = 10.0.












# Specify a fixed modification to apply to the N-terminus of peptides.
# Available from parameter file for crux sequest-search and search-for-matches.
nmod-fixed=NO
# Q-ranker uses enriched feature set derived from the spectra in ms2 files.
# It can be forced to use minimal feature set by setting the –use-spec-features option to F.
# Default T.
# Available for q-ranker and barista.
use-spec-features=true
# Set the maximum width of any set of peaks in a spectrum when computing the results (in
# m/z).Thus, if the value was 5.0, then sets of peaks greater than 5 m/z are divided into smaller
# sets prior to analysis. The default value is 4.0.
# Available for crux hardklor
max-width=4.000000
# Specify a fixed modification to apply to the C-terminus of peptides.
# Available from parameter file for crux sequest-search and search-for-matches.
cmod-fixed=NO
# Optional file into which psm features are printed. Default=F.
# Available for percolator and q-ranker. File will be named <fileroot>.percolator.features.txt
# or <fileroot>.qranker.features.txt.
feature-file=false
# Set the signal-to-noise window length (in m/z). Because noise may be non-uniform across a
# spectra, this value adjusts the segment size considered when calculating a signal-over-noise
# ratio. The default value is 250.0.
# Available for crux hardklor
sn-window=250.000000




# Used in conjunction with the options digestion and missed-cleavages.
# Use ’no-enzyme’ for non-specific digestion. Available from command line or parameter file
# for crux-generate-peptides and crux create-index. Available from parameter file for crux
# search-for-matches. Digestion rules: enzyme name [cuts after one of these











# chymotrypsin [FWY]|{P}, clostripain [R]|[], cyanogen-bromide [M]|[], iodosobenzoate [W]|[],
# proline-endopeptidase [P]|[], staph-protease [E]|[], modified-chymotrypsin [FWYL]|{P},
# elastase-trypsin-chymotrypsin [ALIVKRWFY]|{P},aspn []|[D] (cuts before D).
enzyme=trypsin
# Specifies the data type the column contains (int|real|string) Default: string
# Available for crux extract-rows
column-type=string
# Predict peaks with the given maximum number of h2o neutral loss modifications. Default=0.
# Only available for crux-predict-peptide-ions.
h2o=0
# Ignore peptides with multiple mappings to proteins (T,F). Default=F.
# Available for spectral-counts.
unique-mapping=false
# Set the sensitivity level. There are four levels, 0 (low), 1 (moderate), 2 (high), and 3 (max).
# The default value is 2.
# Available for crux hardklor
sensitivity=2
# Compute p-values for the main score type. Default=F.
# Currently only implemented for XCORR.
compute-p-values=false
# Require an exact match to the precursor ion. Rather than use wide precursor boundaries,
# this flag forces Bullseye to match precursors to the base isotope peak identified in Hardklor.
# The tolerance is set with the –persist-tolerance flag. Default = F.
# Available for crux bullseye
exact-match=false
# Include alternative averagine models in the analysis that incorporate additional atoms or
# isotopic enrichments.
# Available for crux hardklor
averagine-mod=__NULL_STR
# The number of PSMs per spectrum written to the output file(s). Default=5.












# Maximum mass of spectra to search. Default no maximum.
# Available for crux-search-for-matches.
spectrum-max-mass=1000000000.000000
# Include linear peptides in the database. Default=T.
# Available for crux search-for-xlinks program (Default=T).
xlink-include-linears=true
# Specifies the prefix of the protein names that indicates a decoy. Default = rand_.
# Available for q-ranker and barista.
decoy-prefix=rand_
# Include a decoy version of every peptide by shuffling or reversing the target sequence.
# <string>=none|reverse|protein-shuffle|peptide-shuffle. Use ’none’ for no decoys.
# Default=protein-shuffle. For create-index, store the decoys in the index. For search, either
# use decoys in the index or generate them from the fasta file.
decoys=peptide-shuffle
# Set the minimum charge state to look for when analyzing a spectrum. Default=1.
# Available for crux hardklor
min-charge=1
# Print peptide sequence (T,F). Default=F.
# Available only for crux-generate-peptides.
output-sequence=false
# Print the masses of modified sequences in one of three ways ’mod-only’, ’total’ (residue mass
# plus modification), or ’separate’ (for multiple mods to one residue): Default ’mod-only’.
# Available in the parameter file for search-for-matches, sequest-search and generate-peptides.
mod-mass-format=mod-only
# Specify a variable modification to apply to peptides. <mass change>:<aa list>:
# <max per peptide>:<prevents cleavage>:<prevents cross-link>. Sub-parameters prevents
# cleavage and prevents cross-link are optional (T|F). Default=no mods.
# Available from parameter file for crux-generate-peptides and crux-search-for-matches and
# the the same must be used for crux compute-q-value.
mod=NO MODS
# Specify a variable modification to apply to N-terminus of peptides.











# Available from parameter file for crux-generate-peptides and crux-search-for-matches and
# the same must be used for crux compute-q-value.
nmod=NO MODS
# Specify a variable modification to apply to C-terminus of peptides.
# <mass change>:<max distance from protein c-term (-1 for no max)>. Default=no mods.
# Available from parameter file for crux-generate-peptides and crux-search-for-matches and
# the same must be used for crux compute-q-value.
cmod=NO MODS
IPA parameters
The following sets of figures are screenshots that were taken of the parameters used during the
data analysis using IPA. The pictures include how the data was uploaded, what filters were set
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Dataset Filter Summary 
Con s ider only molecules w here 
Provide Feedback I Support Ms. Goosen Close IPA 
,hi iBI l 
Species Human - ~ Se lect all 
SO Mammal 
Tissues & Ce ll lines Al l 11 : ,. .. [;3 Human species _ Uncategorized (e.g. chemicals) OR Human 
Molecule Types Al l - Mouse 
'"' Diseases Al l Un~~egori;;ioj (e.g. chemica ls) 
Biofluids Al l 
Biomarkers Al l 
IE!!IZ!Il!m II I I 
Set Cutoffs 
E><p ress ion Va lue Type Cutoff Range Focus On 
Fold Change c::::::::J -10.557 4 t o 11 .269 180th UplDownregulated ~ I 'bY!!3I' ii! 315 molecules eli gible l or Dat aset Fil t er 
Preview Dataset TB-IRIS_MP _vs_MMJatios.txt 
Filt ered (315) \ Mapped IDs (315) \ unmapped IDs (5) \ Al IIDs (320) \ 
nh&L&!&LU.ZZSJLEd£LSEEHm· Hi'i,'! ~ 
o Fold Change " Not es o 1"1.347 P1l31 0-2 
o 1"1.713 P49748 -2 
o 1"1.420 Q562Rl 
o . -1.815 P1 2814 
o . -2.264 043707 
o 1"2.614 P61163 
o . -1.545 P61160 
o 1"1. 004 P61158 
o . -1. 060 043306-2 
o 1" 1. 039 P02768 
o 1"1. 334 Q9STIO 
o 1"1. 063 P04083 
o 1"1. 035 P07355 -2 
o . -2.271 P12429 
o . -3.605 P08758 
o . -4.981 P08133 
Not es 
, Symbo l Entrez Gene Name 
ACADM acyl -CoA de hydrogenase, C-4 
ACADIA acyl -CoA dehydrogenase, very 
ACT8L2 act in, beta -li ke 2 
ACTNl act inin, alp ha 1 
ACTN4 act inin, alp ha 4 
ACTR1A ARPl act in -relat ed protein 1 
ACTR2 ARP2 act in -relat ed prote in 2 
ACTR3 ARP3 act in -relat ed protein 3 
ADCY6 adenyl at e cyc lase 6 
"" albumin ANP32E ac idic (leuc ine-ri ch) nuclea r p 
ANXAl a nn e~i n Al 
ANXA2 a nn e~i n A2 
ANXA3 a nn e~i n A3 
ANXA5 a nn e~i n A5 


















-D" - Dupli cat es . Gene/Prot ein/Che mica l ident ifi ers marked with an ast eri sk indicat e that mu lt iple ident ifi ers in the dat aset fi le map t o a single gene/chemica l in the Globa l Mo lecular Network 


















-A" - Gene/Prot ein/ChemicaIID marked as Absent. Th e gene/prot ein/chemica l will not be used as a l ocus molecule or appear in netwo rks un less you also e~p li c i t ly overri de th is fi ag with the OVerri de co lumn 
Rows: [1 - 100 ~[ ID BI 
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IPA 0+ 12:45 liam 
Eil e Ed it Ylew ""'indow !::!e lp Provide Feedback I Support Ms. Goosen Close IPA 
Genes and Chemica ls r Funct ions and Diseases r Pathways an d To~ Li st s .. I Enter function or disease names here I I11III1 Advanced Search !j] 
~ create Core Analysis _ [analysis: TBART_MP . vs. MMJ ilteredl 
General Settings p Select all 
ISO Tissues and Prim ary Ce ll s 
Network Generation 0 , , ... [;,3 Ti ssues and P rimary~ot ot h e rwi ~e ~Il ~ c ifi ed 
S~Ce ll $~ __ Data Sources Al l 
Confidence Expe rim enta", 
Species Human 
Tissues & Ce ll lines Ac 
M"t"t;_n h I! 
~.~ ~~Su~ ~\~t~ lle' i fi ~ d 
ti!l Ot her Crii' 
S O Nervous System 
S O Organ Syst ems 
~her Tissues and p~ eM ' 
Ce ll Li ne 
IE!!IZ!a "t $ Ii *" Ii ,I hi Ce ll Li ne not otherwise spec ifi ed 
Set Cutoffs 
E><p ress ion Va lue Type Cutoff Range Focus On 
@ rf; I~;~~~tl ; i~~~ ~ s and relat ionships) 
o ~~i:~e~:li~~~ l eS) 
Fold Change c::::::::J -4.6636 t o 7.0797 Isoth UplDownregulated ~ I 'bY WI' ii! 386 analys is,eady molecules ac ro ss observat ions 
Preview Dataset TBART_MP .vs_MM_filtered 
An alys is-Ready (386) \ Mapped/F ilt ered IDs (386) \ Unmapped IDs (0) \ Al IIDs (386) \ 
nh&L&!&LU.ZZSJLEd£LSZZHW· Hi'I,,! ~ 
o Fold Change " Not es o 1"2.191 P42765 
o 1"1.116 Q9H845 
o 1"5.270 P1131 0-2 
o 1"1. 040 P53396 
o 1"1. 028 Q99798 
o . -1.163 P68133 
o . -2.482 P60709 
o . -1.21 0 Q562Rl 
o . -1. 027 P12814 
o . -1. 056 0 43707 
o . -1. 093 P61160 
o . -1. 028 P61158 
o 1"2.271 043488 
o . -2.450 P02768 
o 1"2.171 P18054 
Notes 















Al OXl 2 
Entrez Gene Name Locat ion 
acetyi -CoA acyit ransfe rase 2 Cytop lasm 
acyi -CoA de hydrogenase fam i Cytop lasm 
acyi -CoA de hydrogenase, C-4 Cytop lasm 
ATP citrate lyase Cytop lasm 
aconitase 2, mitochondrial Cytop lasm 
act in, alpha 1, skeleta l musc l Cytop lasm 
act in, beta Cytop lasm 
act in, beta -li ke 2 unknown 
act inin, alpha 1 Cytop lasm 
act inin, alpha 4 Cytop lasm 
ARP2 act in -relat ed prote in 2 Plasma Membrane 
ARP3 act in -relat ed prote in 3 Plasma Membrane 
aldo -keto r eductase fam ily 7, Cytop lasm 
albumin E><trace llular Space 
arach idonate 12-li poryge nas Cytop lasm 
"So ld" - Focus molecules . GenelProtein/Chemica l ident ifi ers that meet the use r-<lefin ed cutoff and map t o the Globa l Mo lecular Netwo rk are d isplayed with bo ld t e><t 
Analysis Filter Summary 
Con s ider o nly molecules and/o r relationships w here 
(species _ Uncategorized (e.g. chemicals) OR Human) A ND 
(confiden ce _ Experimentally Observed) AND 
d'cf 
(tissues/ce ll lines _ BDCA_l+ dendritic ce ll s OR T 
lymphocytes not otherw ise specified OR Other B 
lymphocytes OR Cyt ot oxic T ce ll s OR Other Dendritic ce lls OR 
Monocyte_derived macrophage OR Central memory helper T 
cells OR Dendritic ce ll s not otherw ise specified OR Naive 
helper T cells OR Immature monocyte_derived dendritic ce ll s 
OR Murine NKT ce ll s OR Naive B cells OR Monocytes OR 
CD56bright NK ce ll s OR NK cells not otherw ise specified OR 
Central memory cyt otoxic T ce ll s OR Mature 
monocyte_derived dendritic ce ll s OR Macrophages ORJ774 
~~::~~_c:.a,~~~~;:I~a~ T.::.~!I~ .?~_~~h~~ ~!r,,~~~..?~~,:~,?~R "D 
Rows: [1 - 100 ~[ ID BI 















''''''''' s u~asa l azi n e , balsa lazide , 5-
"D" - Dupli cat es . GenelProt ein/Che mica l ident ifi ers marked with an ast eri sk indicat e that mu lt iple ident ifi ers in the dat aset fi le map t o a single gene/chemi,al in the Globa l Mo lecular Network 
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IPA 0+ 12:46 liam 
Eil e Ed it Ylew ""'indow !::!e lp Provide Feedback I Support Ms. Goosen Close IPA 
Genes and Chemica ls r Funct ions and Diseases r Pathways an d To~ Li st s .. I Enter function or disease names here I I11III1 Advanced Search !j] 
~ create Core Analysis _ [analysis: TBART_MP _vs_MMJ ilteredl 
General Settings 
Network Generatio n 0 
Data Sources Al l 
so Co lon Cance r Ce ll Li nes 
s !i1i Immune (e~ 
S O Ki dney Cance r Ce ll Li nes 
Confide n ce Experim enta", 
Species Human 
Ti ssues & Cell lines Ac 
S O Leukemia Ce ll Li nes 
S O Lun g Cance r Ce ll Li nes 
S O l ymphoma Ce ll Li nes 
S~acrQP~ge Cancer Ce l~ 
S O Melanoma Ce ll Li nes 
@ rf; I~;~~~tl ; i~~~ ~s and relat ionships) 
o ~~i:~e~:li~~~ l eS) 
S O Myeloma Ce ll Li nes 
Mutatio n Al l S O OVa ri an Cance r Ce ll Li nes 
S O Prost at e Cance r Ce ll Li nes t:t 
IE!!IZ!a "t $ Ii *" Ii ,I H II D other Ce ll Line Fl 
j 
Set Cutoffs 
E><p ress ion Value Type Cutoff Ra nge Focus On 
Fold Change c::::::::J -4.6636 t o 7.0797 180t h UplDownregulat ed ~ I 'bY WI' ii! 386 analys is, eady molecules across observat ions 
Preview Dataset TBART_MP _vs_MM_filtered 
Analys is.f\eady (386) \ Mapped/F ilt ered IDs (386) \ Unmapped IDs (0) \ Al IIDs (386) \ 
nh&L&!&LU.ZZSJLEd£LSZZHW· Hi'I,,! ~ 
D Fold Change " INot es D 1"2.191 P42765 
D 1"1.11 6 Q9H845 
D 1"5.270 P11 310-2 
D 1"1. 040 P53396 
D 1"1. 028 Q99798 
D . -1.1 63 P68133 
D . -2.482 P60709 
D . -1. 210 Q562Rl 
D . -1. 027 P12814 
D . -1. 056 043707 
D . -1. 093 P611 60 
D . -1. 028 P611 58 
D 1"2.271 043488 
D . -2.450 P02768 
D 1"2.171 P18054 
Not es 
, Symbo l Entrez Gene Name 
ACAA2 acetyi -CoA acyit ransferase 2 
ACAD9 acyi -CoA dehydrogenase fa mi 
ACADM acyi -CoA dehydrogenase, C-4 
ACl Y ATP cit rat e lyase 
AC02 (includes EG:11429) aconitase 2, mitochondrial 
ACTAl act in, alph a 1, skelet al musc l 
ACTB act in, beta 
ACT8l2 act in, beta -li ke 2 
ACTNl act inin, alp ha 1 
ACTN4 act inin, alp ha 4 
ACTR2 ARP2 act in -relat ed prote in 2 
ACTR3 ARP3 act in -relat ed prot ein 3 
AKR7A2 aldo -keto r eductase family 7, 
AC' albumin 















Ext race llular Space 
Cytoplasm 
- 80Id" - Focus molecules . Gene/Prot ein/Chemica l ident ifi ers that meet the use r-<lefin ed cutoff and map t o the Globa l Mo lecular Netwo rk are d isp layed with bo ld t ext 
Analysis Filter Summary 
Consider only mo lecules and/o r relati onships w here 
(species _ Uncatego rized (e.g. chemicals) OR Human) AND 
(confidence _ Experimentally Observed) AND 
d'cf 
(tissues/cell lines _ BDCA_l+ dendritic cell s OR T 
ly mpho cytes n ot otherw ise specified OR Other B 
lympho cytes OR Cytot oxic T cells OR Other Dendritic cell s OR 
Mo n o cyte_derived macrophage OR Central memo ry helper T 
cell s OR Dendritic cell s n ot otherw ise specified OR Naive 
helper T cell s OR Immature mo n o cyte_derived dendritic cell s 
OR Murine NKT cell s OR Naive B cell s OR Mo n o cytes OR 
CD56bright NK cells OR NK cell s n ot otherw ise specified OR 
Central memo ry cytot oxic T cell s OR Mature 
mo n o cyte_derived dendritic cell s OR Macrophages ORJ774 
~~::~~_c:.a,~~~~;:I~a~ T.::.~!I~ .?~_~~h~~ ~!r,,~~~..?~~,:~ ,?~R " D 
















''''''''' s u~asa l azi n e , ba lsa lazide , 5-
-D" - Dupli cat es . Gene/Prot ein/Che mica l ident ifi ers marked with an ast eri sk indicat e that mu lt iple ident ifi ers in the dat aset fi le map t o a single gene/chemi,al in the Globa l Mo lecular Network ~ - 0 " - OVerri de molecules . Gene/Prot ein/Chemica l ident ifi ers marked as "OVerri de" are disp layed wit h ~ a li c t ext "A" - Gene/Prot ein/ChemicaIID marked as Absent. Th e gene/prot ein/chemi,al will not be used as a focus molecule or appear in netwo rks un less you also eKpli cit ly overri de th is fi ag with the OVerri de co lumn 
",I 
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IPA 0+ 12:41 l iam 
Eil e Edit Ylew ""'indow !::!e lp Provide Feedback I Support Ms. Goosen Close IPA 
Genes and Chemica ls r Funct ions and Diseases r Pathways an d To~ Li st s .. I Enter function or disease names here I I11III1 Advanced Search !j] 
~ create Core Analysis _ [analysis: TBART_MP _vs_MMJ ilteredl 
Ge n e r a l Settings ~ Se lect all 
Net w o rk Ge n e r ati o n 0 , ... t:3 E><e.eriment..uy Obn !Yed 
>--"'==~====_~ :0 High (predicted) 
Dat a Source s Al l : . .0 Moderate (pred icted) 
t Confid e n ce Experim enta ", 
Species Human 
Tissu es & Ce ll lines Al l 
Mutati o n Al l 
IEmZ!Il!m "t $ Ii *" Ii ,I H II II 
Set Cutoffs 
E><p ress ion Value Type Cut off Range Focus On 
Fo ld Change c::::::::J -4.6636 to 7.0797 180th UplDownregulated ~ I 'bY WI' ii! 386 ana!ys is-ready molecules ac ro ss observat ions 
Preview Dataset T8ART_MP _vs_MM_filtered 
An a!ys is-Ready (386) \ Mapped/F ilt ered IDs (386) \ Unmapped IDs (0 ) \ Al IIDs (386) \ 
nh&L&!&LU.ZZSJLEd£LSZZHW· Hi'I,,! ~ 
D Fo ld Change " Not es D 1"2.191 P42765 
D 1"1.11 6 Q9H845 
D 1"5.270 P11 310-2 
D 1"1. 040 P53396 
D 1"1. 028 Q99798 
D . -1.1 63 P68133 
D . -2.482 P60709 
D . -1. 210 Q562Rl 
D . -1. 027 P1 2814 
D . -1. 056 043707 
D . -1. 093 P611 60 
D . -1. 028 P611 58 
D 1"2.271 043488 
D . -2.450 P02768 
D 1"2.171 P1 8054 
Not es 
, Symbo l Entrez Gene Name 
ACAA2 acetyi -CoA acyitransferase 2 
ACAD9 acyi -CoA dehydrogenase fami 
ACADM acyi -CoA de hydrogenase, C-4 
ACl Y ATP cit rat e lyase 
AC02 (includes EG:1l429) aconit ase 2, mit ochondrial 
ACTAl act in, alph a 1, skelet al musc l 
ACTB act in, beta 
ACT8l2 act in, beta -li ke 2 
ACTNl act inin, alp ha 1 
ACTN4 act inin, alp ha 4 
ACTR2 ARP2 act in -relat ed prote in 2 
ACTR3 ARP3 act in -relat ed protein 3 
AKR7A2 aldo-keto r eductase family 7, 
AC' albumin 















E><t race llular Space 
Cytoplasm 
- 80Id" - Focus molecules . Gene/P rot ein/Chemica l ident ifi ers that meet the use r-<l efin ed cutoff and map t o the Globa l Mo lecular Netwo rk are d isplayed with bo ld t e><t 
Analysis Filter Summary 
Co n s ider o nly mo lecules a n d/o r r e lati o n ships w h e r e 
(species _ Un cat egori zed (e .g . ch e mica ls) OR Huma n) A ND 
(confiden ce _ Experim enta lly Observed) 
,hi IBI I 
Rows: [1 - 100 ~[ ID BI 














t ransport er 
''''''''' s u~a s a l azi n e , ba lsalazide , 5-
-D" - Dupli cat es . Gene/Prot ein/Che mica l ident ifi ers marked with an ast eri sk indicat e that mu lt iple ident ifi ers in the dat aset fi le map t o a single gene/chemi,al in the Globa l Mo lecular Netwo rk ~ - 0 " - OVerri de molecules . Gene/Prot ein/Chemica l ident ifi ers marked as "OVerri de" are displayed wit h ~ a li c t e><t "A" - Gene/Prot ein/ChemicaIID marked as Absent. Th e gene/prot ein/chemi,al will not be used as a focus molecule or appear in netwo rks un less you also eKpli cit ly overri de th is fi ag with the OVerri de co lumn 
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IPA 0+ 12:40 liam 
Eil e Ed it Yl ew ""'indow !::!elp Provide Feedback I Support Ms. Goosen Close IPA 
Genes and Chemicals r Funct ions and Diseases r Pathways an d To~ Li st s .. I Enter funct ion or disease names here I I11III1 Advanced Search !j] 
~ create Core Analysis _ [analysis: TBART_MP . vs. MMJ ilteredl 
General Settings 
Network Generatio n 0 
Data Sources Al l 
Confidence Exp erim enta", 
Species Human 
Tissues & Cell lines Al l 
Mutatio n Al l 
Population of genes to consider for p_value calculations: 
Reference Set L!iigenu it l Kn owledge Base (G enes Onty) 
Relationships to consider: 
Affect, networks and up,tream re ~u l ator anaty, ;, 
@ Direct and Indirect Relat ionships 
o Direct Relat ionships 
~ 
Opt ional Analyses 
s~ My projectL." 
; G!l My Pathwil:/1: 
~ MyU:;ts'-
I .... ",.!. j "t $Iith,,1 H I I I 
Set Cutoffs 
E><p ress ion Value Type Cutoff Range Focus On 
Fold Change c::::::::J -4.6636 t o 7.0797 180th UplDownregulated ~ I 'bY WI' ii! 386 ana!ys is, eady molecules acro ss observat ions 
Preview Dataset TBART_MP .vs_MM_filtered 
An a!ys is-Ready (386) \ Mapped/F ilt ered IDs (386) \ Unmapped IDs (0) \ Al IIDs (386) \ 
nh&L&!&ZU.ZZSJLEd£ZSEEHm· Hi'i,'! ~ 
D Fold Change " Not es D 1"2.191 P42765 
D 1"1.11 6 Q9H845 
D 1"5.270 P11 310-2 
D 1"1. 040 P53396 
D 1"1. 028 Q99798 
D . -1.1 63 P68133 
D . -2.482 P60709 
D . -1. 210 Q562Rl 
D . -1. 027 P12814 
D . -1. 056 0 43707 
D . -1. 093 P611 60 
D . -1. 028 P611 58 
D 1"2.271 043488 
D . -2.450 P02768 
D 1"2.171 P18054 
Not es 
, Symbo l Entrez Gene Name 
ACAA2 acetyi -CoA acyit ransferase 2 
ACAD9 acyi -CoA de hydrogenase fami 
ACADM acyi -CoA de hydrogenase, C-4 
ACl Y ATP cit rat e lyase 
AC02 (includes EG:1l429) aconitase 2, mitochondrial 
ACTAl act in, alph a 1, skelet al musc l 
ACTB act in, beta 
ACTBl2 act in, beta -li ke 2 
ACTNl act inin, alp ha 1 
ACTN4 act inin, alp ha 4 
ACTR2 ARP2 act in -relat ed prote in 2 
ACTR3 ARP3 act in -relat ed prot ein 3 
AKR7A2 aldo-keto r eductase family 7, 
AC' albumin 















E><t race llular Space 
Cytoplasm 
"80Id" - Focus molecules . Gene/P rot ein/Chemical ident ifi ers that meet the use r-<lefin ed cutoff and map t o the Global Mo lecular Netwo rk are d isplayed with bo ld t e><t 
Analysis Filter Summary 
Consider only molecules and/o r relati onships w here 
(species _ Human) AND 
(confidence _ Experimentally Observed) 
,hi IBI I 
Rows: [1 - 100 ~[ ID BI 
Typ e(s) Drug(s) 













tran sport er 
''''''''' s u~asa l <lZi n e , balsa l<lZide , 5-
"D" - Dupli cat es . Gene/Prot ein/Che mical ident ifi ers marked with an ast eri sk indicat e that mu lt iple ident ifi ers in the dat aset fi le map t o a single gene/chemi, al in the Global Mo lecular Network 
"0 " - OVerri de molecules . Gene/Prot ein/Chemical ident ifi ers marked as "OVerri de" are displayed wit h ~ a li c t e><t ~ "A" - Gene/Prot ein/ChemicaIID marked as Ab sent. Th e gene/prot ein/chemi, al will not be used as a focus molecule or appear in netwo rks un less you also eKpli cit ly overri de th is fi ag with the OVerri de co lumn 
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Below are the protein lists of the shared proteins across the three paired datasets that were
studied, namely: TBART MP/MM, TB-IRIS MP/MM and TB-IRIS PP/MM. The lists include
fold change, UniProt ID, Entrez gene name, cellular location and protein type.
The TB-IRIS PP/MM paired dataset (Table 5.1) was generated using proteins commonly identified









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The TB-IRIS MP/MM paired dataset (Table 5.1) was generated using proteins commonly identified



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The TBART PP/MM paired dataset (Table 5.1) was generated using proteins commonly identified
in the TBART PDE PP and the TBART PDE MM datasets (Table 4.2).
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